Antibody combinations for macrophage stimulation

Abstract

Bispecific antibodies and combinations thereof for the treatment of proliferative disease are disclosed. The antibodies target cell surface antigens on immune cells. Methods of treatment of proliferative diseases, including cancers by administering the bispecific antibodies are further disclosed.

Description

ANTIBODY COMBINATIONS FOR MACROPHAGE STIMULATION RELATEDAPPLICATIONS

[0001] This application claims priority under 35 U.S.C.119(e) to U.S. Provisional Application 63 / 661,826 filed June 19, 2024, the entirety of which is incorporated herein by reference. GOVERNMENTSUPPORT

[0002] This invention was made with government support under Grant Numbers W81XWH2210141 awarded by the Department of Defense and CA279259 awarded by the National Institutes of Health. The government has certain rights in the invention.\ REFERENCE TO ANELECTRONICSEQUENCELISTING

[0003] The contents of the electronic sequence listing (W057170067WO00-SEQ-MOD.xml; Size: 37,539 bytes; and Date of Creation: June 17, 2025) are herein incorporated by reference in its entirety. BACKGROUND

[0004] Monoclonal antibodies are among the most effective treatments for patients with blood cancers, and they primarily function by marking cells for destruction by the innate immune system. Macrophages are critical innate effectors of antibody therapies for lymphoma, but their phagocytic capacity is limited by the CD47 / SIRPa interaction, a macrophage immune checkpoint. CD47 acts a “don’t eat me” signal that is highly expressed on the surface of many lymphomas, and it prevents phagocytosis by binding to the inhibitory receptor SIRPa expressed on macrophages. In clinical trials, CD47-blocking therapies have demonstrated encouraging signs of efficacy for B-cell lymphomas, particularly when used in combination with rituximab, an opsonizing anti-CD20 antibody. However, the best antibodies and combination strategies to activate macrophages remain unknown. SUMMARY OF THE INVENTION

[0005] Macrophages are critical effectors of antibody therapies for lymphoma, but the best targets for this purpose remain unknown. Defined herein is a comprehensive repertoire of cell surface antigens that can be targeted to stimulate macrophage-mediated destruction of B-W0571.70067WO001 / 202cell lymphoma. A high-throughput assay to screen hundreds of antibodies for their ability to provoke macrophages to attack B-cell lymphoma cells was developed. Across both mouse and human systems, multiple unappreciated targets of opsonization as well as putative immune checkpoints were identified. This information was used to engineer a compendium of 156 bispecific antibodies, and identify dozens of bispecifics that dramatically stimulate macrophage-mediated cytotoxicity of lymphoma cells. Among these, a bispecific comprising a SIRPα decoy domain and a CD38-targeting arm (WTa2d1xCD38) exhibited maximal efficacy while minimizing the risk of hematologic toxicity. This bispecific stimulated robust anti-tumor responses in multiple xenograft models of aggressive B-cell lymphoma. This approach can be directly applied to other cancers to rapidly discover bispecific antibodies that leverage anti-tumor responses by macrophages or other innate immune cells.

[0006] Overall, multitude of novel therapeutic candidates and combination strategies were developed that can be further explored to employ macrophages as effector cells to benefit patients with B-cell lymphoma. Furthermore, this approach can be rapidly applied to other hematologic malignancies to create innovative bispecifics that leverage anti-tumor responses by macrophages or other innate immune cells.

[0007] In one aspect of the present disclosure, provided is a composition comprising one or more first antigen targeting molecules and for the treatment of proliferative disease.

[0008] In another aspect, provided is one or more nucleic acid constructs encoding the composition of the present disclosure.

[0009] In one aspect of the present disclosure, provided is a vector comprising the nucleic acid of the present disclosure.

[0010] In another aspect, provided is a cell comprising the nucleic acid or the vector of the present disclosure.

[0011] In one aspect, provided is a method for treating proliferative disease in a subject in need thereof, the method comprising administering to a subject an effective amount of two or more antigen targeting molecules wherein the first and second antigen targeting molecules of the two or more antigen targeting molecules are selected from the group consisting of (a) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 1; (b) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 2; (c) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 3;W0571.70067WO002 / 202(d) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 4; (e) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 5; (f) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 6; (g) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 7; (h) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 8; (i) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 9; (j) a single chain binding arm comprising CV1 (a high-affinity SIRPa decoy protein) of the amino acid sequence of SEQ ID NO: 10; (k) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 11; (l) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 12; (m) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 13; (n) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 14; (o) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 15; (p) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 16; (q) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 17; (r) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 18; (s) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 19; (t) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 20;W0571.70067WO003 / 202(u) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 21; (v) a single chain binding arm comprising CV1 (a high-affinity SIRPa decoy protein) of the amino acid sequence of SEQ ID NO: 22; (w) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 23; (x) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 24; and (y) a single chain binding arm comprising WTa2d1 (a low-affinity SIRPa decoy protein) of the amino acid sequence of SEQ ID NO: 25.

[0012] In another aspect, provided is a bispecific antibody comprising a first antigen-binding domain and a second antigen -binding domain, wherein each antigen-binding domain independently targets CD20, CD38, CD47, CD71, CD79b, CD95, CXCR4, CD45RB, CD45RA, CD147, CD98, CD184, HLA-DR, HLA-(A,B,C), HLA-(DR,DP,DQ), MHC I, CD24, CALR, CD40, PD-L1, APMAP, GPR84, VCAM1, CD11b, SIGLEC-10, PD-L2 , PD- 1, B2M, CD73, Galectin-9, CD14, CD80, CD86, SIRPb, SIRPg, SLAMF7, MARCO, AXL, CLEVER-1, ILT4, TIM-3, TIM-4, LRP-1, calreticulin, TREM1, TREM2, GD2, FcgRI, FcgRIIa, FcgRIIb, FcgRIII, MUC1, CD44, CD63, CD36, CD84, CD164, CD82, CD18, SIGLEC-7, CD166, CD39, CD46, LILRA1, LILRA2, LILRA3, LILRA4, LILRB1(CD85j), LILRB2, LILRB3, LILRB4, LILRB5, CD85, CD85j, CD85b, CD85, CD85f, CD276, CD88, CD99, PILRa, Siglec-9, CD206, CD163, CD84, C3aR, and CLEC12A.

[0013] In one aspect, provided is one or more nucleic acid constructs encoding the composition of the present disclosure.

[0014] In another aspect, provided is a method of treating disease in a subject or a cell, the method comprising administering to the subject or cell an effective amount of the bispecific antibody of the present disclosure.

[0015] Additionally provided in one aspect is a kit comprising the bispecific antibody of the present disclosure and a pharmaceutical excipient.

[0016] The details of certain embodiments of the invention are set forth in the Detailed Description of Certain Embodiments, as described below. Other features, objects, and advantages of the invention will be apparent from the Definitions, Examples, figures, and Claims. It should be understood that the aspects described herein are not limited to specific embodiments, methods, or configurations, and as such can, of course, vary. It is also to beW0571.70067WO004 / 202understood that the terminology used herein is for the purpose of describing particular aspects only and, unless specifically defined herein, is not intended to be limiting. BRIEFDESCRIPTION OF THEDRAWINGS

[0017] The accompanying drawings, which constitute a part of this specification, illustrate several embodiments of the invention and together with the description, provide non-limiting examples of the invention.

[0018] FIGs.1A-1H shows an unbiased antibody screen identifies targets for macrophage- directed immunotherapy for murine B-cell lymphoma. FIG.1A shows experimental design of an unbiased functional screen to identify monoclonal antibodies that provoke macrophage- mediated cytotoxicity of lymphoma cells. Primary murine macrophages were co-cultured in 384-well plates with StayGold+ MHC-I A20 cancer cells (a murine B-cell lymphoma cell line). The wells were subjected to three treatment conditions: control (“monotherapy”), 10 ug / mL anti-CD47 antibody, or 10 ug / mL anti-CD20 antibody. An arrayed library of purified monoclonal antibodies targeting murine cell surface antigens (n = 176 antibodies) was overlaid at a concentration of 6.55 ug / mL. The cells were incubated for 156 h (~6.5 days) and the StayGold+ area was quantified by automated microscopy and whole-well image analysis every 8 hours. FIG.1B shows representative whole-well images at the last time point (156h) showing StayGold+ lymphoma area from wells treated with the indicated antibodies that were found to stimulate macrophage-dependent cytotoxicity of A20 cells. Scale bar, 800 um. FIGs.1C-E show results of co-cultures with the antibody library showing growth of StayGold+ A20 MHC-I KO cells under monotherapy conditions (C), in combination with anti-CD47 (D), or in combination with anti-CD20 (E). Each curve represents the growth of lymphoma cells treated with a different antibody in the presence of macrophages. Curves are the mean of two individual co-culture wells. Curve ‘A’ indicates mean - / + SEM of control wells. Curves labeled B-F indicate antibodies against CD24, CD40, CD79b, CD95 and CXCR4. FIGs.1F-H show scatter plots depicting results of quantitative surfaceome profiling by flow cytometry for each library antibody binding to A20 lymphoma cells (x-axis) versus anti-lymphoma function at the last imaging time point (t = 156 hours, y-axis). Lower fluorescent area values indicate greater macrophage anti-lymphoma activity. The darker / labeled points are the antibodies exceeding the 95th percentile (p<0.05). The lines overlaying the data points indicate the linear relationship with 95% CI boundaries between the functional efficacy and binding in the monotherapy condition (F, r=-0.2334, p=0.0011), inW0571.70067WO005 / 202combination with anti-CD47(G, r=-0.2339, p=0.0011), and in combination with anti-CD20 (H, r=-0.009, p=0.8987).

[0019] FIGs.2A-2F shows an unbiased antibody screen identifies targets for macrophage- directed immunotherapy for human B-cell lymphoma. Primary human macrophages were co- cultured in 384-well plates with GFP+ Raji cells (a human Burkitt lymphoma cell line). The wells were subjected to three treatment conditions: control, 10 ug / mL anti-CD47 antibody, or 10 ug / mL anti-CD20 antibody. An arrayed library of purified monoclonal antibodies targeting human cell surface antigens (n = 242 antibodies) was overlaid at a concentration of 6.55 ug / mL. The cells were then incubated for 156 h (6.5 days) and the GFP+ area was quantified by automated microscopy and whole-well image analysis every 8 hours. FIGs. 2A-C show growth of GFP+ Raji cells in co-culture with macrophages under monotherapy conditions (A), in combination with anti-CD47 (B), or in combination with anti-CD20 (C). Each curve represents the growth of lymphoma cells treated with a different antibody or control. Curves are the mean of two individual co-culture wells. ‘A’ curve indicates the mean - / + SEM of control wells. Labeled curves indicate top antibody hits against MHC-related antigens, CD85, CD98 and CD71. FIGs.2D-F show scatter plots depicting results of quantitative surfaceome profiling by flow cytometry for each library antibody binding to GFP+ Raji lymphoma cells (x-axis) versus functional anti-lymphoma effectiveness at the last imaging time point (t = 156 hours, y-axis). Lower fluorescent area values indicate greater macrophage anti-lymphoma activity. The darker / labeled points are the antibodies within the 95th percentile (p<0.05). The lines overlaying the data points indicates the linear relationship with 95% CI boundaries between the functional efficacy and binding in the monotherapy condition (D, r=-0.3364, p<0.0001), in combination with anti-CD47 (E, r=-0.3646, p<0.0001), and in combination with anti-CD20 (F, r=-0.4105, p<0.0001)

[0020] FIGs.3A-3D shows the identification of antibody-targeted combinations that elicit macrophage mediated cytotoxicity of B-cell lymphoma. FIG.3A-B show primary murine macrophages were co-culture with StayGold+ A20 (WT) or MHC-I KO cells. Seven different antibodies identified from our screen and anti-PD-1 were tested alone or in combination as indicated. GFP+ area was measured over time as a representation of growth or elimination of lymphoma cells. Representative images at the last time point (156 h) are shown for each antibody combination for StayGold+ A20 WT (A) and StayGold+ A20 MHC-I KO cells (B). FIG.3C shows a heat map representing StayGold+ area at last time point (152 h) for WT (blue) and MHC I-negative (red) A20 cells. Merged data is shown in purple. For both cell lines, lighter color indicates greater StayGold+ area while darker color indicates lesserW0571.70067WO006 / 202StayGold+ area. Data represents the mean of 2 individual co-cultures per antibody combination. FIG.3D shows antibody combination studies performed using primary human macrophages and GFP+ Raji (WT), GFP+ Raji MHC-I KO, and mScarlet+ Toledo cells treated with 11 different antibodies alone or in combination as indicated. Heatmap depicts the mean normalized fluorescent area of the last time point (152h) from 2 individual co-culture wells. Unbiased hierarchical clustering was used to identify antibodies, combinations and cell lines with similar anti-lymphoma properties when co-cultured with macrophages.

[0021] FIGs.4A-4H shows multiplex generation of bispecific antibodies that stimulate macrophage destruction of human B-cell lymphoma. FIG.4A shows the experimental setup for the generation and functional characterization of a combinatorial matrix of bispecific antibodies. scFvs were created based on publicly available antibody sequences, fused to modified human IgG1 Fc regions containing knob or hole mutations for bispecific assembly, and a combinatorial library of bispecifics antibodies (bsAbs) was expressed in Expi293 cells. The resulting bsAbs were tested for functional activity and binding to multiple lymphoma cell lines and red blood cells. ELISA was performed to evaluate antibody expression. Finally, the fluorescent area at the last time point, binding, and expression by ELISA was used for K- Means unbiased clustering of the antibodies with similar biochemical and functional properties. FIGs.4B-D show growth of human lymphoma cells (B, mScarlet+ Toledo; C, GFP+ Raji; D, mCherry+ SUDHL-8) in co-culture with primary human macrophages. Each curve depicts lymphoma growth in the presence of a different bispecific antibody. Curves represent mean of 2 independent co-culture wells. Each color represents a different cluster of proteins based on functional properties. FIG.4E shows Violin plot of fluorescent area at the last time point for each lymphoma cell line for each unbiased cluster of bsAbs. FIG.4F shows a violin plot depicting binding of the antibodies to each lymphoma cell line as indicated based on clustering. FIG.4G shows the relationship between the different bsAb clusters with respect to binding to human red blood cells and their expression by ELISA. FIG.4H shows representative images of the last time point of the co-culture of macrophages and mScarlet+ Toledo cells and each bsAb from the combinatorial library. Rows indicate hole constructs, columns indicate knob constructs.

[0022] FIGs.5A-5G shows WTa2d1 x CD38 stimulates maximal macrophage-mediated cytotoxicity of B-cell lymphomas. FIG.5A shows AlphaFold2 predicted structure of WTa2d1 x CD38, a bispecific antibody targeting CD47 and CD38. The mutations, "knob" (T270Y,T311Y) and "hole" (Y396T, Y437T) are highlighted at the bottom. FIG.5B shows co-culture assays using primary human macrophages were used to determine the potency ofW0571.70067WO007 / 202WTa2d1 x CD38 across nine different human B-cell lymphoma cell lines, including the indicated wild-type and MHC-I KO variants. Each curve represents an 8-point titration performed in duplicate for each cell line. Fluorescent area was compared at the last imaging time point and normalized based on the maximum value for each cell line. FIG.5C shows co-culture assays of B-cell lymphoma lines with primary human macrophage were used to assess the potency of rituximab as in FIG.5B. FIG.5D shows a comparison of the fluorescent area at the last time point for different B-cell lymphoma cell lines when treated with 10.54 µg / mL of WTa2d1 x CD38 or rituximab. Each point represents the mean value for a different cell line performed in duplicate. FIG.5E shows a comparison of the fluorescent area at the last time point from co-culture assays using the indicated lymphoma cell lines treated with either WTa2d1 x CD38 or rituximab. ns, not significant, ***p<0.001, **** p<0.0001 for the indicated comparisons by two-way ANOVA with correction for multiple comparisons. FIG.5F shows experimental setup of a xenograft experiment using Raji cells engrafted subcutaneously into NSG mice. FIG.5G shows growth curves of Raji lymphoma tumors in NSG mice treated with the indicated therapies (n = 5 mice per treatment cohort). Mice were treated with control, 100 ug WTa2d1 x CD38, or 100 µg rituximab for 14 days. Tumor growth was evaluated over time by caliper measurements. ns, not significant, **** p<0.0001 for the indicated comparisons by one-way ANOVA with correction for multiple comparisons at the indicated time point.

[0023] FIGs.6A-6G shows ScFv-Fc allows for high-throughput screening of bispecific antibodies in vitro. FIG.6A shows a schematic representation of the methodology for the synthesis of conventional bispecific antibodies and engineered Scfv-Fcs bispecific antibodies. Conventional Abs were created by transforming four plasmids containing the VH and VL pairs, whereas ScFv-Fc were created by transforming two plasmids, containing the fused VL- VH for each side of the bispecific antibody. The conventional method can generate up to 4 different isoforms of the same antibody, whereas the ScFv-Fc only generates the main functional isoform. FIG.6B shows a western blot of the supernatant of transformed cultures with equimolar or equal-mass mixture of plasmids stained with antibodies for the Fc-region, the kappa VL, and the loading control (fibronectin). FIG.6B shows quantification of the intensity of the western blot bands depicting a statistically significant difference in the antibody amount between the conventional and the ScFv-Fc method. Two-way ANOVA adjusted for multiple comparisons was used to evaluate the difference between the groups. FIGs.6D-6F shows flow cytometry binding assays of the conventional antibody (‘A’, ‘C’) or the ScFv (‘B’, ‘D’) culture supernatants under different dilution factors to the indicatedW0571.70067WO008 / 202lymphoma cell lines (6D, Raji; 6F, Toledo). FIGs.6E-6G show co-culture assays using primary human macrophages were used to determine the potency of the different dilutions of the conventional antibody (‘A’, ‘C’) or the ScFv (‘B’, ‘D’) culture supernatants across the indicated lymphoma cell lines (6E, Raji; 6G, Toledo).

[0024] FIGs. 7A-7H shows WTa2d1xCD38 stimulates maximal macrophage-mediated cytotoxicity of B-cell lymphomas. FIG.7A shows co-culture assays using primary human macrophages were used to determine the potency of WTa2d1xCD38, LILRB1xWTa2d1, and CXCR4xCD38 antibodies across three different human B-cell lymphoma cell lines, and flow cytometry binding assays were used to evaluate their affinity to the respective cell lines. Each curve represents an 8-point titration performed in triplicate for each cell line. The fluorescent area was compared at the last imaging time point (144h). FIG.7B shows co-culture assays using different human B-cell lymphoma cell lines to determine the efficacy of WTa2d1xCD38 in comparison to single arm antibodies, daratumumab (anti-CD38), anti- CD47 (clone:B6H12), the standard of care rituximab (10.00 µg / mL for each one), and control. The fluorescent area was compared at the last imaging time point (144h). Significance was calculated using Two-way ANOVA adjusted for multiple comparisons. FIG.7C shows co-culture assays using primary human macrophages were used to determine the potency of WTa2d1xCD38 across ten different human B-cell lymphoma cell lines, including the indicated wild-type and MHC-I KO variants. Each curve represents an 8-point titration performed in duplicate for each cell line. Fluorescent area was compared at the last imaging time point and normalized based on the maximum value for each cell line. Data depict mean ± SD. FIG.7D shows representative images at the last timepoint of pairs of co- cultures wells of wild-type or rituximab-resistant lymphoma cell lines and macrophages stimulated with 10.00 µg / mL of rituximab or WTa2d1xCD38. FIG.7E shows immunofluorescence images of co-cultures of CellTracker Green labeled macrophages, mScarlet+ Toledo cells and 1 µg / mL WTa2d1xCD38. Cells were fixed after 30 minutes of incubation at 37 ℃ and 5% CO2, permeabilized and stained with alexa-647 anti-human IgG antibody. FIG.7F shows co-culture assays using primary human macrophages in response to WTa2d1xCD38 using WT, CD38 KO and CD47 KO Raji human lymphoma cell line as target cells. The fluorescent area was compared at the last imaging time point (144h). Each curve represents an 8-point titration performed in triplicate for each cell line. FIG.7G shows phagocytosis assays were performed using CFSE-labeled Toledo human lymphoma cells, as well as leukocytes and RBCs isolated from healthy blood donors, each co-cultured separately with human macrophages, in the presence of WTa2d1xCD38 antibody at various dilutions.W0571.70067WO009 / 202Phagocytic activity was assessed by flow cytometry, measuring the percentage of CFSE⁺ macrophages. Each condition was tested in duplicate. FIG.7H shows phagocytosis assay using CFSE-labeled RBCs from healthy donors co-cultured with human macrophages in the presence of rituximab, anti-CD47 (clone B6H12), daratumumab, and WTa2d1×CD38 antibodies at various dilutions. Phagocytic activity was assessed by flow cytometry, measuring the percentage of CFSE⁺ macrophages. Each condition was tested in duplicate. The data on red blood cell phagocytosis in response to WTa2d1xCD38 is the same as that shown in FIG.7G.

[0025] FIG.8A-8F shows WTa2d1xCD38 exhibits anti-tumor efficacy in xenograft models of aggressive B-cell lymphoma. FIG.8A shows experimental setup of a xenograft experiment using Raji cells engrafted subcutaneously into the flanks of NSG mice. FIG.8B shows growth curves of Raji lymphoma tumors in NSG mice treated with the indicated therapies over time (n = 5 mice per treatment cohort). Tumor growth was evaluated by caliper measurements. Mice were treated with control, 100 µg WTa2d1xCD38, or 100 µg rituximab for 14 days. FIG.8C shows survival analysis of the indicated treatment cohorts. The median survival of Vehicle and Rituximab groups were 38 and 98 days, respectively, whereas the WTa2d1xCD38 was not reached. The Log-Rank test was used to evaluate the difference in the probability of survival. Note the rituximab curve is minimally nudged for visualization. FIG.8D shows experimental setup of the xenograft CNS lymphoma model experiment using Raji cells engrafted stereotactically into NSG mice brains. FIG.8E shows bioluminescence imaging using luciferase reporters of CNS tumors throughout the experiment period (n = 5 mice per treatment cohort). Mice were treated with vehicle control or 200 µg WTa2d1xCD38 three times per week. FIG.8F shows survival analysis comparing the vehicle control and WTa2d1xCD38 treatment cohorts. Log-Rank test was used to evaluate the difference in the probability of survival between vehicle and treatment conditions.

[0026] FIGs.9A-9D shows binding of antibodies from libraries to B-cell lymphoma cells and macrophages. FIG.9A shows scatter plot depicting cell-based binding of individual antibodies from the murine antibody library binding to A20 lymphoma cells and mouse macrophages. Mean fluorescence intensity (MFI) was assessed by flow cytometry. FIG.9B shows scatter plot depicting results of cell-based binding of each antibody from the human antibody library to Raji lymphoma cells and primary human macrophages combined from n = 3 independent donors. A, B The labeled target antigens exceeded the 95thpercentile for binding to cancer or macrophage cells. FIGs.9C, 9D show multiple variable scatter plot depicting the relationship between the binding of the antibody library to lymphoma cellsW0571.70067WO0010 / 202and / or macrophages and the functional anti-tumor effects of each antibody in co-culture with macrophages (color scale) in the murine (C) and human (D) systems. The color scale represents the cancer cell area at the last timepoint in co-culture assays (156h), with blue indicating greater anti-lymphoma activity and yellow indicating lesser anti-lymphoma activity.

[0027] FIGs.10A-10D show comparison of antigens and antibodies evaluated from libraries in the murine and human systems. FIG.10A shows scatter plots depicting the relationship between binding of 92 shared targets in both human (Raji) and murine systems (A20). The labeled antigens are the selected antibody hits that exceeded the 95thpercentile of functional activity from the co-culture assays with macrophages and B-cell lymphomas as single agents. FIGs.10B, 10C show scatter plot depicting relationship between the binding of antibody hits and the functional anti-tumor effects across the three different conditions: antibodies alone (in black circle), in combination with anti-CD47 (black square), and in combination with anti- CD20 (in grey circle), in the murine (B) and the human system (C). FIG.10D shows a heatmap illustrating the functional efficacy of each antibody hit identified in the screening assay using human lymphoma cell lines (Raji, Toledo, and SUDHL-8), cultured with or without human macrophages. Both heatmaps display the fluorescent area (cm² / well) at the final time point (144h) of the co-culture. Color intensity represents antibody efficacy, ranging from black (high efficacy; reduced fluorescence indicating fewer tumor cells) to grey (low efficacy; increased fluorescence indicating more tumor cells). Statistical significance (p- values) was calculated using two-way ANOVA adjusted for multiple comparisons, comparing within each cell line proliferation in the presence or absence of macrophages.

[0028] FIGs.11A-11E show target hits identified in the mouse and human unbiased screenings are expressed across different lymphoma patients. Log2-normalized RNA expression of different hits in two lymphoma datasets (A, PMID: 29713087; B, PMID: 33215701). Flow cytometry binding assays were conducted on lymphoma cell lines (C) and the CD19⁺ cell fraction from peripheral blood mononuclear cells (PBMCs) isolated from three DLBCL patients at diagnosis (D) to assess antibody hits binding.

[0029] FIGs.12A-12D show validation of the structure and biophysical characteristics of the WTa2d1xCD38 antibody. FIG.12A shows Maldi-TOF analysis of the protein population of the purified bsAb. Based on the theoretical mass of the possible homo and heterodimers, the two main peaks were assigned to Wta2d1xWta2d1 and Wta2d1xCD38 species. The abundance of WTa2d1xCD38 was calculated as 94.60% based on the peak area. FIG.12B shows histogram showing binding of the bsAb to wild-type versus CD47 knockout (KO) cellW0571.70067WO0011 / 202lines highlights the ability of the two antibody arms to bind to their respective antigens. Binding was detected with an APC-conjugated anti-human IgG secondary antibody. DLD-1 is a colorectal cancer cell line that expresses CD47 but not CD38. FIG.12C shows binding of WTa2d1xCD38 to the indicated human lymphoma cell lines and macrophages combined from 3 donors indicates the cell-based affinity for the antibody. FIG.12D shows flow cytometry binding assays were performed on the CD19⁺ cell fraction of peripheral blood mononuclear cells (PBMCs) isolated from three DLBCL patients at diagnosis to assess WTa2d1xCD38 binding. Binding intensity is shown as APC fluorescence.

[0030] FIGs.13A-13J show antibody bridging of cancer cells with macrophages and their response curves comparison between different standards of care. FIG.13A shows immunofluorescence images of co-cultures assays with CellTracker green labeled macrophages, mScarlet+ Toledo cells and 1 µg / mL of WTa2d1xCD38. Cells were fixed with 4% PFA in PBS after 30 minutes incubation with the bispecific antibody at 37 ℃ and 5% CO2, permeabilized with 0.5% tween-20 and stained with Alexa-647 anti-human IgG Fc-ɣ chain specific. The images were visualized using a 40x objective lens with 4-channel fluorescence microscope. The figure depicts the images separated by channel, the final merged figure, and the selected highlighted spots showcased in FIG.7E. Primary human macrophages were co-cultured in 384-well plates with StayGold+ Raji (B), RL (C), U-2932 (D), their respective Rituximab-resistant homologs (E, Raji 4RH; F, RL 4RH; G, U-2932) induced by successive exposure to human plasma and rituximab, and other common lymphoma cell lines (H, HBL-1; I, Toledo; J, SUD-HL-8) Each point depicts the mean fluorescent area at the last time point (144h) of three wells containing different concentrations of the WTa2d1xCD38, Daratumumab, Rituximab, or anti-CD47 (clone: B6H12). Response curves were fitted using a 4-parameter sigmoidal non-linear regression model. The data at the highest concentration for each antibody is the same as FIG.7B.

[0031] FIGs.14A-14N show macrophage-dependent variations in antibody responses in the mouse and human systems. FIG.14A shows flow cytometry-based binding assay of the WTa2d1xCD38 bsAb in bone-marrow-derived mouse macrophages and primary human macrophages. Cancer cell area remaining after 144-hour co-culture of human lymphoma cell lines with either mouse or human-derived macrophages in the presence of various antibodies at their maximum concentration (10 µg / mL). Antibodies tested include WTa2d1xCD38 (B), anti-CD47 (clone: B6H12) (C), rituximab (D), and daratumumab (E). Statistical significance between groups was determined using a ratio paired two-tailed t-test. The data used for the fluorescent area with human macrophages at the highest concentration for each of theW0571.70067WO0012 / 202antibody is the same as in FIG.13. Growth inhibitory concentration (IC50) curves showing the potency of different antibodies in co-culture with NSG-derived mouse macrophages in across a panel of human lymphoma cell lines: Raji (F), RL (G), U-2932 (H), Raji 4RH (I), RL 4RH (J), U-29324RH (K), HBL-1 (L), Toledo (M), and SUD-HL-8 (N). The data for maximum concentration points (B-E) are derived from the same IC50 curves shown here. IC50 curves were fitted from a sigmoidal 4-parameter equation.

[0032] FIG.15 shows meta-analysis of survival data from two independent, identically designed in vivo experiments comparing treatments in mice bearing CNS lymphoma. Bioluminescence imaging using luciferase reporters of CNS tumors was employed throughout the experiment period, starting at day 5 post-tumor injection. Survival curves compare the efficacy of WTa2d1xCD38 treatment (B) versus vehicle control (A). Data were pooled from both experiments (n=5 mice per group per experiment; total n=10 per group) to increase statistical power and robustness of the analysis. Mice were treated with vehicle control or 200 µg WTa2d1xCD38 three times per week. Log-Rank test was used to evaluate the difference in the probability of survival between vehicle and treatment conditions.

[0033] FIG.16 shows putative mechanisms of action for the WTa2d1xCD38 bispecific antibody. Representation of the biological functions performed by the bsAb to enhance macrophage-mediated destruction of B-cell lymphoma cells. The WTa2d1xCD38 bispecific can act as an opsonin and engage Fc receptors on macrophages (1). It can also block immunosuppressive pathways on both the cancer and macrophage cell surface (2 and 3). Additionally, it can enhance the biophysical interactions of macrophages and B-cell lymphoma cells, bringing their cell membranes in close proximity to promote phagocytosis (4). Together, these functions maximally activate macrophage-mediated cytotoxicity of aggressive B-cell lymphoma cells.W0571.70067WO0013 / 202DEFINITIONS

[0034] As used herein, Sirpα and WTa2d1 are used interchangeably.

[0035] As used herein and in the claims, the singular forms “a,” “an,” and “the” include the singular and the plural reference unless the context clearly indicates otherwise. Thus, for example, a reference to “an agent” includes a single agent and a plurality of such agents.

[0036] Other than in the examples, or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein should be understood as modified in all instances by the term “about.” “About” and “approximately” shall generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements.

[0037] The term “small molecule” refers to molecules, whether naturally-occurring or artificially created (e.g., via chemical synthesis) that have a relatively low molecular weight. Typically, a small molecule is an organic compound (i.e., it contains carbon). The small molecule may contain multiple carbon-carbon bonds, stereocenters, and other functional groups (e.g., amines, hydroxyl, carbonyls, and heterocyclic rings, etc.). In certain embodiments, the molecular weight of a small molecule is not more than about 1,000 g / mol, not more than about 900 g / mol, not more than about 800 g / mol, not more than about 700 g / mol, not more than about 600 g / mol, not more than about 500 g / mol, not more than about 400 g / mol, not more than about 300 g / mol, not more than about 200 g / mol, or not more than about 100 g / mol. In certain embodiments, the molecular weight of a small molecule is at least about 100 g / mol, at least about 200 g / mol, at least about 300 g / mol, at least about 400 g / mol, at least about 500 g / mol, at least about 600 g / mol, at least about 700 g / mol, at least about 800 g / mol, or at least about 900 g / mol, or at least about 1,000 g / mol. Combinations of the above ranges (e.g., at least about 200 g / mol and not more than about 500 g / mol) are also possible. In certain embodiments, the small molecule is a therapeutically active agent such as a drug (e.g., a molecule approved by the U.S. Food and Drug Administration as provided in the Code of Federal Regulations (C.F.R.)). The small molecule may also be complexed with one or more metal atoms and / or metal ions. In this instance, the small molecule is also referred to as a “small organometallic molecule.” Preferred small molecules are biologically active in that they produce a biological effect in animals, preferably mammals, more preferably humans. Small molecules include, but are not limited to, radionuclides and imaging agents. In certain embodiments, the small molecule is a drug. Preferably, though not necessarily, the drug is one that has already been deemed safe and effective for use in humans or animals by the appropriate governmental agency or regulatory body. For example, drugs approved forW0571.70067WO0014 / 202human use are listed by the FDA under 21 C.F.R. §§ 330.5, 331 through 361, and 440 through 460, incorporated herein by reference; drugs for veterinary use are listed by the FDA under 21 C.F.R. §§ 500 through 589, incorporated herein by reference. All listed drugs are considered acceptable for use in accordance with the present disclosure.

[0038] A “protein,” “peptide,” or “polypeptide” comprises a polymer of amino acid residues linked together by peptide bonds. The term refers to proteins, polypeptides, and peptides of any size, structure, or function. Typically, a protein will be at least three amino acids long. A protein may refer to an individual protein or a collection of proteins. Proteins preferably contain only natural amino acids, although non-natural amino acids (i.e., compounds that do not occur in nature but that can be incorporated into a polypeptide chain) and / or amino acid analogs as are known in the art may alternatively be employed. Also, one or more of the amino acids in a protein may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a hydroxyl group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation or functionalization, or other modification. A protein may also be a single molecule or may be a multi-molecular complex. A protein may be a fragment of a naturally occurring protein or peptide. A protein may be naturally occurring, recombinant, synthetic, or any combination of these.

[0039] The term “inhibit” or “inhibition” in the context of modulating level (e.g., expression and / or activity) of a target is not limited to only total inhibition. Thus, in some embodiments, partial inhibition or relative reduction is included within the scope of the term “inhibition.” In some embodiments, the term refers to a reduction of the level (e.g., expression, and / or activity) of a target to a level that is reproducibly and / or statistically significantly lower than an initial or other appropriate reference level, which may, for example, be a baseline level of a target. In some embodiments, the term refers to a reduction of the level (e.g., expression and / or activity) of a target to a level that is less than 75%, less than 50%, less than 40%, less than 30%, less than 25%, less than 20%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.1%, less than 0.01%, less than 0.001%, or less than 0.0001% of an initial level, which may, for example, be a baseline level of a target.

[0040] As used herein, the term "inhibitor" refers to an agent whose presence or level correlates with decreased level or activity of a target to be modulated. In some embodiments, an inhibitor may act directly (in which case it exerts its influence directly upon its target, for example by binding to the target); in some embodiments, an inhibitor may act indirectly (in which case it exerts its influence by interacting with and / or otherwise altering a regulator of aW0571.70067WO0015 / 202target, so that level and / or activity of the target is reduced). In some embodiments, an inhibitor is one whose presence or level correlates with a target level or activity that is reduced relative to a particular reference level or activity (e.g., that observed under appropriate reference conditions, such as presence of a known inhibitor, or absence of the inhibitor as disclosed herein, etc.).

[0041] The terms “composition” and “formulation” are used interchangeably.

[0042] A “subject” refers to a human (i.e., male or female of any age group, e.g., pediatric subject (e.g., infant, child, or adolescent) or adult subject (e.g., young adult, middle–aged adult, or senior adult)) or non–human animal. In certain embodiments, the non–human animal is a mammal (e.g., primate (e.g., cynomolgus monkey or rhesus monkey), commercially relevant mammal (e.g., cattle, pig, horse, sheep, goat, cat, or dog), or bird (e.g., commercially relevant bird, such as chicken, duck, goose, or turkey)). In certain embodiments, the non- human animal is a fish, reptile, or amphibian. The non-human animal may be a male or female at any stage of development. The non-human animal may be a transgenic animal or genetically engineered animal. A “patient” refers to a human subject in need of treatment of a disease.

[0043] The term “biological sample” refers to any sample including tissue samples (such as tissue sections and needle biopsies of a tissue); cell samples (e.g., cytological smears (such as Pap or blood smears) or samples of cells obtained by microdissection); samples of whole organisms (such as samples of yeasts or bacteria); or cell fractions, fragments or organelles (such as obtained by lysing cells and separating the components thereof by centrifugation or otherwise). Other examples of biological samples include blood, serum, urine, semen, fecal matter, cerebrospinal fluid, interstitial fluid, mucous, tears, sweat, pus, biopsied tissue (e.g., obtained by a surgical biopsy or needle biopsy), nipple aspirates, milk, vaginal fluid, saliva, swabs (such as buccal swabs), or any material containing biomolecules that is derived from a first biological sample.

[0044] The terms “administer,” “administering,” or “administration” refers to implanting, absorbing, ingesting, injecting, inhaling, or otherwise introducing a compound described herein, or a composition thereof, in or on a subject. The compounds and compositions provided herein can be administered by any route, including enteral (e.g., oral), parenteral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (as by powders, ointments, creams, and / or drops), mucosal, nasal, bucal, sublingual; by intratracheal instillation, bronchial instillation, and / or inhalation; and / or as an oral spray, nasal spray,W0571.70067WO0016 / 202and / or aerosol. Specifically contemplated routes are oral administration, intravenous administration (e.g., systemic intravenous injection), regional administration via blood and / or lymph supply, and / or direct administration to an affected site. In general, the most appropriate route of administration will depend upon a variety of factors including the nature of the agent (e.g., its stability in the environment of the gastrointestinal tract), and / or the condition of the subject (e.g., whether the subject is able to tolerate oral administration). In certain embodiments, the compound or pharmaceutical composition described herein is suitable for intravenous or subcutaneous injection into a subject.

[0045] The terms “treatment,” “treat,” and “treating” refer to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease described herein. In some embodiments, treatment may be administered after one or more signs or symptoms of the disease have developed or have been observed. In other embodiments, treatment may be administered in the absence of signs or symptoms of the disease. For example, treatment may be administered to a susceptible subject prior to the onset of symptoms (e.g., in light of a history of symptoms and / or in light of exposure to a pathogen). Treatment may also be continued after symptoms have resolved, for example, to delay and / or prevent recurrence.

[0046] The term “prevent,” “preventing,” or “prevention” refers to a prophylactic treatment of a subject who is not and was not with a disease but is at risk of developing the disease or who was with a disease, is not with the disease, but is at risk of regression of the disease. In certain embodiments, the subject is at a higher risk of developing the disease or at a higher risk of regression of the disease than an average healthy member of a population.

[0047] The terms “condition,” “disease,” and “disorder” are used interchangeably.

[0048] An “effective amount” of a compound described herein refers to an amount sufficient to elicit the desired biological response. An effective amount of a compound described herein may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound, the condition being treated, the mode of administration, and the age and health of the subject. In certain embodiments, an effective amount is a therapeutically effective amount. In certain embodiments, an effective amount is a prophylactic treatment. In certain embodiments, an effective amount is the amount of a compound described herein in a single dose. In certain embodiments, an effective amount is the combined amounts of a compound described herein in multiple doses.

[0049] A “therapeutically effective amount” of a compound described herein is an amount sufficient to provide a therapeutic benefit in the treatment of a condition or to delay or minimize one or more symptoms associated with the condition. A therapeutically effectiveW0571.70067WO0017 / 202amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the condition. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms, signs, or causes of the condition, and / or enhances the therapeutic efficacy of another therapeutic agent.

[0050] A “prophylactically effective amount” of a compound described herein is an amount effective to prevent a condition, or one or more symptoms associated with the condition and / or prevent its recurrence. A prophylactically effective amount of a compound means an amount of a therapeutic agent, alone or in combination with other agents, which provides a prophylactic benefit in the prevention of the condition. The term “prophylactically effective amount” can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.

[0051] A “proliferative disease” refers to a disease that occurs due to abnormal growth or extension by the multiplication of cells (Walker, Cambridge Dictionary of Biology; Cambridge University Press: Cambridge, UK, 1990). A proliferative disease may be associated with: 1) the pathological proliferation of normally quiescent cells; 2) the pathological migration of cells from their normal location (e.g., metastasis of neoplastic cells); 3) the pathological expression of proteolytic enzymes such as the matrix metalloproteinases (e.g., collagenases, gelatinases, and elastases); or 4) the pathological angiogenesis as in proliferative retinopathy and tumor metastasis. Exemplary proliferative diseases include cancers (i.e., “malignant neoplasms”), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases.

[0052] The term “angiogenesis” refers to the physiological process through which new blood vessels form from pre-existing vessels. Angiogenesis is distinct from vasculogenesis, which is the de novo formation of endothelial cells from mesoderm cell precursors. The first vessels in a developing embryo form through vasculogenesis, after which angiogenesis is responsible for most blood vessel growth during normal or abnormal development. Angiogenesis is a vital process in growth and development, as well as in wound healing and in the formation of granulation tissue. However, angiogenesis is also a fundamental step in the transition of tumors from a benign state to a malignant one, leading to the use of angiogenesis inhibitors in the treatment of cancer. Angiogenesis may be chemically stimulated by angiogenic proteins, such as growth factors (e.g., VEGF). “Pathological angiogenesis” refers to abnormal (e.g., excessive or insufficient) angiogenesis that amounts to and / or is associated with a disease.W0571.70067WO0018 / 202

[0053] The terms “neoplasm” and “tumor” are used herein interchangeably and refer to an abnormal mass of tissue wherein the growth of the mass surpasses and is not coordinated with the growth of a normal tissue. A neoplasm or tumor may be “benign” or “malignant,” depending on the following characteristics: degree of cellular differentiation (including morphology and functionality), rate of growth, local invasion, and metastasis. A “benign neoplasm” is generally well differentiated, has characteristically slower growth than a malignant neoplasm, and remains localized to the site of origin. In addition, a benign neoplasm does not have the capacity to infiltrate, invade, or metastasize to distant sites. Exemplary benign neoplasms include, but are not limited to, lipoma, chondroma, adenomas, acrochordon, senile angiomas, seborrheic keratoses, lentigos, and sebaceous hyperplasias. In some cases, certain “benign” tumors may later give rise to malignant neoplasms, which may result from additional genetic changes in a subpopulation of the tumor’s neoplastic cells, and these tumors are referred to as “pre-malignant neoplasms.” An exemplary pre-malignant neoplasm is a teratoma. In contrast, a “malignant neoplasm” is generally poorly differentiated (anaplasia) and has characteristically rapid growth accompanied by progressive infiltration, invasion, and destruction of the surrounding tissue. Furthermore, a malignant neoplasm generally has the capacity to metastasize to distant sites. The term “metastasis,” “metastatic,” or “metastasize” refers to the spread or migration of cancerous cells from a primary or original tumor to another organ or tissue and is typically identifiable by the presence of a “secondary tumor” or “secondary cell mass” of the tissue type of the primary or original tumor and not of that of the organ or tissue in which the secondary (metastatic) tumor is located. For example, a prostate cancer that has migrated to bone is said to be metastasized prostate cancer and includes cancerous prostate cancer cells growing in bone tissue.

[0054] The term “cancer” refers to a class of diseases characterized by the development of abnormal cells that proliferate uncontrollably and have the ability to infiltrate and destroy normal body tissues. See, e.g., Stedman’s Medical Dictionary, 25th ed.; Hensyl ed.; Williams & Wilkins: Philadelphia, 1990. Exemplary cancers include, but are not limited to, hematological malignancies. The term “hematological malignancy” refers to tumors that affect blood, bone marrow, and / or lymph nodes. Exemplary hematological malignancies include, but are not limited to, leukemia, such as acute lymphocytic leukemia (ALL) (e.g., B- cell ALL, T-cell ALL), acute myelocytic leukemia (AML) (e.g., B-cell AML, T-cell AML), chronic myelocytic leukemia (CML) (e.g., B-cell CML, T-cell CML), and chronic lymphocytic leukemia (CLL) (e.g., B-cell CLL, T-cell CLL)); lymphoma, such as Hodgkin lymphoma (HL) (e.g., B-cell HL, T-cell HL) and non-Hodgkin lymphoma (NHL) (e.g., B-W0571.70067WO0019 / 202cell NHL, such as diffuse large cell lymphoma (DLCL) (e.g., diffuse large B-cell lymphoma (DLBCL, e.g., activated B-cell (ABC) DLBCL (ABC-DLBCL))), follicular lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), mantle cell lymphoma (MCL), marginal zone B-cell lymphoma (e.g., mucosa-associated lymphoid tissue (MALT) lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt lymphoma, Waldenström’s macroglobulinemia (WM, lymphoplasmacytic lymphoma), hairy cell leukemia (HCL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, central nervous system (CNS) lymphoma (e.g., primary CNS lymphoma and secondary CNS lymphoma); and T-cell NHL, such as precursor T-lymphoblastic lymphoma / leukemia, peripheral T-cell lymphoma (PTCL) (e.g., cutaneous T-cell lymphoma (CTCL) (e.g., mycosis fungoides, Sezary syndrome), angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma, enteropathy type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, and anaplastic large cell lymphoma); lymphoma of an immune privileged site (e.g., cerebral lymphoma, ocular lymphoma, lymphoma of the placenta, lymphoma of the fetus, testicular lymphoma); a mixture of one or more leukemia / lymphoma as described above; myelodysplasia; and multiple myeloma (MM). Additional exemplary cancers include, but are not limited to, lung cancer (e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung); kidney cancer (e.g., nephroblastoma, a.k.a. Wilms’ tumor, renal cell carcinoma); acoustic neuroma; adenocarcinoma; adrenal gland cancer; anal cancer; angiosarcoma (e.g., lymphangiosarcoma, lymphangioendotheliosarcoma, hemangiosarcoma); appendix cancer; benign monoclonal gammopathy; biliary cancer (e.g., cholangiocarcinoma); bladder cancer; breast cancer (e.g., adenocarcinoma of the breast, papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast); brain cancer (e.g., meningioma, glioblastomas, glioma (e.g., astrocytoma, oligodendroglioma), medulloblastoma); bronchus cancer; carcinoid tumor; cervical cancer (e.g., cervical adenocarcinoma); choriocarcinoma; chordoma; craniopharyngioma; colorectal cancer (e.g., colon cancer, rectal cancer, colorectal adenocarcinoma); connective tissue cancer; epithelial carcinoma; ependymoma; endotheliosarcoma (e.g., Kaposi’s sarcoma, multiple idiopathic hemorrhagic sarcoma); endometrial cancer (e.g., uterine cancer, uterine sarcoma); esophageal cancer (e.g., adenocarcinoma of the esophagus, Barrett’s adenocarcinoma); Ewing’s sarcoma; ocular cancer (e.g., intraocular melanoma, retinoblastoma); familiar hypereosinophilia; gall bladder cancer; gastric cancer (e.g., stomach adenocarcinoma); gastrointestinal stromal tumor (GIST);W0571.70067WO0020 / 202germ cell cancer; head and neck cancer (e.g., head and neck squamous cell carcinoma, oral cancer (e.g., oral squamous cell carcinoma), throat cancer (e.g., laryngeal cancer, pharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer)); heavy chain disease (e.g., alpha chain disease, gamma chain disease, mu chain disease; hemangioblastoma; hypopharynx cancer; inflammatory myofibroblastic tumors; immunocytic amyloidosis; liver cancer (e.g., hepatocellular cancer (HCC), malignant hepatoma); leiomyosarcoma (LMS); mastocytosis (e.g., systemic mastocytosis); muscle cancer; myelodysplastic syndrome (MDS); mesothelioma; myeloproliferative disorder (MPD) (e.g., polycythemia vera (PV), essential thrombocytosis (ET), agnogenic myeloid metaplasia (AMM) a.k.a. myelofibrosis (MF), chronic idiopathic myelofibrosis, chronic myelocytic leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES)); neuroblastoma; neurofibroma (e.g., neurofibromatosis (NF) type 1 or type 2, schwannomatosis); neuroendocrine cancer (e.g., gastroenteropancreatic neuroendoctrine tumor (GEP-NET), carcinoid tumor); osteosarcoma (e.g.,bone cancer); ovarian cancer (e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma); papillary adenocarcinoma; pancreatic cancer (e.g., pancreatic andenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), Islet cell tumors); penile cancer (e.g., Paget’s disease of the penis and scrotum); pinealoma; primitive neuroectodermal tumor (PNT); plasma cell neoplasia; paraneoplastic syndromes; intraepithelial neoplasms; prostate cancer (e.g., prostate adenocarcinoma); rectal cancer; rhabdomyosarcoma; salivary gland cancer; skin cancer (e.g., squamous cell carcinoma (SCC), keratoacanthoma (KA), melanoma, basal cell carcinoma (BCC)); small bowel cancer (e.g., appendix cancer); soft tissue sarcoma (e.g., malignant fibrous histiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath tumor (MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma); sebaceous gland carcinoma; small intestine cancer; sweat gland carcinoma; synovioma; testicular cancer (e.g., seminoma, testicular embryonal carcinoma); thyroid cancer (e.g., papillary carcinoma of the thyroid, papillary thyroid carcinoma (PTC), medullary thyroid cancer); urethral cancer; vaginal cancer; and vulvar cancer (e.g., Paget’s disease of the vulva).

[0055] The term “immunotherapy” refers to a treatment of disease by inducing, enhancing, or suppressing an immune response. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress an immune response are classified as suppression immunotherapies. Immunotherapy may encompass treatment with a molecular entity (e.g., immunotherapeutic agent) and / or a non-molecular entity (e.g., adoptive cell transfer).W0571.70067WO0021 / 202

[0056] The term “macrophage-directed immunotherapy” refers to an immunotherapy that derives its therapeutic effect by stimulating macrophages. Such stimulation can mobilize macrophage and myeloid components to destroy a tumor and its stroma, including the tumor vasculature. Macrophages can be induced to secrete antitumor cytokines and / or to perform phagocytosis, including antibody-dependent cellular phagocytosis.

[0057] The term “immunotherapeutic agent” refers to a molecular entity that induces, enhances, or suppresses an immune response. Immunotherapeutic agents include, but are not limited to, monoclonal antibodies, cytokines, chemokines, vaccines, small molecule inhibitors, and small molecule agonists.

[0058] The term “immune checkpoint inhibitor” refers to an agent that blocks certain proteins made by some types of immune system cells (e.g., T cells, macrophages) and some cancer cells. These proteins function to keep immune responses in check and can also function to keep immune system cells (e.g., T cells, macrophages) from killing cancer cells. When these proteins are blocked, immune system function is restored and the immune system is released enabling the desired immune system cells to kill cancer cells. Some immune checkpoint inhibitors are useful in treating cancer. A “macrophage immune checkpoint inhibitor” functions to stimulate macrophage phagocytosis of cancer cells. For example, CD47 is associated with a macrophage immune checkpoint (CD47 / SIRPα as described herein). CD47- blocking therapies thus stimulate macrophage phagocytosis of cancer cells and are effective in treating cancer.

[0059] An “autoimmune disease” refers to a disease arising from an inappropriate immune response of the body of a subject against substances and tissues normally present in the body. In other words, the immune system mistakes some part of the body as a pathogen and attacks its own cells. This may be restricted to certain organs (e.g., in autoimmune thyroiditis) or involve a particular tissue in different places (e.g., Goodpasture’s disease which may affect the basement membrane in both the lung and kidney). The treatment of autoimmune diseases is typically with immunosuppression, e.g., medications which decrease the immune response. Exemplary autoimmune diseases include, but are not limited to, glomerulonephritis, Goodpasture’s syndrome, necrotizing vasculitis, lymphadenitis, peri-arteritis nodosa, systemic lupus erythematosis, rheumatoid arthritis, psoriatic arthritis, , psoriasis, ulcerative colitis, systemic sclerosis, dermatomyositis / polymyositis, anti-phospholipid antibody syndrome, scleroderma, pemphigus vulgaris, ANCA-associated vasculitis (e.g., Wegener’s granulomatosis, microscopic polyangiitis), uveitis, Sjogren’s syndrome, Crohn’s disease,W0571.70067WO0022 / 202Reiter’s syndrome, ankylosing spondylitis, Lyme disease, Guillain-Barré syndrome, Hashimoto’s thyroiditis, and cardiomyopathy.

[0060] The terms “biologic,” “biologic drug,” and “biological product” refer to a wide range of products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, nucleic acids, and proteins. Biologics may include sugars, proteins, or nucleic acids, or complex combinations of these substances, or may be living entities such as cells and tissues. Biologics may be isolated from a variety of natural sources (e.g., human, animal, microorganism) and / or may be produced by biotechnological methods and / or other technologies.

[0061] The term “antibody” refers to a functional component of serum and is often referred to either as a collection of molecules (antibodies or immunoglobulins) or as one molecule (the antibody molecule or immunoglobulin molecule). An antibody is capable of binding to or reacting with a specific antigenic determinant (the antigen or the antigenic epitope), which in turn may lead to induction of immunological effector mechanisms. Each antibody has a unique structure that enables it to bind specifically to its corresponding antigen, or antigens. Antibodies are also known collectively as immunoglobulins. An antibody may be of human or non-human (for example, rodent such as murine, dog, camel, etc) origin (e.g., may have a sequence originally developed in a human or non-human cell or organism), or may be or comprise a chimeric, humanized, reshaped, or reformatted antibody based, e.g., on a such a human or non-human antibody (or, in some embodiments, on an antigen-binding portion thereof).

[0062] All natural antibodies have the same overall basic structure of an immunoglobulin (Ig) molecule comprised of four polypeptide chains, two heavy (H) chains and two light (L) chains, or any functional fragment, mutant, variant, or derivation thereof, which retains the essential epitope binding features of an Ig molecule. Such mutant, variant, or derivative antibody formats are known in the art. Such mutants, variants, or derivatives may be a single- domain antibody, a Fab fragment, scFv, affibody, nanobody, peptide, DARPin, adnectin, anticalin, or fragment thereof.

[0063] In a full-length antibody, each heavy chain is comprised of a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, CH1, CH2 and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as LCVR or VL) and a light chain constant region. The light chain constant region is comprised of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, termedW0571.70067WO0023 / 202complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. Immunoglobulin molecules can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG 1, IgG2, IgG 3, IgG4, IgA1 and IgA2) or subclass.

[0064] The term “antigen-binding domain” as used herein, refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Such antibody embodiments may also be bispecific, dual specific, or multi-specific formats; specifically binding to two or more different antigens. Multispecific, dual specific, and bispecific antibody constructs are well known in the art and described and characterized in Kontermann (ed.), Bispecific Antibodies, Springer, NY (2011), and Spiess et al., Mol. Immunol.67(2):96-106 (2015).

[0065] Examples of binding fragments encompassed within the term “antigen-binding portion” of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) Nature 341:544-546, Winter et al., PCT publication WO 90 / 05144 A1 herein incorporated by reference), which comprises a single variable domain; and (vi) an isolated complementarity determining region (CDR). Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883). Such single chain antibodies are also intended to be encompassed within the term “antigen- binding portion” of an antibody. Other forms of single chain antibodies, such as diabodies are also encompassed. Diabodies are bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites (see e.g., Holliger, P., et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak, R. J., etW0571.70067WO0024 / 202al. (1994) Structure 2:1121-1123). Such antibody binding portions are known in the art (Kontermann and Dubel eds., Antibody Engineering (2001) Springer-Verlag. New York.790 pp. (ISBN 3-540-41354-5).

[0066] An “antibody heavy chain,” as used herein, refers to the larger of the two types of polypeptide chains present in all antibody molecules in their naturally occurring conformations.

[0067] An “antibody light chain,” as used herein, refers to the smaller of the two types of polypeptide chains present in all antibody molecules in their naturally occurring conformations, kappa and lambda light chains refer to the two major antibody light chain isotypes.

[0068] The term “synthetic antibody” as used herein, refers an antibody which is generated using recombinant DNA technology, such as, for example, an antibody expressed by a viral vector. The term should also be construed to mean an antibody which has been generated by the synthesis of a DNA molecule encoding the antibody and which DNA molecule expresses an antibody protein, or an amino acid sequence specifying the antibody, wherein the DNA or amino acid sequence has been obtained using synthetic DNA or amino acid sequence technology which is available and well known in the art.

[0069] In some embodiments, the term “antigen” or “Ag” as used herein is defined as a molecule that provokes an immune response. This immune response may involve either antibody production, or the activation of specific immunologically competent cells, or both. The skilled artisan will understand that any macromolecule, including virtually all proteins or peptides, can serve as an antigen. Furthermore, antigens can be derived from recombinant or genomic DNA. A skilled artisan will understand that any DNA, which comprises a nucleotide sequences or a partial nucleotide sequence encoding a protein that elicits an immune response therefore encodes an “antigen” as that term is used herein. Furthermore, one skilled in the art will understand that an antigen need not be encoded solely by a full-length nucleotide sequence of a gene. It is readily apparent that the present invention includes, but is not limited to, the use of partial nucleotide sequences of more than one gene and that these nucleotide sequences are arranged in various combinations to elicit the desired immune response. Moreover, a skilled artisan will understand that an antigen need not be encoded by a “gene” at all. It is readily apparent that an antigen can be generated synthesized or can be derived from a biological sample. Such a biological sample can include, but is not limited to a tissue sample, a tumor sample, a cell or a biological fluid.W0571.70067WO0025 / 202

[0070] In some embodiments, as will be clear from context, the term “antibody” as used herein encompasses formats that include epitope-binding sequences of an antibody, which such formats include, for example chimeric and / or single chain antibodies (e.g., a nanobody or Fcab), as well as binding fragments of antibodies, such as Fab, Fv fragments or single chain Fv (scFv) fragments, as well as multimeric forms such as dimeric IgA molecules or pentavalent IgM molecules. Also included are bispecific antibodies, bispecific T cell engagers (BiTEs), immune mobilizing monoclonal T cell receptors against cancer (ImmTACs), dual-affinity re-targeting (DART); alternative scaffolds or antibody mimetics (e.g., anticalins, FN3 monobodies, DARPins, Affibodies, Affilins, Affimers, Affitins, Alphabodies, Avimers, Fynomers, Im7, VLR, VNAR, Trimab, CrossMab, Trident); nanobodies, binanobodies, F(ab’)2, Fab’, di-sdFv, single domain antibodies, trifunctional antibodies, diabodies, and minibodies.

[0071] The term “therapeutic agent” refers to an agent having one or more therapeutic properties that produce a desired, usually beneficial, effect. For example, a therapeutic agent may treat, ameliorate, and / or prevent disease. In some embodiments, a therapeutic agent may be or comprise a biologic, a small molecule, or a combination thereof.

[0072] The term “chemotherapeutic agent” refers to a therapeutic agent known to be of use in chemotherapy for cancer.

[0073] The term “targeted agent” refers to an anticancer agent that blocks the growth and spread of cancer by interfering with specific proteins ("molecular targets") that are involved in the growth, progression, and spread of cancer. Targeted agents are sometimes called “targeted therapies,” “targeted cancer therapies,” "molecularly targeted drugs," "molecularly targeted therapies," or "precision medicines." Targeted agents differ from standard chemotherapy in that targeted agents act on specific molecular targets that are associated with cancer, whereas many chemotherapeutic agents act on all rapidly dividing cells (e.g., whether or not the cells are cancerous). Targeted agents are deliberately chosen or designed to interact with their target, whereas many standard chemotherapies are identified because they may indiscriminately kill cells.

[0074] A “cell” or “target cell” as used herein, may be present in a population of cells (e.g., in a tissue, an organ, or an organoid). In some embodiments, a population of cells is composed of a plurality of cell types. Cells for use in the methods of the present disclosure can be present within an organism, a single cell type derived from an organism, or a mixture of cell types. Included are naturally occurring cells and cell populations, genetically engineered cell lines, cells derived from transgenic animals, etc. Virtually any cell type andW0571.70067WO0026 / 202size can be accommodated in the methods and systems described herein. Suitable cells include bacterial, fungal, plant, and animal cells. In some embodiments, the cells are mammalian cells (e.g., complex cell populations such as naturally occurring tissues). In some embodiments, the cells are from a human. In certain embodiments, the cells are collected from a subject (e.g., a human) through a medical procedure such as a biopsy. Alternatively, the cells may be a cultured population (e.g., a culture derived from a complex population or a culture derived from a single cell type where the cells have differentiated into multiple lineages).

[0075] In particular, the term “target cell” refers to a cell (e.g., inflicted cells such as cancer cells, infected cells, etc.) that is targeted for phagocytosis by a macrophage. The target cell can be any cell as described herein. Examples of target cells include but are not limited to neoplastic cells, such as cancer cells, and disease associated cells. Examples of cancers include but are not limited to solid tumors, breast cancer, pancreatic cancer, colon cancer, non-small cell lung cancer, leukemias, lymphomas, such as mantle cell lymphoma, and myelomas, such as multiple myeloma. The term “cancer cells” can also be used to refer to cancer or tumor cell lines.

[0076] The terms “assessing”, “determining”, “evaluating”, and “assaying” are used interchangeably herein to refer to any form of detection or measurement, and include determining whether a substance, signal, enzymatic activity, disease, condition, etc., is present or not. The result of an assessment may be expressed in qualitative and / or quantitative terms. Assessing may be relative or absolute. “Assessing the presence of” includes determining the amount of something that is present or determining whether it is present or absent.

[0077] Unless otherwise required by context, singular terms shall include pluralities, and plural terms shall include the singular. DETAILEDDESCRIPTION OFCERTAINEMBODIMENTS

[0078] B-cell non-Hodgkin lymphoma is the most common hematologic malignancy worldwide and remains with a large, unmet clinical need. It is a highly heterogeneous disease, with multiple subtypes distinguished by variations in both genetic alterations and the immune microenvironment1,2. Diffuse Large B Cell Lymphoma (DLBCL) is the most common subtype and accounts for approximately 35% of all B cell lymphomas. Despite advances in frontline rituximab-based chemoimmunotherapy (e.g., R-CHOP), a significant proportion of patients become refractory or relapse after the first line of treatment3.W0571.70067WO0027 / 202Subsequent treatment strategies have focused on promoting T-cell cytotoxicity, such as CAR T-cell therapy and bispecific T cell engagers. However, these therapies only cure a subset of patients4,5, and many patients exhibit inadequate T-cell infiltration and function6–8. Additionally, more than 50% of B cell lymphomas exhibit genetic alterations that cause these cells to evade recognition by T cells, such as downregulation or loss of the Major Histocompatibility Complex (MHC) antigen presentation machinery or overexpression of immune checkpoint receptors.9While these lymphomas may be less vulnerable to T-cell- dependent killing, these features create opportunities for orthogonal approaches that target innate immune cells, particularly macrophages.

[0079] In B-cell lymphoma, the presence of CD68+ macrophages was linked to favorable prognosis in patients treated with R-CHOP, while it correlated with poor outcomes in the absence of rituximab10. Antibody-dependent phagocytosis (ADCP) is a major mechanism that contributes to the efficacy of rituximab in vivo11, likely underlying this effect. However, ADCP is often limited by the CD47 / SIRPa macrophage immune checkpoint. CD47 is a cell- surface antigen expressed by many normal and neoplastic tissues and acts as a “don’t eat me signal” to prevent macrophage phagocytosis12. Therapies that block the CD47 / SIRPa interaction can enhance ADCP and synergize with rituximab for B-cell lymphoma in preclinical models13-15. These therapies have moved into clinical trials and show encouraging signs of activity in patients with B-cell malignancies16. Similarly, downregulation of MHC-I may make lymphoma cells more vulnerable to macrophage phagocytosis in the presence of tumor-opsonizing antibodies or CD47-blocking therapies17.

[0080] Despite the success of monoclonal antibodies for hematologic malignancies, there have been limited efforts to identify novel antibodies that stimulate macrophages to attack lymphoma cells. To address this limitation, a high-throughput platform to screen libraries of monoclonal antibodies to diverse surface antigens on B-cell lymphoma cells was developed. This approach is target agnostic and “function first” to identify and prioritize novel antibodies that stimulate macrophages to attack and eliminate lymphoma cells. Screens across both the murine and human systems to identify the most effective antibodies for inducing macrophage-mediated cytotoxicity of lymphoma cells were performed. The results from these screens were used to engineer an extensive collection of bispecific antibodies (bsAbs) that could maximally activate macrophage anti-tumor functions against aggressive B-cell lymphomas.W0571.70067WO0028 / 202

[0081] Provided herein are therapeutic strategies and therapeutic agents to provoke macrophages to attack B-cell lymphoma. These efforts can be translated to the clinic and be rapidly applied to identify new therapies for other types of cancer.

[0082] Screens were conducted using each antibody as a single agent, in combination with anti-CD20, or in combination with anti-CD47. From these efforts, CD24, CD38, CXCR4, CD71, and multiple other novel and unique antigens that could be targeted alone or in combination to exert maximal macrophage-mediated destruction of B-cell lymphoma were identified. Of note, some of the identified targets are predominantly expressed by the lymphoma cells, whereas others are expressed by the macrophages and act as unappreciated immune checkpoints.

[0083] In validation studies, a multitude of new antibody combinations that robustly stimulate macrophages to attack and eliminate lymphoma cells were defined. Since some anti-CD47-antibodies have been limited by on-target hematologic toxicity, the identified targets were used to engineer an extensive collection of novel bispecific antibodies that maximally activate macrophage anti-tumor functions against B-cell lymphoma without causing hematologic toxicity.156 bispecific antibodies were produced recombinantly and demonstrated maximal macrophage-mediated cytotoxicity of human B-cell lymphoma cells while minimizing binding to healthy blood cells. In mouse xenograft models, these bispecific antibodies exhibited significant single-agent activity in a model of aggressive B-cell lymphoma. Thus, this assessment has led to the development of new therapeutic strategies, therapeutic agents, and combination strategies to provoke macrophages to attack B-cell lymphoma and that can be developed further to maximize anti-tumor function and benefit patients with lymphoma. Furthermore, this approach can be rapidly applied to other hematologic malignancies to create innovative bispecific agents that maximize anti-tumor responses by macrophages or other innate immune cells. These efforts can be translated to the clinic, and it is expected that this approach can be rapidly applied to identify new therapies for other hematologic malignancies.

[0084] In one aspect of the present disclosure, provided is a composition comprising one or more first antigen targeting molecules and for the treatment of proliferative disease.

[0085] In some embodiments, the composition further comprises one or more second antigen targeting molecules.

[0086] In some embodiments, the one or more first antigen targeting molecules and / or the one or more second targeting molecules target an antigen selected from CD20, CD22, CD27, CD38, CD47, CD71, CD79b, CD95, CXCR4, CD45RB, CD45RA, CD147, CD98, CD184,W0571.70067WO0029 / 202CD11b, 4-1BBL, Ly6A / E, HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DP, HLA-DO, HLA- (A,B,C), HLA-(DR,DP,DQ), MHC I, CD24, CALR, CD40, PD-L1, APMAP, GPR84, VCAM1, CD11b, SIGLEC-10, PD-L2 , PD-1, B2M, CD73, Galectin-9, CD14, CD80, CD86, SIRPb, SIRPg, SLAMF7, MARCO, AXL, CLEVER-1, ILT4, TIM-3, TIM-4, LRP-1, calreticulin, TREM1, TREM2, GD2, FcgRI, FcgRIIa, FcgRIIb, FcgRIII, MUC1, CD44, CD63, CD36, CD84, CD164, CD82, CD18, SIGLEC-7, CD166, CD39, CD46, LILRA1, LILRA2, LILRA3, LILRA4, LILRB1(CD85), LILRB2, LILRB3, LILRB4, LILRB5, CD85j, CD85b, CD85f, CD85m, CD276, CD88, CD99, PILRa, Siglec-9, CD206, CD163, CD84, C3aR, and CLEC12A.

[0087] In embodiments, the one or more first antigen targeting molecules and one or more second targeting molecules target an antigen selected from CD20, CD24, CD24-2, CD38, CD40, CD71, CD95, CXCR4, PD-1, CD79b, CD85j, CD47, CD45RB, CD45RA, β2M, CD147, CD98, CD184, HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DP, HLA-DO, HLA- (A,B,C), and HLA-(DR,DP,DQ).

[0088] In some embodiments, the one or more first antigen targeting molecules is selected from CD47, CD20, CD85j, and CD38.

[0089] In some embodiments, the one or more first antigen targeting molecules target an antigen selected from CD20, CD47, CD85j, and CD38, and one or more second targeting molecules target an antigen selected from CD20, CD24, CD24-2, CD38, CD40, CD71, CD95, CXCR4, PD-1, CD79b, CD85j, CD47, CD45RB, CD45RA, β2M, CD147, CD98, CD184, HLA-DR, HLA-(A, B, C), and HLA-(DR, DP, DQ).

[0090] In some embodiments, the one or more first antigen targeting molecules is selected from CD20, CD47, CD85j, and CD38, and one or more second targeting molecules target an antigen selected from CD20, CD24, CD24-2, CD38, CD40, CD71, CD95, PD-1, CD79b, CD85j, CD47, CD147, and CD184.

[0091] In some embodiments, the one or more first antigen targeting molecules targets CD47.

[0092] In some embodiments, the one or more first antigen targeting molecules targets CD47 and one or more second targeting molecules target an antigen selected from CD20, CD24, CD24-2, CD38, CD40, CD71, PD-1 CD85j, CD147, and CD184.

[0093] In some embodiments, the one or more first antigen targeting molecules targets CD85j.

[0094] In some embodiments, the one or more first antigen targeting molecules targets CD85j and one or more second targeting molecules target an antigen selected from CD20, CD40, CD38, CD71, CD47, CD147, and CD184.W0571.70067WO0030 / 202

[0095] In some embodiments, the one or more first antigen targeting molecules targets CD85j and one or more second targeting molecules target an antigen selected from CD38, CD47, CD71, and CD147.

[0096] In some embodiments, the one or more first antigen targeting molecules targets CD38.

[0097] In some embodiments, the one or more first antigen targeting molecules targets CD38 and one or more second targeting molecules target an antigen selected from CD20, CD24, CD24-2, CD38, CD-79b, CD40, CD71, CD95, PD-1, CD79b, CD85j, CD47, CD147, and CD184.

[0098] In some embodiments, the one or more first antigen targeting molecules targets CD20.

[0099] In some embodiments, the one or more first antigen targeting molecules targets CD20 and one or more second targeting molecules target an antigen selected from CD24, CD24-2, CD38, CD40, CD71, CD95, PD-1, CD79b, CD85j, CD47, CD147, and CD184.

[0100] In some embodiments, the one or more first antigen targeting molecules targets CD20 and one or more second targeting molecules target an antigen selected from CD38 and CD184.

[0101] In some embodiments, the one or more first antigen targeting molecules and one or more second antigen targeting molecules are selected from antibody, single-domain antibody, a Fab fragment, scFv, affibody, nanobody, peptide, DARPin, adnectin, anticalin, or fragment thereof.

[0102] In some embodiments, the one or more first antigen targeting molecules and one or more second antigen targeting molecules are operably linked to each other.

[0103] In some embodiments, the one or more first antigen targeting molecules and one or more antigen second targeting molecules are operably linked to each other by a covalent linker.

[0104] In some embodiments, the one or more first antigen targeting molecules and one or more second antigen targeting molecules are antibodies.

[0105] In some embodiments, the antibodies are selected from an anti-CD85j antibody, an anti-CD20 antibody, an anti-CD38 antibody, an anti-CD71 antibody, an anti-CD79b antibody, an anti-CD95 antibody, an anti-CXCR4 antibody, an anti-CD45RB antibody, an anti-CD45RA antibody, an anti-CD147 antibody, an anti-CD98 antibody, an anti-CD184 antibody, an anti-HLA-A antibody, an anti-HLA-B antibody, an anti-HLA-C antibody, an anti-HLA-DR antibody, an anti-HLA-DP antibody, an anti-HLA-DQ antibody, an anti-HLA- (A,B,C) antibody, an anti-HLA-(DR,DP,DQ) antibody, an anti-CD47 antibody, an anti- SIRPα antibody, a SIRPα-Fc fusion protein, an anti-MHC I antibody, an anti-CD24 antibody,W0571.70067WO0031 / 202an anti-CALR antibody, an anti-CD40 antibody, an anti-PD-L1 antibody, an anti-APMAP antibody, an anti-GPR84 antibody, an anti-VCAM1 antibody, an anti-CD11b antibody, an anti-SIGLEC-10 antibody, an anti-PD-L2 antibody, an anti-PD-1 antibody, an anti-B2M antibody, an anti-CD73 antibody, an anti-Galectin-9 antibody, an anti-CD14 antibody, an anti-CD80 antibody, an anti-CD86 antibody, an anti-SIRPb antibody, an anti-SIRPg antibody, an anti-SLAMF7 antibody, an anti-MARCO antibody, an anti-AXL antibody, an anti-CLEVER-1 antibody, an anti-ILT4 antibody, an anti-TIM-3 antibody, an anti-TIM-4 antibody, an anti-LRP-1 antibody, an anti-calreticulin antibody, an anti-TREM1 antibody, an anti-TREM2 antibody, an anti-GD2 antibody, an anti-FcgRI antibody, an anti-FcgRIIa antibody, an anti-FcgRIIb antibody, an anti-FcgRIII antibody, an anti-MUC1 antibody, an anti-CD44 antibody, an anti-CD63 antibody, an anti-CD36 antibody, an anti-CD84 antibody, an anti-CD164 antibody, an anti-CD82 antibody, an anti-CD18 antibody, an anti-SIGLEC-7 antibody, an anti-CD166 antibody, an anti-CD39 antibody, an anti-CD46 antibody, an anti- LILRA1 antibody, an anti-LILRA2 antibody, an anti-LILRA3 antibody, an anti-LILRA4 antibody, an anti-LILRB1 antibody (an anti-CD85 antibody), an anti-LILRB2 antibody, an anti-LILRB3 antibody, an anti-LILRB4 antibody, an anti-LILRB5 antibody, an anti-CD85b antibody, an anti-CD85m antibody, an anti-CD85f antibody, an anti-CD276 antibody, an anti-CD88 antibody, an anti-CD99 antibody, an anti-PILRa antibody, an anti-Siglec-9 antibody, an anti-CD206 antibody, an anti-CD163 antibody, an anti-CD84 antibody, an anti- C3aR antibody, and an anti-CLEC12A antibody.

[0106] In some embodiments, the antibodies are selected from an anti-CD85 antibody, an anti-CD85j antibody, an anti-CD20 antibody, an anti-CD38 antibody, an anti-CD71 antibody, an anti-CD79b antibody, an anti-CD95 antibody, an anti-CXCR4 antibody, an anti-CD45RB antibody, an anti-CD45RA antibody, an anti-CD147 antibody, an anti-CD98 antibody, an anti-CD184 antibody, HLA-A antibody, an anti-HLA-B antibody, an anti-HLA-C antibody, an anti-HLA-DR antibody, an anti-HLA-DP antibody, an anti-HLA-DQ antibody, an anti- HLA-(A,B,C) antibody, an anti-HLA-(DR,DP,DQ) antibody, an anti-CD47 antibody, an anti-SIRPα antibody, a SIRPα-Fc fusion protein, an anti-MHC I antibody, an anti-CD24 antibody, an anti-CD24-2, antibody, an anti-CD40 antibody, an anti-PD-L1 antibody, an anti- PD-L2 antibody, an anti-PD-1 antibody, an anti-B2M antibody, an anti-SIRPb antibody, an anti-SIRPg antibody, an anti-CD85b antibody, an anti-CD85m antibody, and an anti-CD85f antibody.

[0107] In some embodiments, at least one antibody binds an antigen on a cell.

[0108] In some embodiments, the cell is a human cell.W0571.70067WO0032 / 202

[0109] In some embodiments, the human cell is an immune cell.

[0110] In some embodiments, the immune cell is a macrophage.

[0111] In some embodiments, the cell is a cancer cell.

[0112] In some embodiments, the cancer cell is a lymphoma cell.

[0113] In some embodiments, the lymphoma cell is a B-cell lymphoma cell.

[0114] In some embodiments, the cancer cell is a B-cell lymphoma cell.

[0115] In some embodiments, the cancer cell is therapy resistant. For example, the therapy resistant cancer cells can have reduced or absent MHC activity via mutation or knock-out of the MHC genes.

[0116] In some embodiments, the wherein the cell is a lymphoma cell or a macrophage.

[0117] In some embodiments, the antibodies comprise an amino acid sequence at least 85% identical, or optionally 90% identical, or optionally 95% identical to the amino acid sequences set forth in the CDR and binding features of SEQ ID NOs: 1-25. In some embodiments, the antibodies comprise an amino acid sequence at least 85% identical to the amino acid sequences set forth in the CDR and binding features of SEQ ID NOs: 1-25. In some embodiments, the antibodies comprise an amino acid sequence at least 90% identical to the amino acid sequences set forth in the CDR and binding features of SEQ ID NOs: 1-25. In some embodiments, the antibodies comprise an amino acid sequence at least 95% identical to the amino acid sequences set forth in the CDR and binding features of SEQ ID NOs: 1-25. In some embodiments, the antibodies comprise an amino acid sequence at least 99% identical to the amino acid sequences set forth in the CDR and binding features of SEQ ID NOs: 1-25. In some embodiments, the antibodies comprise the CDRs of SEQ ID NOs: 1-25.

[0118] In some embodiments, composition comprises at least one of SEQ ID NOs: 1-12.

[0119] In some embodiments, the composition contains at least one of SEQ ID NOs: 13-25.

[0120] In some embodiments, the composition further comprises at least two of SEQ ID NOs: 1-25.

[0121] In some embodiments, the proliferative disease is cancer.

[0122] In some embodiments, the cancer is selected from the following: B-cell malignancies that include Hodgkin Lymphoma, specifically Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL); Non-Hodgkin Lymphomas (NHL) such as Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma (Nodal, Extranodal MALT, and Splenic), Small Lymphocytic Lymphoma (SLL), Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Intravascular Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma (including Waldenström'sW0571.70067WO0033 / 202Macroglobulinemia), Primary Effusion Lymphoma, and Hairy Cell Leukemia. Additionally, there are Chronic Lymphocytic Leukemia (CLL), B-cell precursor Acute Lymphoblastic Leukemia (B-ALL), Plasma Cell Neoplasms such as Multiple Myeloma, Solitary Plasmacytoma, Monoclonal Gammopathy of Undetermined Significance (MGUS), and POEMS syndrome. Other rare B-cell malignancies include B-cell Prolymphocytic Leukemia (B-PLL), Splenic Diffuse Red Pulp Small B-cell Lymphoma, and Lymphomatoid Granulomatosis.

[0123] Myeloid malignancies include Acute Myeloid Leukemia (AML) with various subtypes, Chronic Myeloproliferative Neoplasms (MPNs) such as Chronic Myeloid Leukemia (CML), Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary Myelofibrosis (PMF), Chronic Neutrophilic Leukemia (CNL), Chronic Eosinophilic Leukemia (CEL-NOS), and Myeloproliferative Neoplasm, unclassifiable (MPN-U). Myelodysplastic Syndromes (MDS) include MDS with single lineage dysplasia, multilineage dysplasia, ring sideroblasts, isolated del(5q), excess blasts, and MDS, unclassifiable. Myelodysplastic / Myeloproliferative Neoplasms (MDS / MPN) include Chronic Myelomonocytic Leukemia (CMML), Atypical Chronic Myeloid Leukemia (aCML), Juvenile Myelomonocytic Leukemia (JMML), and MDS / MPN, unclassifiable. Other rare myeloid malignancies are Mastocytosis, Myeloid Sarcoma, and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Pathologic B cells; and Pathologic myeloid cells.

[0124] For example, LILRB1(CD85j)-targeting therapy could deplete pathologic myeloid cells in solid tumors as a therapeutic strategy. It could also be used for B-cell or myeloid- driven chronic inflammatory syndromes and autoimmune diseases

[0125] In another aspect, provided is one or more nucleic acid constructs encoding the composition of the present disclosure.

[0126] In some embodiments, the nucleic acid comprises DNA or RNA.

[0127] In some embodiments, the nucleic acid construct comprises DNA.

[0128] In some embodiments, the nucleic acid construct comprises RNA.

[0129] In some embodiments, the nucleic acid construct comprises a sequence at least 85% identical, or optionally 90% identical, or optionally 95% identical to a nucleotide sequence encoding a feature of SEQ ID NOs: 1-25. In some embodiments, the nucleic acid construct comprises a sequence at least 85% identical to a nucleotide sequence encoding a feature of SEQ ID NOs: 1-25. In some embodiments, the nucleic acid construct comprises a sequence at least 90% identical to a nucleotide sequence encoding a feature of SEQ ID NOs: 1-25. In some embodiments, the nucleic acid construct comprises a sequence at least 95% identical toW0571.70067WO0034 / 202a nucleotide sequence encoding a feature of SEQ ID NOs: 1-25. In some embodiments, the nucleic acid construct comprises a sequence at least 99% identical to a nucleotide sequence encoding a feature of SEQ ID NOs: 1-25. In some embodiments, the nucleic acid construct comprises a sequence at least 100% identical to a nucleotide sequence encoding a feature of SEQ ID NOs: 1-25.

[0130] In one aspect of the present disclosure, provided is a vector comprising the nucleic acid of the present disclosure.

[0131] In another aspect, provided is a cell comprising the nucleic acid or the vector of the present disclosure.

[0132] In some embodiments, the cell is an animal cell.

[0133] In some embodiments, the cell is a human cell.

[0134] In some embodiments, the cell is an immune cell.

[0135] In some embodiments, the immune cell is a T-cell.

[0136] In one aspect, provided is a method for treating proliferative disease in a subject in need thereof, the method comprising administering to a subject an effective amount of two or more antigen targeting molecules wherein the first and second antigen targeting molecules of the two or more antigen targeting molecules are selected from the group consisting of (a) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 1; (b) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 2; (c) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 3; (d) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 4; (e) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 5; (f) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 6; (g) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 7; (h) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 8;W0571.70067WO0035 / 202(i) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 9; (j) a single chain binding arm comprising CV1 (a high-affinity SIRPa decoy protein) of the amino acid sequence of SEQ ID NO: 10; (k) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 11; (l) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 12; (m) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 13; (n) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 14; (o) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 15; (p) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 16; (q) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 17; (r) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 18; (s) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 19; (t) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 20; (u) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 21; (v) a single chain binding arm comprising CV1 (a high-affinity SIRPa decoy protein) of the amino acid sequence of SEQ ID NO: 22; (w) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 23; (x) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 24; and (y) a single chain binding arm comprising WTa2d1 (a low-affinity SIRPa decoy protein) of the amino acid sequence of SEQ ID NO: 25.W0571.70067WO0036 / 202

[0137] In some embodiments, the two or more antigen targeting molecules comprise first and second antigen targeting molecules wherein the two or more antigen targeting molecules are selected from the group consisting of (aa) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 1; (bb) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 2; (cc) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 3; (dd) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 4; (ee) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 5; (ff) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 6; (gg) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 7; (hh) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 8; (ii) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 9; (jj) a single chain binding arm comprising CV1 (a high-affinity SIRPa decoy protein) of the amino acid sequence of SEQ ID NO: 10; (kk) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 11; (ll) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 12; (mm) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 13; (nn) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 14; (oo) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 15;W0571.70067WO0037 / 202(pp) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 16; (qq) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 17; (rr) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 18; (ss) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 19; (tt) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 20; (uu) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 21; (vv) a single chain binding arm comprising CV1 (a high-affinity SIRPa decoy protein) of the amino acid sequence of SEQ ID NO: 22; (ww) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 23; (xx) an antibody comprising HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 24; and (yy) a single chain binding arm comprising WTa2d1 (a low-affinity SIRPa decoy protein) of the amino acid sequence of SEQ ID NO: 25.

[0138] In some embodiments, the proliferative disease is cancer.

[0139] In some embodiments, the cancer is lymphoma.

[0140] In other embodiments, the cancer is selected from the group consisting of B-cell malignancies that include Hodgkin Lymphoma, specifically Nodular Lymphocyte- Predominant Hodgkin Lymphoma (NLPHL); Non-Hodgkin Lymphomas (NHL) such as Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma (Nodal, Extranodal MALT, and Splenic), Small Lymphocytic Lymphoma (SLL), Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Intravascular Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma (including Waldenström's Macroglobulinemia), Primary Effusion Lymphoma, and Hairy Cell Leukemia. Additionally, there are Chronic Lymphocytic Leukemia (CLL), B-cell precursor Acute Lymphoblastic Leukemia (B-ALL), Plasma Cell Neoplasms such as Multiple Myeloma, Solitary Plasmacytoma, Monoclonal Gammopathy of Undetermined SignificanceW0571.70067WO0038 / 202(MGUS), and POEMS syndrome. Other rare B-cell malignancies include B-cell Prolymphocytic Leukemia (B-PLL), Splenic Diffuse Red Pulp Small B-cell Lymphoma, and Lymphomatoid Granulomatosis.

[0141] Myeloid malignancies include Acute Myeloid Leukemia (AML) with various subtypes, Chronic Myeloproliferative Neoplasms (MPNs) such as Chronic Myeloid Leukemia (CML), Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary Myelofibrosis (PMF), Chronic Neutrophilic Leukemia (CNL), Chronic Eosinophilic Leukemia (CEL-NOS), and Myeloproliferative Neoplasm, unclassifiable (MPN-U). Myelodysplastic Syndromes (MDS) include MDS with single lineage dysplasia, multilineage dysplasia, ring sideroblasts, isolated del(5q), excess blasts, and MDS, unclassifiable. Myelodysplastic / Myeloproliferative Neoplasms (MDS / MPN) include Chronic Myelomonocytic Leukemia (CMML), Atypical Chronic Myeloid Leukemia (aCML), Juvenile Myelomonocytic Leukemia (JMML), and MDS / MPN, unclassifiable. Other rare myeloid malignancies are Mastocytosis, Myeloid Sarcoma, and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Pathologic B cells; and Pathologic myeloid cells. Bispecific Antibodies

[0142] In another aspect, provided is a bispecific antibody comprising a first antigen- binding domain and a second antigen-binding domain, wherein each antigen-binding domain independently targets CD20, CD38, CD47, CD71, CD79b, CD95, CXCR4, CD45RB, CD45RA, CD147, CD98, CD184, HLA-DR, HLA-(A,B,C), HLA-(DR,DP,DQ), MHC I, CD24, CALR, CD40, PD-L1, APMAP, GPR84, VCAM1, CD11b, SIGLEC-10, PD-L2 , PD- 1, B2M, CD73, Galectin-9, CD14, CD80, CD86, SIRPb, SIRPg, SLAMF7, MARCO, AXL, CLEVER-1, ILT4, TIM-3, TIM-4, LRP-1, calreticulin, TREM1, TREM2, GD2, FcgRI, FcgRIIa, FcgRIIb, FcgRIII, MUC1, CD44, CD63, CD36, CD84, CD164, CD82, CD18, SIGLEC-7, CD166, CD39, CD46, LILRA1, LILRA2, LILRA3, LILRA4, LILRB1(CD85j), LILRB2, LILRB3, LILRB4, LILRB5, CD85, CD85j, CD85b, CD85, CD85f, CD276, CD88, CD99, PILRa, Siglec-9, CD206, CD163, CD84, C3aR, and CLEC12A.

[0143] In some embodiments, each antigen-binding domain independently targets CD3, CD20, CD38, CD47, CD71, CD79b, CD95, CXCR4, CD45RB, CD45RA, CD147, CD98, CD184, HLA-DR, HLA-(A,B,C), HLA-(DR,DP,DQ), MHC I, CD24, CALR, CD40, PD-L1, APMAP, GPR84, VCAM1, CD11b, SIGLEC-10, PD-L2 , PD-1, B2M, CD73, Galectin-9, CD14, CD80, CD86, SIRPb, SIRPg, SLAMF7, MARCO, AXL, CLEVER-1, ILT4, TIM-3, TIM-4, LRP-1, calreticulin, TREM1, TREM2, GD2, FcgRI, FcgRIIa, FcgRIIb, FcgRIII,W0571.70067WO0039 / 202MUC1, CD44, CD63, CD36, CD84, CD164, CD82, CD18, SIGLEC-7, CD166, CD39, CD46, LILRA1, LILRA2, LILRA3, LILRA4, LILRB1(CD85j), LILRB2, LILRB3, LILRB4, LILRB5, CD85, CD85j, CD85b, CD85, CD85f, CD276, CD88, CD99, PILRa, Siglec-9, CD206, CD163, CD84, C3aR, and CLEC12A.

[0144] In some embodiments, each antigen-binding domain independently targets CD20, CD24, CD24-2, CD38, CD40, CD71, CD95, CXCR4, PD-1, CD79b, CD85j, LILRB1(CD85j), CD47, CD45RB, CD45RA, β2M, CD147, CD98, CD184, CD3, HLA-DR, HLA-(A,B,C), and HLA-(DR,DP,DQ).

[0145] In some embodiments, each antigen-binding domain independently targets CD20, CD24, CD24-2, CD38, CD40, CD71, CD95, CXCR4, PD-1, CD79b, CD85j, CD47, CD45RB, CD45RA, β2M, CD147, CD98, CD184, HLA-DR, HLA-(A,B,C), and HLA- (DR,DP,DQ).

[0146] In some embodiments, the first antigen-binding domain or the second antigen binding domain targets CXCR4.

[0147] In some embodiments, the first antigen-binding domain or the second antigen binding domain targets LILRB1(CD85j).

[0148] In some embodiments, the first antigen-binding domain targets CXCR4 and the second antigen binding domain targets LILRB1(CD85j).

[0149]

[0150] In some embodiments, the first antigen-binding domain or the second antigen- binding domain targets CD3.

[0151] In some embodiments, the first antigen-binding domain targets an antigen selected from CD20, CD47, CD85j, and CD38, and the second antigen-binding domain targets an antigen selected from CD20, CD24, CD24-2, CD38, CD40, CD71, CD95, CXCR4, PD-1, CD79b, CD85j, CD47, CD45RB, CD45RA, β2M, CD147, CD98, CD184, HLA-DR, HLA- (A, B, C), and HLA-(DR, DP, DQ).

[0152] In some embodiments, the first antigen-binding domain targets an antigen selected from CD20, CD47, CD85j, and CD38, and the second antigen-binding domain targets an antigen selected from CD3, CD20, CD24, CD24-2, CD38, CD40, CD71, CD95, CXCR4, PD-1, CD79b, CD85j, CD47, CD45RB, CD45RA, β2M, CD147, CD98, CD184, HLA-DR, HLA-(A, B, C), and HLA-(DR, DP, DQ).

[0153] In some embodiments, the first antigen-binding domain targets CD20, and the second antigen-binding domain targets an antigen selected from CD20, CD24, CD24-2,W0571.70067WO0040 / 202CD38, CD40, CD71, CD95, CXCR4, PD-1, CD79b, CD85j, CD47, CD45RB, CD45RA, β2M, CD147, CD98, CD184, HLA-DR, HLA-(A, B, C), and HLA-(DR, DP, DQ).

[0154] In some embodiments, the first antigen-binding domain targets CD38, and the second antigen-binding domain targets an antigen selected from CD20, CD24, CD24-2, CD38, CD40, CD71, CD95, CXCR4, PD-1, CD79b, CD85j, CD47, CD45RB, CD45RA, β2M, CD147, CD98, CD184, HLA-DR, HLA-(A, B, C), and HLA-(DR, DP, DQ).

[0155] In some embodiments, the first antigen-binding domain targets CD47 and the second antigen-binding domain targets an antigen selected from CD20, CD24, CD24-2, CD38, CD40, CD71, CD95, CXCR4, PD-1, CD79b, CD85j, CD47, CD45RB, CD45RA, β2M, CD147, CD98, CD184, HLA-DR, HLA-(A, B, C), and HLA-(DR, DP, DQ).

[0156] In some embodiments, the first antigen-binding domain targets CD85j and the second antigen-binding domain targets an antigen selected from CD20, CD24, CD24-2, CD38, CD40, CD71, CD95, CXCR4, PD-1, CD79b, CD85j, CD47, CD45RB, CD45RA, β2M, CD147, CD98, CD184, HLA-DR, HLA-(A, B, C), and HLA-(DR, DP, DQ).

[0157] In some embodiments, the first antigen-binding domain targets an antigen selected from CD20, CD47, CD85j, and CD38, and the second antigen-binding domain targets an antigen selected from CD20, CD24, CD24-2, CD38, CD40, CD71, CD95, PD-1, CD79b, CD85j, CD47, CD147, and CD184.

[0158] In some embodiments, the first antigen-binding domain targets an antigen selected from CD47, CD20, CD85j, and CD38.

[0159] In some embodiments, the first antigen-binding domain targets CD47.

[0160] The bispecific antibody of the preceding claim, wherein the first antigen-binding domain targets CD47 and second antigen-binding domain targets an antigen selected from CD20, CD24, CD38, CD40, CD71 , PD-1, CD85j, CD147, and CD184.

[0161] In some embodiments, the first antigen-binding domain targets CD85j.

[0162] In some embodiments, the first antigen-binding domain targets CD85j and the second antigen-binding domain targets an antigen selected from CD20, CD40, CD38, CD71, CD47, CD147, and CD184.

[0163] In some embodiments, the first antigen-binding domain targets an antigen selected from CD85j and the second antigen-binding domain targets an antigen selected from CD38, CD47, and CD147.

[0164] In some embodiments, the first antigen-binding domain targets CD38.W0571.70067WO0041 / 202

[0165] In some embodiments, the first antigen-binding domain targets CD38 and the second antigen-binding domain targets an antigen selected from CD20, CD24, CD24-2, CD38, CD- 79b, CD40, CD71, CD95, PD-1, CD79b, CD85j, CD47, CD147, and CD184.

[0166] In some embodiments, the first antigen-binding domain targets CD38 and the second antigen-binding domain targets an antigen selected from CD47.

[0167] In some embodiments, the first antigen-binding domain targets CD20.

[0168] In some embodiments, the first antigen-binding domain targets CD20 and the second antigen-binding domain targets an antigen selected from CD24, CD24-2, CD38, CD40, CD71, CD95, PD-1, CD79b, CD85, CD47, CD147, and CD184.

[0169] In some embodiments, the first antigen-binding domain targets CD20 and the second antigen-binding domain targets an antigen selected from CD38 and CD184. In some embodiments, the first antigen-binding domain targets CD20 and the second antigen-binding domain targets CD38. In some embodiments, the first antigen-binding domain targets CD20 and the second antigen-binding domain targets CD184.

[0170] In some embodiments, the bispecific comprises a SIRPα decoy domain and an antigen-binding domain that targets CD20, CD38, CD47, CD71, CD79b, CD95, CXCR4, CD45RB, CD45RA, CD147, CD98, CD184, HLA-DR, HLA-(A,B,C), HLA-(DR,DP,DQ), MHC I, CD24, CALR, CD40, PD-L1, APMAP, GPR84, VCAM1, CD11b, SIGLEC-10, PD- L2 , PD-1, B2M, CD73, Galectin-9, CD14, CD80, CD86, SIRPb, SIRPg, SLAMF7, MARCO, AXL, CLEVER-1, ILT4, TIM-3, TIM-4, LRP-1, calreticulin, TREM1, TREM2, GD2, FcgRI, FcgRIIa, FcgRIIb, FcgRIII, MUC1, CD44, CD63, CD36, CD84, CD164, CD82, CD18, SIGLEC-7, CD166, CD39, CD46, LILRA1, LILRA2, LILRA3, LILRA4, LILRB1, LILRB2, LILRB3, LILRB4, LILRB5, CD85, CD85j, CD85b, CD85, CD85f.

[0171] In some embodiments, the bispecific comprises a SIRPα decoy domain and an antigen-binding domain that targets CD20, CD24, CD24-2, CD38, CD40, CD71, CD95, CXCR4, PD-1, CD79b, CD85j, CD47, CD45RB, CD45RA, β2M, CD147, CD98, CD184, HLA-DR, HLA-(A, B, C), and HLA-(DR, DP, DQ).

[0172] In some embodiments, the bispecific comprises a SIRPα decoy domain and an antigen-binding domain that targets CD20. In some embodiments, the bispecific comprises a SIRPα decoy domain and an antigen-binding domain that targets CD38.

[0173] In some embodiments, the SIRPα decoy domain is CV1. In some embodiments, the SIRPα decoy domain is WTa2d1.

[0174] A bispecific comprising a SIRPα decoy domain and an antigen-binding domain that targets LILRB1(CD85j), CD20, CD24, CD24-2, CD38, CD40, CD71, CD95, CXCR4, PD-1,W0571.70067WO0042 / 202CD79b, CD85j, CD47, CD45RB, CD45RA, β2M, CD147, CD98, CD184, HLA-DR, HLA- (A, B, C), and HLA-(DR, DP, DQ).

[0175] In some embodiments, the antigen-binding domain targets LILRB1(CD85j), CD38, or CD20.

[0176] In some embodiments the antigen-binding domain targets CD38.

[0177] In some embodiments the antigen-binding domain targets LILRB1(CD85j).

[0178] In some embodiments, the bispecific antibody of the present disclosure comprises at least one scFv.

[0179] In some embodiments, the bispecific antibody comprises at least two of: (a) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 1; (b) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 2; (c) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 3; (d) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 4; (e) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 5; (f) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 6; (g) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 7; (h) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 8; (i) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 9; (j) a single chain binding arm comprising CV1 (a high-affinity SIRPa decoy protein) of the amino acid sequence of SEQ ID NO: 10; (k) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 11; (l) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 12;W0571.70067WO0043 / 202(m) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 13; (n) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 14; (o) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 15; (p) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 16; (q) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 17; (r) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 18; (s) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 19; (t) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 20; (u) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 21; (v) a single chain binding arm comprising CV1 (a high-affinity SIRPa decoy protein) of the amino acid sequence of SEQ ID NO: 22; (w) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 23; (x) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 24; or (y) a single chain binding arm comprising WTa2d1 (a low-affinity SIRPa decoy protein) of the amino acid sequence of SEQ ID NO: 25.

[0180] In some embodiments, the bispecific antibody comprises: (a ) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 4; (b) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 8; (c) a single chain binding arm comprising CV1 (a high-affinity SIRPa decoy protein) of the amino acid sequence of SEQ ID NO: 10;W0571.70067WO0044 / 202(d) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 16; (e) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 20; (f) a single chain binding arm comprising CV1 (a high-affinity SIRPa decoy protein) of the amino acid sequence of SEQ ID NO: 22; and / or (g) a single chain binding arm comprising WTa2d1 (a low-affinity SIRPa decoy protein) of the amino acid sequence of SEQ ID NO: 25.

[0181] In some embodiments, the bispecific antibody comprises a “knob” sequence and a "hole” sequence.

[0182] In some embodiments, the “knob” sequence comprises an amino acid sequence selected from SEQ ID NO: 1-12.

[0183] T In some embodiments, the “hole” sequence comprises an amino acid sequence SEQ ID NO: 13-25.

[0184] In some embodiments, the bispecific antibody of any one of the preceding claims comprises a “knob” sequence selected from SEQ ID NOs: 1-12 and one heavy chain comprises a "hole” sequence selected from SEQ ID NOs: 13-25.

[0185] In some embodiments, the bispecific antibody comprises an amino acid sequence at least 85% identical, or optionally 90% identical, or optionally 95% identical to the amino acid sequences set forth in REF ID NOs: 26-181. In some embodiments, the bispecific antibody comprises an amino acid sequence at least 85% identical to the amino acid sequences set forth in REF ID NOs: 26-181. In some embodiments, the bispecific antibody comprises an amino acid sequence at least 90% identical to the amino acid sequences set forth in REF ID NOs: 26-181. In some embodiments, the bispecific antibody comprises an amino acid sequence at least 95% identical to the amino acid sequences set forth in REF ID NOs: 26- 181. In some embodiments, the bispecific antibody comprises an amino acid sequence at least 99% identical to the amino acid sequences set forth in REF ID NOs: 26-181. In some embodiments, the bispecific antibody comprises an amino acid sequences set forth in REF ID NOs: 26-181.

[0186] In some embodiments, the bispecific antibody consists of an amino acid sequence at least 85% identical, or optionally 90% identical, or optionally 95% identical to the amino acid sequences set forth in REF ID NOs: 26-181. In some embodiments, the bispecific antibody consists of an amino acid sequence at least 85% to the amino acid sequences set forth in REF ID NOs: 26-181. In some embodiments, the bispecific antibody consists of an amino acidW0571.70067WO0045 / 202sequence at least 90% to the amino acid sequences set forth in REF ID NOs: 26-181. In some embodiments, the bispecific antibody consists of an amino acid sequence at least 95% to the amino acid sequences set forth in REF ID NOs: 26-181. In some embodiments, the bispecific antibody consists of an amino acid sequence at least 99% to the amino acid sequences set forth in REF ID NOs: 26-181. In some embodiments, the bispecific antibody consists of an amino acid sequence set forth in REF ID NOs: 26-181.

[0187] In some embodiments, the bispecific antibody comprises of an amino acid sequence of REF ID NOs: 26, 29, or 165.

[0188] In one aspect, provided is one or more nucleic acid constructs encoding the composition of the present disclosure.

[0189] In some embodiments, the nucleic acid comprises DNA or RNA.

[0190] In some embodiments, the nucleic acid construct comprises DNA.

[0191] In some embodiments, the nucleic acid construct comprises RNA.

[0192] In some embodiments, the nucleic acid construct comprises a sequence at least 85% identical, or optionally 90% identical, or optionally 95% identical a nucleotide sequence encoding a feature of sequence of SEQ ID NOs (1-25).

[0193] In one aspect, provided is a vector comprising the nucleic acid provided herein.

[0194] In another aspect, provided is a cell comprising the nucleic acid of any one of the preceding claims or the vector of the preceding claim.

[0195] In some embodiments, wherein the cell is an animal cell.

[0196] In some embodiments, the cell is a human cell.

[0197] In some embodiments, the cell is an immune cell.

[0198] In some embodiments, the immune cell is a T-cell.

[0199] In some embodiments, the immune cell is an NK cell.

[0200] In some embodiments, the immune cell is a B-cell.

[0201] In another aspect, provided is a method of treating disease in a subject or a cell, the method comprising administering to the subject or cell an effective amount of the bispecific antibody of the present disclosure.

[0202] In some embodiments a bispecific antibody disclosed herein is administered to treat a subject suffering from a cancer containing cells (e.g., cancer cells and / or cells within the tumor microenvironment) that express a target antigen to which an antigen-binding domain of the antibody binds. Expression of a target antigen may be detected and / or measured using, for example, molecular diagnostics, immunohistochemistry, or flow cytometry.W0571.70067WO0046 / 202

[0203] In some embodiments, the disease is a proliferative disease or an autoimmune disease.

[0204] In some embodiments, the disease is a proliferative disease.

[0205] In some embodiments, the disease is an autoimmune disease.

[0206] In some embodiments, the proliferative disease is cancer.

[0207] In some embodiments the cancer is a solid cancer (i.e., tumor).

[0208] In some embodiments the cancer is a liquid cancer (i.e., hematological).

[0209] In some embodiments, the cancer is a hematological cancer.

[0210] In some embodiments, the cancer is lymphoma.

[0211] In some embodiments, the method further comprises administering an additional pharmaceutical agent. The additional pharmaceutical agent may comprise an antineoplastic drug, chemotherapy, immunotherapy (anti-CTLA-4, anti-PD-1, anti-PD-L1, anti-LAG3) anti- angiogenesis (bevacizumab), ADC, radioligand therapy, radiation therapy, neoantigen or vaccine.

[0212] Additionally provided in one aspect is a kit comprising the bispecific antibody of the present disclosure and a pharmaceutical excipient.

[0213] In some embodiments, a bispecific antibody targets at least one specific antigen. For example, in some embodiments, a bispecific antibody comprises a first binding domain, e.g., a first antigen binding domain, that targets the protein to a target site (e.g., an organ, a cell or cell type (e.g., a diseased cell, such as a tumor cell), a tissue, or a site of disease) and a second binding domain, e.g., a second antigen binding domain, that provides a function, e.g., a therapeutic function. In some embodiments, at least one of the first antigen binding domain or at least one second antigen binding domain binds / targets immune cells. In some embodiments, the first antigen binding domain binds / targets immune cells. In some embodiments, the second antigen binding domain binds / targets immune cells. In some embodiments, the first and second antigen binding domains bind / target immune cells. In some embodiments, the immune cell is a T-cell or an natural killer (NK) cell.

[0214] In some embodiments a binding domain is conjugated to a therapeutic agent, for example, a small molecule, or a therapeutic polypeptide. In some embodiments such conjugation is performed using click chemistry. For example, conjugation may be used to produce a bifunctional, bivalent, or bispecific agent by installing click chemistry handles on each of two polypeptides (e.g., scFvs and / or sdAbs) or other molecules, which are then conjugated to each other via a click chemistry reaction (e.g., as discussed further below).W0571.70067WO0047 / 202

[0215] In certain embodiments an agent is a trifunctional agent. A trifunctional agent may be a trivalent agent, e.g., a trispecific agent. Trivalent agents or agents of even higher valency may be produced as single polypeptides comprising three or more scFv, sdAb, or a combination thereof. By including scFv and / or or sdAb with different specificities in a single polypeptide chain, multispecific (e.g., bispecific, trispecific) agents are produced. Such agents may have multiple distinct functions conferred by binding to different molecules or entities.

[0216] Exemplary Bispecific antibody knob and hole sequences, full sequences, and features thereof are provided below. * indicates end of sequence and "|” indicates the point at which the knob sequence meets the hole sequence.

[0217] Table 1. CD20 Knob

[0218] Features:

[0219] GSQIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATS NLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKGG GGSGGGGSGGGGSQVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTP GRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCA RSTYYGGDWYFNVWGAGTTVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVS VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 1)

[0220] Table 2. CD24 Knob Features:W0571.70067WO0048 / 202

[0221] CD24 Knob:

[0222] GSDIVMTQTPLSLSVTPGQPASISCKSSQSLLMSDGKTYLNWYLQKPGQSPQ RLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGAHFPYTFGQGT KLEIKGGGGSGGGGSGGGGSQVQLVESGGGVVQPGRSLRLSCAASGFTFSRYWMS WVRQAPGKGLEWIAEINPDSSTINYTPSLRDKFTISRDNSKNTLYLQNSSLRAEDTAV YYCARQGDYWGQGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 2)

[0223] Table 3. CD24 -2 Knob Features:

[0224] CD24 -2 Knob:

[0225] GSENVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSTTSPKLWIYD TSKLASGVPGRFSGSGSGNSYSLTISSMEAEDVATYYCFQGSGYPLTFGGGTKLEIKG GGGSGGGGSGGGGSQGPPSLKESGPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPP GKGLEWIGVIWAGGSTNYNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAW0571.70067WO0049 / 202VYYGYLFFAYWGQGTLVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 3)

[0226] Table 4. CD38 Knob Features:

[0227] CD38 Knob:

[0228] GSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDA SNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKGG GGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGK GLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKD KILWFGEPVFDYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 4)

[0229] Table 5. CD40 Knob Features:W0571.70067WO0050 / 202

[0230] CD40 Knob:

[0231] GSDIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPK LLIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKV EIKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVR QAPGKGLEWVARVIPNAGGTSNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVY YCAREGIYWWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 5)

[0232] Table 6. CD71 Knob Features:

[0233] CD71 Knob:

[0234] GSDIQMTQSPSSLSASVGDRVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAA TNLADGVPRFSGSGSGTDYTLTISSLQPEDFATYYCQHFWGTPLTFGGGTKVEIKGG GGSGGGGSGGGGSVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPG QGLEWIGEINPINGRSNYAEKFQGRVTLTVDTSSSTAYMELSRLRSDDTAVYYCARG TRAMHYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 6)

[0235] Table 7. CD79b Knob Features:W0571.70067WO0051 / 202

[0236] CD79b Knob:

[0237] GSDIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSFLNWYQKPGQPPKLFI YAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPLTFGAGTELEL KGGGGSGGGGSGGGGSEVQLQQSGAELMKPGASVKISCKATGYTFSSYWIEWKQRP GHGLEWIGEILPGGGDTNYNEIFKGKATETADTSSNTAYMLSSLISEDSAVYYCTRRV PVYFDYWGQGTSVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 7)

[0238] Table 8. CD85(CD85j) Knob Features:

[0239] CD85(CD85j) Knob:

[0240] GSDIQLTQSPSFLSASVGDRVTITCQASQTIYTNLAWYQQKPGKAPKLLIYAA STLASGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQSYYGSSTTGNGFGGGTKVEIK GGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFSFSSSYCMCWVRQAW0571.70067WO0052 / 202PGKGLELVSCIYTDSSGATYYASWAKGRFTISRHNSKNTLYLQMNSLRAEDTAVYY CARGWDYEDPGYTDTTYFSLWGRGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 8)

[0241] Table 9. CD95 Knob Features:

[0242] CD95 Knob:

[0243] GSDIVMTQSPDSLAVSLGERATISCRASESVEYYGTSLMQWYQQKPGQPPKL LIYVASNVESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYFCQQSTKVPWTFGQGTKL EIKGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLRLSCAASGFTFNTNAMNWV RQAPGKGLEWVARIRSKSNNYATYYAESVKDRFTISRDDSKNTLYLQMNSLKTEDT AVYYCVTDGYYWGQGTTLTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 9)

[0244] CV1 Knob Sequence:

[0245] GSEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQ RQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGT ELSVRAKPSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAW0571.70067WO0053 / 202VEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK* (SEQ ID NO: 10)

[0246] Table 10. CXCR4 Knob Features:

[0247] CXCR4 Hole:

[0248] GSDIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYA ASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIKG GGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAP GKGLEWVSYISSRSRTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAR DYGGQPPYYYYYGMDVWGQGTTVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKS RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 11)

[0249] Table 11. PD-1 Knob Features:

[0250] PD-1 Knob:W0571.70067WO0054 / 202

[0251] GSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDA SNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKGG GGSGGGGSGGGGSQVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPG KGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCA TNDDYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 12)

[0252] Table 12. CD20 Hole Features:

[0253] CD20 Hole:

[0254] GSQIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATS NLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKGG GGSGGGGSGGGGSQVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTP GRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCA RSTYYGGDWYFNVWGAGTTVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVS VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN QVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 13)

[0255] Table 13. CD24 Hole Features:W0571.70067WO0055 / 202

[0256] CD24 Hole:

[0257] GSDIVMTQTPLSLSVTPGQPASISCKSSQSLLMSDGKTYLNWYLQKPGQSPQ RLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGAHFPYTFGQGT KLEIKGGGGSGGGGSGGGGSQVQLVESGGGVVQPGRSLRLSCAASGFTFSRYWMS WVRQAPGKGLEWIAEINPDSSTINYTPSLRDKFTISRDNSKNTLYLQNSSLRAEDTAV YYCARQGDYWGQGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL YCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 14)

[0258] Table 14. CD24-2 Hole Features:

[0259] CD24-2 Hole:

[0260] GSENVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSTTSPKLWIYD TSKLASGVPGRFSGSGSGNSYSLTISSMEAEDVATYYCFQGSGYPLTFGGGTKLEIKG GGGSGGGGSGGGGSQGPPSLKESGPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPP GKGLEWIGVIWAGGSTNYNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCA VYYGYLFFAYWGQGTLVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTW0571.70067WO0056 / 202VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 15)

[0261] Table 15. CD38 Hole Features:

[0262] CD38 Hole:

[0263] GSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDA SNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKGG GGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGK GLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKD KILWFGEPVFDYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 16)

[0264] Table 16. CD40 Hole Features:W0571.70067WO0057 / 202

[0265] CD40 Hole:

[0266] GSDIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPK LLIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKV EIKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVR QAPGKGLEWVARVIPNAGGTSNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVY YCAREGIYWWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL YCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 17)

[0267] Table 17. CD71 Hole Features:

[0268] CD71 Hole:

[0269] GSDIQMTQSPSSLSASVGDRVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAA TNLADGVPRFSGSGSGTDYTLTISSLQPEDFATYYCQHFWGTPLTFGGGTKVEIKGG GGSGGGGSGGGGSVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPG QGLEWIGEINPINGRSNYAEKFQGRVTLTVDTSSSTAYMELSRLRSDDTAVYYCARG TRAMHYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 18)

[0270] Table 18. CD79b Hole Features:W0571.70067WO0058 / 202

[0271] CD79b Hole:

[0272] GSDIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSFLNWYQKPGQPPKLFI YAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPLTFGAGTELEL KGGGGSGGGGSGGGGSEVQLQQSGAELMKPGASVKISCKATGYTFSSYWIEWKQRP GHGLEWIGEILPGGGDTNYNEIFKGKATETADTSSNTAYMLSSLISEDSAVYYCTRRV PVYFDYWGQGTSVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 19)

[0273] Table 19. CD85(CD85j) Hole Features:

[0274] CD85(CD85j) Hole:

[0275] GSDIQLTQSPSFLSASVGDRVTITCQASQTIYTNLAWYQQKPGKAPKLLIYAA STLASGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQSYYGSSTTGNGFGGGTKVEIK GGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFSFSSSYCMCWVRQA PGKGLELVSCIYTDSSGATYYASWAKGRFTISRHNSKNTLYLQMNSLRAEDTAVYY CARGWDYEDPGYTDTTYFSLWGRGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFLW0571.70067WO0059 / 202FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR EEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 20)

[0276] Table 20. CD95 Hole Features:

[0277] CD95 Hole:

[0278] GSDIVMTQSPDSLAVSLGERATISCRASESVEYYGTSLMQWYQQKPGQPPKL LIYVASNVESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYFCQQSTKVPWTFGQGTKL EIKGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLRLSCAASGFTFNTNAMNWV RQAPGKGLEWVARIRSKSNNYATYYAESVKDRFTISRDDSKNTLYLQMNSLKTEDT AVYYCVTDGYYWGQGTTLTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 21)

[0279] CV1 Hole Sequence:

[0280] GSEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQ RQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGT ELSVRAKPSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK* (SEQ ID NO: 22)

[0281] CXCR4 - HoleW0571.70067WO0060 / 202

[0282] Table 21. CXCR4 Hole Features:

[0283] CXCR4 Hole:

[0284] GSDIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYA ASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIKG GGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAP GKGLEWVSYISSRSRTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAR DYGGQPPYYYYYGMDVWGQGTTVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM TKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 23)

[0285] Table 22. PD-1 Hole Features:

[0286] PD-1 Hole:

[0287] GSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDA SNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKGGW0571.70067WO0061 / 202GGSGGGGSGGGGSQVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPG KGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCA TNDDYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 24)

[0288] SIRPα Hole Sequence:

[0289] GSEEELQVIQPDKSVLVAAGETATLRCTATSLIPVGPIQWFRGAGPGRELIYN QKEGHFPRVTTVSDLTKRNNMDFSIRIGNITPADAGTYYCVKFRKGSPDDVEFKSGA GTELSVRAKPSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGK* (SEQ ID NO: 25)

[0290] Table 23. Bispecific AntibodiesW0571.70067WO0062 / 202W0571.70067WO0063 / 202W0571.70067WO0064 / 202

[0291] Bispecific Antibody Sequences:

[0292] The bispecific antibody comprising a knob sequence of SEQ ID NO: 1 and a hole sequence of SEQ ID NO: 13 (REF ID NO: 26). GSQIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSN LASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKGGG GSGGGGSGGGGSQVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPG RGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSW0571.70067WO0065 / 202TYYGGDWYFNVWGAGTTVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 1) |GSQIVLSQSPAILSASPG EKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTI SRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKGGGGSGGGGSGGGGSQVQLQQPG AELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQK FKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVT VSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPGK* (SEQ ID NO: 13)

[0293] The bispecific antibody comprising a knob sequence of SEQ ID NO: 1 and a hole sequence of SEQ ID NO: 14 (REF ID NO: 27). GSQIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSN LASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKGGG GSGGGGSGGGGSQVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPG RGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARS TYYGGDWYFNVWGAGTTVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 1) |GSDIVMTQTPLSLSVTP GQPASISCKSSQSLLMSDGKTYLNWYLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGS GTDFTLKISRVEAEDVGVYYCWQGAHFPYTFGQGTKLEIKGGGGSGGGGSGGGGSQ VQLVESGGGVVQPGRSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWIAEINPDSSTI NYTPSLRDKFTISRDNSKNTLYLQNSSLRAEDTAVYYCARQGDYWGQGTLVTVSSA AADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA PIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPE NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS PGK* (SEQ ID NO: 14)W0571.70067WO0066 / 202

[0294] The bispecific antibody comprising a knob sequence of SEQ ID NO: 1 and a hole sequence of SEQ ID NO: 15 (REF ID NO: 28). GSQIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSN LASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKGGG GSGGGGSGGGGSQVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPG RGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARS TYYGGDWYFNVWGAGTTVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 1) |GSENVLTQSPAIMSASP GEKVTMTCSASSSVSYMHWYQQKSTTSPKLWIYDTSKLASGVPGRFSGSGSGNSYS LTISSMEAEDVATYYCFQGSGYPLTFGGGTKLEIKGGGGSGGGGSGGGGSQGPPSLK ESGPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPGKGLEWIGVIWAGGSTNYNSA LMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAVYYGYLFFAYWGQGTLVTVSA AAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL PAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS LSPGK* (SEQ ID NO: 15)

[0295] The bispecific antibody comprising a knob sequence of SEQ ID NO: 1 and a hole sequence of SEQ ID NO: 16 (REF ID NO: 29). GSQIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSN LASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKGGG GSGGGGSGGGGSQVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPG RGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARS TYYGGDWYFNVWGAGTTVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 1) |GSEIVLTQSPATLSLSPG ERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLT ISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLLESGG GLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKW0571.70067WO0067 / 202GRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVS SAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA LPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL SLSPGK* (SEQ ID NO: 16)

[0296] The bispecific antibody comprising a knob sequence of SEQ ID NO: 1 and a hole sequence of SEQ ID NO: 17 (REF ID NO: 30). GSQIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSN LASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKGGG GSGGGGSGGGGSQVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPG RGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARS TYYGGDWYFNVWGAGTTVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 1) |GSDIQMTQSPSSLSASV GDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSG TDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVEIKGGGGSGGGGSGGGGSEVQ LVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVIPNAGGTS NQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGTLVTVSSA AAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL SPGK* (SEQ ID NO: 17)

[0297] The bispecific antibody comprising a knob sequence of SEQ ID NO: 1 and a hole sequence of SEQ ID NO: 18 (REF ID NO: 31). GSQIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSN LASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKGGG GSGGGGSGGGGSQVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPG RGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARS TYYGGDWYFNVWGAGTTVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLW0571.70067WO0068 / 202TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 1) |GSDIQMTQSPSSLSASV GDRVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAATNLADGVPRFSGSGSGTDYTL TISSLQPEDFATYYCQHFWGTPLTFGGGTKVEIKGGGGSGGGGSGGGGSVQLVQSG AEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWIGEINPINGRSNYAEK FQGRVTLTVDTSSSTAYMELSRLRSDDTAVYYCARGTRAMHYWGQGTLVTVSSAA AADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA PIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPE NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS PGK* (SEQ ID NO: 18)

[0298] The bispecific antibody comprising a knob sequence of SEQ ID NO: 1 and a hole sequence of SEQ ID NO: 19 (REF ID NO: 32). GSQIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSN LASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKGGG GSGGGGSGGGGSQVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPG RGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARS TYYGGDWYFNVWGAGTTVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 1) |GSDIVLTQSPASLAVSL GQRATISCKASQSVDYDGDSFLNWYQKPGQPPKLFIYAASNLESGIPARFSGSGSGTD FTLNIHPVEEEDAATYYCQQSNEDPLTFGAGTELELKGGGGSGGGGSGGGGSEVQL QQSGAELMKPGASVKISCKATGYTFSSYWIEWKQRPGHGLEWIGEILPGGGDTNYN EIFKGKATETADTSSNTAYMLSSLISEDSAVYYCTRRVPVYFDYWGQGTSVTVSSAA AADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA PIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPE NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS PGK* (SEQ ID NO: 19)

[0299] The bispecific antibody comprising a knob sequence of SEQ ID NO: 1 and a hole sequence of SEQ ID NO: 20 (REF ID NO: 33).W0571.70067WO0069 / 202GSQIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSN LASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKGGG GSGGGGSGGGGSQVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPG RGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARS TYYGGDWYFNVWGAGTTVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 1) |GSDIQLTQSPSFLSASVG DRVTITCQASQTIYTNLAWYQQKPGKAPKLLIYAASTLASGVPSRFSGSGSGTEFTLTI SSLQPEDFATYYCQSYYGSSTTGNGFGGGTKVEIKGGGGSGGGGSGGGGSEVQLVE SGGGLVQPGGSLRLSCAASGFSFSSSYCMCWVRQAPGKGLELVSCIYTDSSGATYYA SWAKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARGWDYEDPGYTDTTYFSLW GRGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDI AVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH NHYTQKSLSLSPGK* (SEQ ID NO: 20)

[0300] The bispecific antibody comprising a knob sequence of SEQ ID NO: 1 and a hole sequence of SEQ ID NO: 21 (REF ID NO: 34). GSQIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSN LASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKGGG GSGGGGSGGGGSQVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPG RGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARS TYYGGDWYFNVWGAGTTVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 1) |GSDIVMTQSPDSLAVSL GERATISCRASESVEYYGTSLMQWYQQKPGQPPKLLIYVASNVESGVPDRFSGSGSG TDFTLTISSLQAEDVAVYFCQQSTKVPWTFGQGTKLEIKGGGGSGGGGSGGGGSEVQ LVESGGGLVKPGGSLRLSCAASGFTFNTNAMNWVRQAPGKGLEWVARIRSKSNNY ATYYAESVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCVTDGYYWGQGTTLTV SSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVW0571.70067WO0070 / 202KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA LPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL SLSPGK* (SEQ ID NO: 21)

[0301] The bispecific antibody comprising a knob sequence of SEQ ID NO: 1 and a hole sequence of SEQ ID NO: 22 (REF ID NO: 35). GSQIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSN LASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKGGG GSGGGGSGGGGSQVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPG RGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARS TYYGGDWYFNVWGAGTTVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 1) |GSEEELQIIQPDKSVLVA AGETATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQRQGPFPRVTTVSDTTKRNNMDF SIRIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGTELSVRAKPSAAADKTHTCPPCP APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 22)

[0302] The bispecific antibody comprising a knob sequence of SEQ ID NO: 1 and a hole sequence of SEQ ID NO: 23 (REF ID NO: 36). GSQIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSN LASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKGGG GSGGGGSGGGGSQVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPG RGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARS TYYGGDWYFNVWGAGTTVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 1) |GSDIQMTQSPSSLSASV GDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLW0571.70067WO0071 / 202TISSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLVESG GGLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPGKGLEWVSYISSRSRTIYYADSV KGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARDYGGQPPYYYYYGMDVWGQG TTVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK* (SEQ ID NO: 23)

[0303] The bispecific antibody comprising a knob sequence of SEQ ID NO: 1 and a hole sequence of SEQ ID NO: 24 (REF ID NO: 37). GSQIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSN LASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKGGG GSGGGGSGGGGSQVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPG RGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARS TYYGGDWYFNVWGAGTTVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 1) |GSEIVLTQSPATLSLSPG ERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLT ISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKGGGGSGGGGSGGGGSQVQLVESG GGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADS VKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSAAAAD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 24)

[0304] The bispecific antibody comprising a knob sequence of SEQ ID NO: 1 and a hole sequence of SEQ ID NO: 25 (REF ID NO: 38). GSQIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSN LASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKGGG GSGGGGSGGGGSQVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPG RGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSW0571.70067WO0072 / 202TYYGGDWYFNVWGAGTTVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 1) |GSEEELQVIQPDKSVLV AAGETATLRCTATSLIPVGPIQWFRGAGPGRELIYNQKEGHFPRVTTVSDLTKRNNM DFSIRIGNITPADAGTYYCVKFRKGSPDDVEFKSGAGTELSVRAKPSAAADKTHTCPP CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 25)

[0305] The bispecific antibody comprising a knob sequence of SEQ ID NO: 3 and a hole sequence of SEQ ID NO: 13 (REF ID NO: 39). GSENVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSTTSPKLWIYDT SKLASGVPGRFSGSGSGNSYSLTISSMEAEDVATYYCFQGSGYPLTFGGGTKLEIKGG GGSGGGGSGGGGSQGPPSLKESGPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPG KGLEWIGVIWAGGSTNYNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAV YYGYLFFAYWGQGTLVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 3) |GSQIVLSQSPAILSASPGEK VTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISR VEAEDAATYYCQQWTSNPPTFGGGTKLEIKGGGGSGGGGSGGGGSQVQLQQPGAE LVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFK GKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVS AAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA LPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL SLSPGK* (SEQ ID NO: 13)

[0306] The bispecific antibody comprising a knob sequence of SEQ ID NO: 3 and a hole sequence of SEQ ID NO: 14 (REF ID NO: 40).W0571.70067WO0073 / 202GSENVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSTTSPKLWIYDT SKLASGVPGRFSGSGSGNSYSLTISSMEAEDVATYYCFQGSGYPLTFGGGTKLEIKGG GGSGGGGSGGGGSQGPPSLKESGPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPG KGLEWIGVIWAGGSTNYNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAV YYGYLFFAYWGQGTLVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 3) |GSDIVMTQTPLSLSVTPGQ PASISCKSSQSLLMSDGKTYLNWYLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTD FTLKISRVEAEDVGVYYCWQGAHFPYTFGQGTKLEIKGGGGSGGGGSGGGGSQVQL VESGGGVVQPGRSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWIAEINPDSSTINYT PSLRDKFTISRDNSKNTLYLQNSSLRAEDTAVYYCARQGDYWGQGTLVTVSSAAAD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 14)

[0307] The bispecific antibody comprising a knob sequence of SEQ ID NO: 3 and a hole sequence of SEQ ID NO: 15 (REF ID NO: 41). GSENVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSTTSPKLWIYDT SKLASGVPGRFSGSGSGNSYSLTISSMEAEDVATYYCFQGSGYPLTFGGGTKLEIKGG GGSGGGGSGGGGSQGPPSLKESGPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPG KGLEWIGVIWAGGSTNYNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAV YYGYLFFAYWGQGTLVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 3) |GSENVLTQSPAIMSASPGE KVTMTCSASSSVSYMHWYQQKSTTSPKLWIYDTSKLASGVPGRFSGSGSGNSYSLTI SSMEAEDVATYYCFQGSGYPLTFGGGTKLEIKGGGGSGGGGSGGGGSQGPPSLKES GPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPGKGLEWIGVIWAGGSTNYNSALM SRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAVYYGYLFFAYWGQGTLVTVSAAA AADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW0571.70067WO0074 / 202WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA PIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPE NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS PGK* (SEQ ID NO: 15)

[0308] The bispecific antibody comprising a knob sequence of SEQ ID NO: 3 and a hole sequence of SEQ ID NO: 16 (REF ID NO: 42). GSENVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSTTSPKLWIYDT SKLASGVPGRFSGSGSGNSYSLTISSMEAEDVATYYCFQGSGYPLTFGGGTKLEIKGG GGSGGGGSGGGGSQGPPSLKESGPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPG KGLEWIGVIWAGGSTNYNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAV YYGYLFFAYWGQGTLVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 3) |GSEIVLTQSPATLSLSPGER ATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTIS SLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLLESGGG LVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKG RFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSS AAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL PAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS LSPGK* (SEQ ID NO: 16)

[0309] The bispecific antibody comprising a knob sequence of SEQ ID NO: 3 and a hole sequence of SEQ ID NO: 17 (REF ID NO: 43). GSENVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSTTSPKLWIYDT SKLASGVPGRFSGSGSGNSYSLTISSMEAEDVATYYCFQGSGYPLTFGGGTKLEIKGG GGSGGGGSGGGGSQGPPSLKESGPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPG KGLEWIGVIWAGGSTNYNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAV YYGYLFFAYWGQGTLVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNW0571.70067WO0075 / 202VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 3) |GSDIQMTQSPSSLSASVGD RVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSGTD FTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLV ESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVIPNAGGTSNQ KFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGTLVTVSSAAA ADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI EKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP GK* (SEQ ID NO: 17)

[0310] The bispecific antibody comprising a knob sequence of SEQ ID NO: 3 and a hole sequence of SEQ ID NO: 18 (REF ID NO: 44). GSENVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSTTSPKLWIYDT SKLASGVPGRFSGSGSGNSYSLTISSMEAEDVATYYCFQGSGYPLTFGGGTKLEIKGG GGSGGGGSGGGGSQGPPSLKESGPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPG KGLEWIGVIWAGGSTNYNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAV YYGYLFFAYWGQGTLVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 3) |GSDIQMTQSPSSLSASVGD RVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAATNLADGVPRFSGSGSGTDYTLTIS SLQPEDFATYYCQHFWGTPLTFGGGTKVEIKGGGGSGGGGSGGGGSVQLVQSGAEV KKPGASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWIGEINPINGRSNYAEKFQG RVTLTVDTSSSTAYMELSRLRSDDTAVYYCARGTRAMHYWGQGTLVTVSSAAAAD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 18)

[0311] The bispecific antibody comprising a knob sequence of SEQ ID NO: 3 and a hole sequence of SEQ ID NO: 19 (REF ID NO: 45). GSENVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSTTSPKLWIYDT SKLASGVPGRFSGSGSGNSYSLTISSMEAEDVATYYCFQGSGYPLTFGGGTKLEIKGGW0571.70067WO0076 / 202GGSGGGGSGGGGSQGPPSLKESGPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPG KGLEWIGVIWAGGSTNYNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAV YYGYLFFAYWGQGTLVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 3) |GSDIVLTQSPASLAVSLGQ RATISCKASQSVDYDGDSFLNWYQKPGQPPKLFIYAASNLESGIPARFSGSGSGTDFT LNIHPVEEEDAATYYCQQSNEDPLTFGAGTELELKGGGGSGGGGSGGGGSEVQLQQ SGAELMKPGASVKISCKATGYTFSSYWIEWKQRPGHGLEWIGEILPGGGDTNYNEIF KGKATETADTSSNTAYMLSSLISEDSAVYYCTRRVPVYFDYWGQGTSVTVSSAAAA DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG K* (SEQ ID NO: 19)

[0312] The bispecific antibody comprising a knob sequence of SEQ ID NO: 3 and a hole sequence of SEQ ID NO: 20 (REF ID NO: 46). GSENVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSTTSPKLWIYDT SKLASGVPGRFSGSGSGNSYSLTISSMEAEDVATYYCFQGSGYPLTFGGGTKLEIKGG GGSGGGGSGGGGSQGPPSLKESGPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPG KGLEWIGVIWAGGSTNYNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAV YYGYLFFAYWGQGTLVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 3) |GSDIQLTQSPSFLSASVGDR VTITCQASQTIYTNLAWYQQKPGKAPKLLIYAASTLASGVPSRFSGSGSGTEFTLTISS LQPEDFATYYCQSYYGSSTTGNGFGGGTKVEIKGGGGSGGGGSGGGGSEVQLVESG GGLVQPGGSLRLSCAASGFSFSSSYCMCWVRQAPGKGLELVSCIYTDSSGATYYAS WAKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARGWDYEDPGYTDTTYFSLWG RGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAW0571.70067WO0077 / 202VEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK* (SEQ ID NO: 20)

[0313] The bispecific antibody comprising a knob sequence of SEQ ID NO: 3 and a hole sequence of SEQ ID NO: 21 (REF ID NO: 47). GSENVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSTTSPKLWIYDT SKLASGVPGRFSGSGSGNSYSLTISSMEAEDVATYYCFQGSGYPLTFGGGTKLEIKGG GGSGGGGSGGGGSQGPPSLKESGPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPG KGLEWIGVIWAGGSTNYNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAV YYGYLFFAYWGQGTLVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 3) |GSDIVMTQSPDSLAVSLGE RATISCRASESVEYYGTSLMQWYQQKPGQPPKLLIYVASNVESGVPDRFSGSGSGTD FTLTISSLQAEDVAVYFCQQSTKVPWTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLV ESGGGLVKPGGSLRLSCAASGFTFNTNAMNWVRQAPGKGLEWVARIRSKSNNYAT YYAESVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCVTDGYYWGQGTTLTVSSA AADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA PIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPE NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS PGK* (SEQ ID NO: 21)

[0314] The bispecific antibody comprising a knob sequence of SEQ ID NO: 3 and a hole sequence of SEQ ID NO: 22 (REF ID NO: 48). GSENVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSTTSPKLWIYDT SKLASGVPGRFSGSGSGNSYSLTISSMEAEDVATYYCFQGSGYPLTFGGGTKLEIKGG GGSGGGGSGGGGSQGPPSLKESGPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPG KGLEWIGVIWAGGSTNYNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAV YYGYLFFAYWGQGTLVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 3) |GSEEELQIIQPDKSVLVAAG ETATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQRQGPFPRVTTVSDTTKRNNMDFSIW0571.70067WO0078 / 202RIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGTELSVRAKPSAAADKTHTCPPCPAP ELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 22)

[0315] The bispecific antibody comprising a knob sequence of SEQ ID NO: 3 and a hole sequence of SEQ ID NO: 23 (REF ID NO: 49). GSENVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSTTSPKLWIYDT SKLASGVPGRFSGSGSGNSYSLTISSMEAEDVATYYCFQGSGYPLTFGGGTKLEIKGG GGSGGGGSGGGGSQGPPSLKESGPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPG KGLEWIGVIWAGGSTNYNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAV YYGYLFFAYWGQGTLVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 3) |GSDIQMTQSPSSLSASVGD RVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTIS SLQPEDFVTYYCQQYNSYPRTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGG LVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPGKGLEWVSYISSRSRTIYYADSVKGR FTISRDNAKNSLYLQMNSLRDEDTAVYYCARDYGGQPPYYYYYGMDVWGQGTTV TVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS NKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPGK* (SEQ ID NO: 23)

[0316] The bispecific antibody comprising a knob sequence of SEQ ID NO: 3 and a hole sequence of SEQ ID NO: 24 (REF ID NO: 50). GSENVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSTTSPKLWIYDT SKLASGVPGRFSGSGSGNSYSLTISSMEAEDVATYYCFQGSGYPLTFGGGTKLEIKGG GGSGGGGSGGGGSQGPPSLKESGPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPG KGLEWIGVIWAGGSTNYNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAV YYGYLFFAYWGQGTLVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVW0571.70067WO0079 / 202LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 3) |GSEIVLTQSPATLSLSPGER ATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTIS SLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKGGGGSGGGGSGGGGSQVQLVESGGG VVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVK GRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSAAAADKT HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI SKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 24)

[0317] The bispecific antibody comprising a knob sequence of SEQ ID NO: 3 and a hole sequence of SEQ ID NO: 25 (REF ID NO: 51). GSENVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSTTSPKLWIYDT SKLASGVPGRFSGSGSGNSYSLTISSMEAEDVATYYCFQGSGYPLTFGGGTKLEIKGG GGSGGGGSGGGGSQGPPSLKESGPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPG KGLEWIGVIWAGGSTNYNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAV YYGYLFFAYWGQGTLVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 3) |GSEEELQVIQPDKSVLVAA GETATLRCTATSLIPVGPIQWFRGAGPGRELIYNQKEGHFPRVTTVSDLTKRNNMDFS IRIGNITPADAGTYYCVKFRKGSPDDVEFKSGAGTELSVRAKPSAAADKTHTCPPCPA PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 25)

[0318] The bispecific antibody comprising a knob sequence of SEQ ID NO: 2 and a hole sequence of SEQ ID NO: 13 (REF ID NO: 52). GSDIVMTQTPLSLSVTPGQPASISCKSSQSLLMSDGKTYLNWYLQKPGQSPQR LIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGAHFPYTFGQGTKW0571.70067WO0080 / 202LEIKGGGGSGGGGSGGGGSQVQLVESGGGVVQPGRSLRLSCAASGFTFSRYWMSW VRQAPGKGLEWIAEINPDSSTINYTPSLRDKFTISRDNSKNTLYLQNSSLRAEDTAVY YCARQGDYWGQGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 2) |GSQIVLSQSPAILSASPGEKVTM TCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAE DAATYYCQQWTSNPPTFGGGTKLEIKGGGGSGGGGSGGGGSQVQLQQPGAELVKP GASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKAT LTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSAAAA ADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI EKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP GK* (SEQ ID NO: 13)

[0319] The bispecific antibody comprising a knob sequence of SEQ ID NO: 2 and a hole sequence of SEQ ID NO: 14 (REF ID NO: 53). GSDIVMTQTPLSLSVTPGQPASISCKSSQSLLMSDGKTYLNWYLQKPGQSPQR LIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGAHFPYTFGQGTK LEIKGGGGSGGGGSGGGGSQVQLVESGGGVVQPGRSLRLSCAASGFTFSRYWMSW VRQAPGKGLEWIAEINPDSSTINYTPSLRDKFTISRDNSKNTLYLQNSSLRAEDTAVY YCARQGDYWGQGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 2) |GSDIVMTQTPLSLSVTPGQPASI SCKSSQSLLMSDGKTYLNWYLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTL KISRVEAEDVGVYYCWQGAHFPYTFGQGTKLEIKGGGGSGGGGSGGGGSQVQLVES GGGVVQPGRSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWIAEINPDSSTINYTPSL RDKFTISRDNSKNTLYLQNSSLRAEDTAVYYCARQGDYWGQGTLVTVSSAAADKT HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI SKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKW0571.70067WO0081 / 202TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 14)

[0320] The bispecific antibody comprising a knob sequence of SEQ ID NO: 2 and a hole sequence of SEQ ID NO: 15 (REF ID NO: 54). GSDIVMTQTPLSLSVTPGQPASISCKSSQSLLMSDGKTYLNWYLQKPGQSPQR LIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGAHFPYTFGQGTK LEIKGGGGSGGGGSGGGGSQVQLVESGGGVVQPGRSLRLSCAASGFTFSRYWMSW VRQAPGKGLEWIAEINPDSSTINYTPSLRDKFTISRDNSKNTLYLQNSSLRAEDTAVY YCARQGDYWGQGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 2) |GSENVLTQSPAIMSASPGEKVT MTCSASSSVSYMHWYQQKSTTSPKLWIYDTSKLASGVPGRFSGSGSGNSYSLTISSM EAEDVATYYCFQGSGYPLTFGGGTKLEIKGGGGSGGGGSGGGGSQGPPSLKESGPGL VAPSQSLSITCTVSGFSLTSYGVHWVRQPPGKGLEWIGVIWAGGSTNYNSALMSRLSI SKDNSKSQVFLKMNSLQTDDTAMYYCAVYYGYLFFAYWGQGTLVTVSAAAAADK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI SKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 15)

[0321] The bispecific antibody comprising a knob sequence of SEQ ID NO: 2 and a hole sequence of SEQ ID NO: 16 (REF ID NO: 55). GSDIVMTQTPLSLSVTPGQPASISCKSSQSLLMSDGKTYLNWYLQKPGQSPQR LIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGAHFPYTFGQGTK LEIKGGGGSGGGGSGGGGSQVQLVESGGGVVQPGRSLRLSCAASGFTFSRYWMSW VRQAPGKGLEWIAEINPDSSTINYTPSLRDKFTISRDNSKNTLYLQNSSLRAEDTAVY YCARQGDYWGQGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 2) |GSEIVLTQSPATLSLSPGERATL SCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPW0571.70067WO0082 / 202EDFAVYYCQQRSNWPPTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLLESGGGLVQP GGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTIS RDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSSAAAA DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG K* (SEQ ID NO: 16)

[0322] The bispecific antibody comprising a knob sequence of SEQ ID NO: 2 and a hole sequence of SEQ ID NO: 17 (REF ID NO: 56). GSDIVMTQTPLSLSVTPGQPASISCKSSQSLLMSDGKTYLNWYLQKPGQSPQR LIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGAHFPYTFGQGTK LEIKGGGGSGGGGSGGGGSQVQLVESGGGVVQPGRSLRLSCAASGFTFSRYWMSW VRQAPGKGLEWIAEINPDSSTINYTPSLRDKFTISRDNSKNTLYLQNSSLRAEDTAVY YCARQGDYWGQGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 2) |GSDIQMTQSPSSLSASVGDRVTI TCRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSGTDFTLT ISSLQPEDFATYFCSQTTHVPWTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLVESGG GLVQPGGSLRLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVIPNAGGTSNQKFKG RFTLSVDNSKNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGTLVTVSSAAAADKT HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI SKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 17)

[0323] The bispecific antibody comprising a knob sequence of SEQ ID NO: 2 and a hole sequence of SEQ ID NO: 18 (REF ID NO: 57). GSDIVMTQTPLSLSVTPGQPASISCKSSQSLLMSDGKTYLNWYLQKPGQSPQR LIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGAHFPYTFGQGTK LEIKGGGGSGGGGSGGGGSQVQLVESGGGVVQPGRSLRLSCAASGFTFSRYWMSW VRQAPGKGLEWIAEINPDSSTINYTPSLRDKFTISRDNSKNTLYLQNSSLRAEDTAVYW0571.70067WO0083 / 202YCARQGDYWGQGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 2) |GSDIQMTQSPSSLSASVGDRVTI TCRTSENIYNNLAWYQQKPGKSPKLLIYAATNLADGVPRFSGSGSGTDYTLTISSLQP EDFATYYCQHFWGTPLTFGGGTKVEIKGGGGSGGGGSGGGGSVQLVQSGAEVKKP GASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWIGEINPINGRSNYAEKFQGRVT LTVDTSSSTAYMELSRLRSDDTAVYYCARGTRAMHYWGQGTLVTVSSAAAADKTH TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 18)

[0324] The bispecific antibody comprising a knob sequence of SEQ ID NO: 2 and a hole sequence of SEQ ID NO: 19 (REF ID NO: 58). GSDIVMTQTPLSLSVTPGQPASISCKSSQSLLMSDGKTYLNWYLQKPGQSPQR LIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGAHFPYTFGQGTK LEIKGGGGSGGGGSGGGGSQVQLVESGGGVVQPGRSLRLSCAASGFTFSRYWMSW VRQAPGKGLEWIAEINPDSSTINYTPSLRDKFTISRDNSKNTLYLQNSSLRAEDTAVY YCARQGDYWGQGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 2) |GSDIVLTQSPASLAVSLGQRATI SCKASQSVDYDGDSFLNWYQKPGQPPKLFIYAASNLESGIPARFSGSGSGTDFTLNIH PVEEEDAATYYCQQSNEDPLTFGAGTELELKGGGGSGGGGSGGGGSEVQLQQSGAE LMKPGASVKISCKATGYTFSSYWIEWKQRPGHGLEWIGEILPGGGDTNYNEIFKGKA TETADTSSNTAYMLSSLISEDSAVYYCTRRVPVYFDYWGQGTSVTVSSAAAADKTH TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 19)W0571.70067WO0084 / 202

[0325] The bispecific antibody comprising a knob sequence of SEQ ID NO: 2 and a hole sequence of SEQ ID NO: 20 (REF ID NO: 59). GSDIVMTQTPLSLSVTPGQPASISCKSSQSLLMSDGKTYLNWYLQKPGQSPQR LIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGAHFPYTFGQGTK LEIKGGGGSGGGGSGGGGSQVQLVESGGGVVQPGRSLRLSCAASGFTFSRYWMSW VRQAPGKGLEWIAEINPDSSTINYTPSLRDKFTISRDNSKNTLYLQNSSLRAEDTAVY YCARQGDYWGQGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 2) |GSDIQLTQSPSFLSASVGDRVTI TCQASQTIYTNLAWYQQKPGKAPKLLIYAASTLASGVPSRFSGSGSGTEFTLTISSLQP EDFATYYCQSYYGSSTTGNGFGGGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGGL VQPGGSLRLSCAASGFSFSSSYCMCWVRQAPGKGLELVSCIYTDSSGATYYASWAK GRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARGWDYEDPGYTDTTYFSLWGRGT LVTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV SNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEW ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPGK* (SEQ ID NO: 20)

[0326] The bispecific antibody comprising a knob sequence of SEQ ID NO: 2 and a hole sequence of SEQ ID NO: 21 (REF ID NO: 60). GSDIVMTQTPLSLSVTPGQPASISCKSSQSLLMSDGKTYLNWYLQKPGQSPQR LIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGAHFPYTFGQGTK LEIKGGGGSGGGGSGGGGSQVQLVESGGGVVQPGRSLRLSCAASGFTFSRYWMSW VRQAPGKGLEWIAEINPDSSTINYTPSLRDKFTISRDNSKNTLYLQNSSLRAEDTAVY YCARQGDYWGQGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 2) |GSDIVMTQSPDSLAVSLGERAT ISCRASESVEYYGTSLMQWYQQKPGQPPKLLIYVASNVESGVPDRFSGSGSGTDFTL TISSLQAEDVAVYFCQQSTKVPWTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVES GGGLVKPGGSLRLSCAASGFTFNTNAMNWVRQAPGKGLEWVARIRSKSNNYATYYW0571.70067WO0085 / 202AESVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCVTDGYYWGQGTTLTVSSAAA DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG K* (SEQ ID NO: 21)

[0327] The bispecific antibody comprising a knob sequence of SEQ ID NO: 2 and a hole sequence of SEQ ID NO: 22 (REF ID NO: 61). GSDIVMTQTPLSLSVTPGQPASISCKSSQSLLMSDGKTYLNWYLQKPGQSPQR LIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGAHFPYTFGQGTK LEIKGGGGSGGGGSGGGGSQVQLVESGGGVVQPGRSLRLSCAASGFTFSRYWMSW VRQAPGKGLEWIAEINPDSSTINYTPSLRDKFTISRDNSKNTLYLQNSSLRAEDTAVY YCARQGDYWGQGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 2) |GSEEELQIIQPDKSVLVAAGET ATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQRQGPFPRVTTVSDTTKRNNMDFSIRIG NITPADAGTYYCIKFRKGSPDDVEFKSGAGTELSVRAKPSAAADKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP REEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 22)

[0328] The bispecific antibody comprising a knob sequence of SEQ ID NO: 2 and a hole sequence of SEQ ID NO: 23 (REF ID NO: 62). GSDIVMTQTPLSLSVTPGQPASISCKSSQSLLMSDGKTYLNWYLQKPGQSPQR LIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGAHFPYTFGQGTK LEIKGGGGSGGGGSGGGGSQVQLVESGGGVVQPGRSLRLSCAASGFTFSRYWMSW VRQAPGKGLEWIAEINPDSSTINYTPSLRDKFTISRDNSKNTLYLQNSSLRAEDTAVY YCARQGDYWGQGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 2) |GSDIQMTQSPSSLSASVGDRVTIW0571.70067WO0086 / 202TCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQP EDFVTYYCQQYNSYPRTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGGLVQP GGSLRLSCAAAGFTFSSYSMNWVRQAPGKGLEWVSYISSRSRTIYYADSVKGRFTIS RDNAKNSLYLQMNSLRDEDTAVYYCARDYGGQPPYYYYYGMDVWGQGTTVTVSS AAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL PAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS LSPGK* (SEQ ID NO: 23)

[0329] The bispecific antibody comprising a knob sequence of SEQ ID NO: 2 and a hole sequence of SEQ ID NO: 24 (REF ID NO: 63). GSDIVMTQTPLSLSVTPGQPASISCKSSQSLLMSDGKTYLNWYLQKPGQSPQR LIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGAHFPYTFGQGTK LEIKGGGGSGGGGSGGGGSQVQLVESGGGVVQPGRSLRLSCAASGFTFSRYWMSW VRQAPGKGLEWIAEINPDSSTINYTPSLRDKFTISRDNSKNTLYLQNSSLRAEDTAVY YCARQGDYWGQGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 2) |GSEIVLTQSPATLSLSPGERATL SCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEP EDFAVYYCQQSSNWPRTFGQGTKVEIKGGGGSGGGGSGGGGSQVQLVESGGGVVQ PGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRF TISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSAAAADKTHTC PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 24)

[0330] The bispecific antibody comprising a knob sequence of SEQ ID NO: 2 and a hole sequence of SEQ ID NO: 25 (REF ID NO: 64). GSDIVMTQTPLSLSVTPGQPASISCKSSQSLLMSDGKTYLNWYLQKPGQSPQR LIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGAHFPYTFGQGTK LEIKGGGGSGGGGSGGGGSQVQLVESGGGVVQPGRSLRLSCAASGFTFSRYWMSWW0571.70067WO0087 / 202VRQAPGKGLEWIAEINPDSSTINYTPSLRDKFTISRDNSKNTLYLQNSSLRAEDTAVY YCARQGDYWGQGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 2) |GSEEELQVIQPDKSVLVAAGET ATLRCTATSLIPVGPIQWFRGAGPGRELIYNQKEGHFPRVTTVSDLTKRNNMDFSIRI GNITPADAGTYYCVKFRKGSPDDVEFKSGAGTELSVRAKPSAAADKTHTCPPCPAPE LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP QVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 25)

[0331] The bispecific antibody comprising a knob sequence of SEQ ID NO: 4 and a hole sequence of SEQ ID NO: 13 (REF ID NO: 65). GSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDAS NRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKGGG GSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKG LEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKI LWFGEPVFDYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 4) |GSQIVLSQSPAILSASPGEK VTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISR VEAEDAATYYCQQWTSNPPTFGGGTKLEIKGGGGSGGGGSGGGGSQVQLQQPGAE LVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFK GKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVS AAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA LPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL SLSPGK* (SEQ ID NO: 13)

[0332] The bispecific antibody comprising a knob sequence of SEQ ID NO: 4 and a hole sequence of SEQ ID NO: 14 (REF ID NO: 66).W0571.70067WO0088 / 202GSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDAS NRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKGGG GSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKG LEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKI LWFGEPVFDYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 4) |GSDIVMTQTPLSLSVTPGQ PASISCKSSQSLLMSDGKTYLNWYLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTD FTLKISRVEAEDVGVYYCWQGAHFPYTFGQGTKLEIKGGGGSGGGGSGGGGSQVQL VESGGGVVQPGRSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWIAEINPDSSTINYT PSLRDKFTISRDNSKNTLYLQNSSLRAEDTAVYYCARQGDYWGQGTLVTVSSAAAD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 14)

[0333] The bispecific antibody comprising a knob sequence of SEQ ID NO: 4 and a hole sequence of SEQ ID NO: 15 (REF ID NO: 67). GSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDAS NRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKGGG GSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKG LEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKI LWFGEPVFDYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 4) |GSENVLTQSPAIMSASPGE KVTMTCSASSSVSYMHWYQQKSTTSPKLWIYDTSKLASGVPGRFSGSGSGNSYSLTI SSMEAEDVATYYCFQGSGYPLTFGGGTKLEIKGGGGSGGGGSGGGGSQGPPSLKES GPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPGKGLEWIGVIWAGGSTNYNSALM SRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAVYYGYLFFAYWGQGTLVTVSAAA AADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW0571.70067WO0089 / 202WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA PIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPE NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS PGK* (SEQ ID NO: 15)

[0334] The bispecific antibody comprising a knob sequence of SEQ ID NO: 4 and a hole sequence of SEQ ID NO: 16 (REF ID NO: 68). GSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDAS NRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKGGG GSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKG LEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKI LWFGEPVFDYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 4) |GSEIVLTQSPATLSLSPGER ATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTIS SLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLLESGGG LVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKG RFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSS AAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL PAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS LSPGK* (SEQ ID NO: 16)

[0335] The bispecific antibody comprising a knob sequence of SEQ ID NO: 4 and a hole sequence of SEQ ID NO: 17 (REF ID NO: 69). GSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDAS NRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKGGG GSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKG LEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKI LWFGEPVFDYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNW0571.70067WO0090 / 202VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 4) |GSDIQMTQSPSSLSASVGD RVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSGTD FTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLV ESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVIPNAGGTSNQ KFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGTLVTVSSAAA ADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI EKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP GK* (SEQ ID NO: 17)

[0336] The bispecific antibody comprising a knob sequence of SEQ ID NO: 4 and a hole sequence of SEQ ID NO: 18 (REF ID NO: 70). GSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDAS NRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKGGG GSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKG LEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKI LWFGEPVFDYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 4) |GSDIQMTQSPSSLSASVGD RVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAATNLADGVPRFSGSGSGTDYTLTIS SLQPEDFATYYCQHFWGTPLTFGGGTKVEIKGGGGSGGGGSGGGGSVQLVQSGAEV KKPGASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWIGEINPINGRSNYAEKFQG RVTLTVDTSSSTAYMELSRLRSDDTAVYYCARGTRAMHYWGQGTLVTVSSAAAAD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 18)

[0337] The bispecific antibody comprising a knob sequence of SEQ ID NO: 4 and a hole sequence of SEQ ID NO: 19 (REF ID NO: 71). GSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDAS NRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKGGGW0571.70067WO0091 / 202GSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKG LEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKI LWFGEPVFDYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 4) |GSDIVLTQSPASLAVSLGQ RATISCKASQSVDYDGDSFLNWYQKPGQPPKLFIYAASNLESGIPARFSGSGSGTDFT LNIHPVEEEDAATYYCQQSNEDPLTFGAGTELELKGGGGSGGGGSGGGGSEVQLQQ SGAELMKPGASVKISCKATGYTFSSYWIEWKQRPGHGLEWIGEILPGGGDTNYNEIF KGKATETADTSSNTAYMLSSLISEDSAVYYCTRRVPVYFDYWGQGTSVTVSSAAAA DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG K* (SEQ ID NO: 19)

[0338] The bispecific antibody comprising a knob sequence of SEQ ID NO: 4 and a hole sequence of SEQ ID NO: 20 (REF ID NO: 72). GSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDAS NRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKGGG GSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKG LEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKI LWFGEPVFDYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 4) |GSDIQLTQSPSFLSASVGDR VTITCQASQTIYTNLAWYQQKPGKAPKLLIYAASTLASGVPSRFSGSGSGTEFTLTISS LQPEDFATYYCQSYYGSSTTGNGFGGGTKVEIKGGGGSGGGGSGGGGSEVQLVESG GGLVQPGGSLRLSCAASGFSFSSSYCMCWVRQAPGKGLELVSCIYTDSSGATYYAS WAKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARGWDYEDPGYTDTTYFSLWG RGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAW0571.70067WO0092 / 202VEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK* (SEQ ID NO: 20)

[0339] The bispecific antibody comprising a knob sequence of SEQ ID NO: 4 and a hole sequence of SEQ ID NO: 21 (REF ID NO: 73). GSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDAS NRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKGGG GSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKG LEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKI LWFGEPVFDYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 4) |GSDIVMTQSPDSLAVSLGE RATISCRASESVEYYGTSLMQWYQQKPGQPPKLLIYVASNVESGVPDRFSGSGSGTD FTLTISSLQAEDVAVYFCQQSTKVPWTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLV ESGGGLVKPGGSLRLSCAASGFTFNTNAMNWVRQAPGKGLEWVARIRSKSNNYAT YYAESVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCVTDGYYWGQGTTLTVSSA AADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA PIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPE NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS PGK* (SEQ ID NO: 21)

[0340] The bispecific antibody comprising a knob sequence of SEQ ID NO: 4 and a hole sequence of SEQ ID NO: 22 (REF ID NO: 74). GSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDAS NRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKGGG GSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKG LEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKI LWFGEPVFDYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 4) |GSEEELQIIQPDKSVLVAAG ETATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQRQGPFPRVTTVSDTTKRNNMDFSIW0571.70067WO0093 / 202RIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGTELSVRAKPSAAADKTHTCPPCPAP ELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 22)

[0341] The bispecific antibody comprising a knob sequence of SEQ ID NO: 4 and a hole sequence of SEQ ID NO: 23 (REF ID NO: 75). GSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDAS NRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKGGG GSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKG LEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKI LWFGEPVFDYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 4) |GSDIQMTQSPSSLSASVGD RVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTIS SLQPEDFVTYYCQQYNSYPRTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGG LVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPGKGLEWVSYISSRSRTIYYADSVKGR FTISRDNAKNSLYLQMNSLRDEDTAVYYCARDYGGQPPYYYYYGMDVWGQGTTV TVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS NKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPGK* (SEQ ID NO: 23)

[0342] The bispecific antibody comprising a knob sequence of SEQ ID NO: 4 and a hole sequence of SEQ ID NO: 24 (REF ID NO: 76). GSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDAS NRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKGGG GSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKG LEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKI LWFGEPVFDYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVW0571.70067WO0094 / 202LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 4) |GSEIVLTQSPATLSLSPGER ATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTIS SLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKGGGGSGGGGSGGGGSQVQLVESGGG VVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVK GRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSAAAADKT HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI SKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 24)

[0343] The bispecific antibody comprising a knob sequence of SEQ ID NO: 4 and a hole sequence of SEQ ID NO: 25 (REF ID NO: 77). GSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDAS NRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKGGG GSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKG LEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKI LWFGEPVFDYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 4) |GSEEELQVIQPDKSVLVAA GETATLRCTATSLIPVGPIQWFRGAGPGRELIYNQKEGHFPRVTTVSDLTKRNNMDFS IRIGNITPADAGTYYCVKFRKGSPDDVEFKSGAGTELSVRAKPSAAADKTHTCPPCPA PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 25)

[0344] The bispecific antibody comprising a knob sequence of SEQ ID NO: 5 and a hole sequence of SEQ ID NO: 13 (REF ID NO: 78). GSDIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKL LIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVEW0571.70067WO0095 / 202IKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQ APGKGLEWVARVIPNAGGTSNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYY CAREGIYWWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 5) |GSQIVLSQSPAILSASPGEKVT MTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVE AEDAATYYCQQWTSNPPTFGGGTKLEIKGGGGSGGGGSGGGGSQVQLQQPGAELV KPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGK ATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSAA AAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL SPGK* (SEQ ID NO: 13)

[0345] The bispecific antibody comprising a knob sequence of SEQ ID NO: 5 and a hole sequence of SEQ ID NO: 14 (REF ID NO: 79). GSDIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKL LIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVE IKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQ APGKGLEWVARVIPNAGGTSNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYY CAREGIYWWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 5) |GSDIVMTQTPLSLSVTPGQPA SISCKSSQSLLMSDGKTYLNWYLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFT LKISRVEAEDVGVYYCWQGAHFPYTFGQGTKLEIKGGGGSGGGGSGGGGSQVQLV ESGGGVVQPGRSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWIAEINPDSSTINYTP SLRDKFTISRDNSKNTLYLQNSSLRAEDTAVYYCARQGDYWGQGTLVTVSSAAADK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI SKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKW0571.70067WO0096 / 202TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 14)

[0346] The bispecific antibody comprising a knob sequence of SEQ ID NO: 5 and a hole sequence of SEQ ID NO: 15 (REF ID NO: 80). GSDIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKL LIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVE IKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQ APGKGLEWVARVIPNAGGTSNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYY CAREGIYWWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 5) |GSENVLTQSPAIMSASPGEKV TMTCSASSSVSYMHWYQQKSTTSPKLWIYDTSKLASGVPGRFSGSGSGNSYSLTISS MEAEDVATYYCFQGSGYPLTFGGGTKLEIKGGGGSGGGGSGGGGSQGPPSLKESGP GLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPGKGLEWIGVIWAGGSTNYNSALMSR LSISKDNSKSQVFLKMNSLQTDDTAMYYCAVYYGYLFFAYWGQGTLVTVSAAAAA DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG K* (SEQ ID NO: 15)

[0347] The bispecific antibody comprising a knob sequence of SEQ ID NO: 5 and a hole sequence of SEQ ID NO: 16 (REF ID NO: 81). GSDIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKL LIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVE IKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQ APGKGLEWVARVIPNAGGTSNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYY CAREGIYWWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 5) |GSEIVLTQSPATLSLSPGERAT LSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEW0571.70067WO0097 / 202PEDFAVYYCQQRSNWPPTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLLESGGGLVQ PGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSSAAA ADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI EKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP GK* (SEQ ID NO: 16)

[0348] The bispecific antibody comprising a knob sequence of SEQ ID NO: 5 and a hole sequence of SEQ ID NO: 17 (REF ID NO: 82). GSDIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKL LIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVE IKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQ APGKGLEWVARVIPNAGGTSNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYY CAREGIYWWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 5) |GSDIQMTQSPSSLSASVGDRV TITCRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSGTDFT LTISSLQPEDFATYFCSQTTHVPWTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLVES GGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVIPNAGGTSNQKF KGRFTLSVDNSKNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGTLVTVSSAAAAD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 17)

[0349] The bispecific antibody comprising a knob sequence of SEQ ID NO: 5 and a hole sequence of SEQ ID NO: 18 (REF ID NO: 83). GSDIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKL LIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVE IKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQ APGKGLEWVARVIPNAGGTSNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYYW0571.70067WO0098 / 202CAREGIYWWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 5) |GSDIQMTQSPSSLSASVGDRV TITCRTSENIYNNLAWYQQKPGKSPKLLIYAATNLADGVPRFSGSGSGTDYTLTISSL QPEDFATYYCQHFWGTPLTFGGGTKVEIKGGGGSGGGGSGGGGSVQLVQSGAEVK KPGASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWIGEINPINGRSNYAEKFQGR VTLTVDTSSSTAYMELSRLRSDDTAVYYCARGTRAMHYWGQGTLVTVSSAAAADK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI SKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 18)

[0350] The bispecific antibody comprising a knob sequence of SEQ ID NO: 5 and a hole sequence of SEQ ID NO: 19 (REF ID NO: 84). GSDIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKL LIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVE IKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQ APGKGLEWVARVIPNAGGTSNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYY CAREGIYWWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 5) |GSDIVLTQSPASLAVSLGQRA TISCKASQSVDYDGDSFLNWYQKPGQPPKLFIYAASNLESGIPARFSGSGSGTDFTLNI HPVEEEDAATYYCQQSNEDPLTFGAGTELELKGGGGSGGGGSGGGGSEVQLQQSGA ELMKPGASVKISCKATGYTFSSYWIEWKQRPGHGLEWIGEILPGGGDTNYNEIFKGK ATETADTSSNTAYMLSSLISEDSAVYYCTRRVPVYFDYWGQGTSVTVSSAAAADKT HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI SKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 19)W0571.70067WO0099 / 202

[0351] The bispecific antibody comprising a knob sequence of SEQ ID NO: 5 and a hole sequence of SEQ ID NO: 20 (REF ID NO: 85). GSDIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKL LIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVE IKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQ APGKGLEWVARVIPNAGGTSNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYY CAREGIYWWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 5) |GSDIQLTQSPSFLSASVGDRVT ITCQASQTIYTNLAWYQQKPGKAPKLLIYAASTLASGVPSRFSGSGSGTEFTLTISSLQ PEDFATYYCQSYYGSSTTGNGFGGGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGG LVQPGGSLRLSCAASGFSFSSSYCMCWVRQAPGKGLELVSCIYTDSSGATYYASWA KGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARGWDYEDPGYTDTTYFSLWGRG TLVTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK* (SEQ ID NO: 20)

[0352] The bispecific antibody comprising a knob sequence of SEQ ID NO: 5 and a hole sequence of SEQ ID NO: 21 (REF ID NO: 86). GSDIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKL LIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVE IKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQ APGKGLEWVARVIPNAGGTSNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYY CAREGIYWWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 5) |GSDIVMTQSPDSLAVSLGERA TISCRASESVEYYGTSLMQWYQQKPGQPPKLLIYVASNVESGVPDRFSGSGSGTDFT LTISSLQAEDVAVYFCQQSTKVPWTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVES GGGLVKPGGSLRLSCAASGFTFNTNAMNWVRQAPGKGLEWVARIRSKSNNYATYYW0571.70067WO00100 / 202AESVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCVTDGYYWGQGTTLTVSSAAA DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG K* (SEQ ID NO: 21)

[0353] The bispecific antibody comprising a knob sequence of SEQ ID NO: 5 and a hole sequence of SEQ ID NO: 22 (REF ID NO: 87). GSDIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKL LIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVE IKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQ APGKGLEWVARVIPNAGGTSNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYY CAREGIYWWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 5) |GSEEELQIIQPDKSVLVAAGET ATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQRQGPFPRVTTVSDTTKRNNMDFSIRIG NITPADAGTYYCIKFRKGSPDDVEFKSGAGTELSVRAKPSAAADKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP REEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 22)

[0354] The bispecific antibody comprising a knob sequence of SEQ ID NO: 5 and a hole sequence of SEQ ID NO: 23 (REF ID NO: 88). GSDIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKL LIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVE IKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQ APGKGLEWVARVIPNAGGTSNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYY CAREGIYWWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 5) |GSDIQMTQSPSSLSASVGDRVW0571.70067WO00101 / 202TITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSL QPEDFVTYYCQQYNSYPRTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGGLV QPGGSLRLSCAAAGFTFSSYSMNWVRQAPGKGLEWVSYISSRSRTIYYADSVKGRFT ISRDNAKNSLYLQMNSLRDEDTAVYYCARDYGGQPPYYYYYGMDVWGQGTTVTV SSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK ALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK* (SEQ ID NO: 23)

[0355] The bispecific antibody comprising a knob sequence of SEQ ID NO: 5 and a hole sequence of SEQ ID NO: 24 (REF ID NO: 89). GSDIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKL LIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVE IKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQ APGKGLEWVARVIPNAGGTSNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYY CAREGIYWWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 5) |GSEIVLTQSPATLSLSPGERAT LSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLE PEDFAVYYCQQSSNWPRTFGQGTKVEIKGGGGSGGGGSGGGGSQVQLVESGGGVV QPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGR FTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSAAAADKTHT CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 24)

[0356] The bispecific antibody comprising a knob sequence of SEQ ID NO: 5 and a hole sequence of SEQ ID NO: 25 (REF ID NO: 90). GSDIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKL LIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVE IKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQW0571.70067WO00102 / 202APGKGLEWVARVIPNAGGTSNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYY CAREGIYWWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 5) |GSEEELQVIQPDKSVLVAAGE TATLRCTATSLIPVGPIQWFRGAGPGRELIYNQKEGHFPRVTTVSDLTKRNNMDFSIRI GNITPADAGTYYCVKFRKGSPDDVEFKSGAGTELSVRAKPSAAADKTHTCPPCPAPE LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP QVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 25)

[0357] The bispecific antibody comprising a knob sequence of SEQ ID NO: 6 and a hole sequence of SEQ ID NO: 13 (REF ID NO: 91). GSDIQMTQSPSSLSASVGDRVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAA TNLADGVPRFSGSGSGTDYTLTISSLQPEDFATYYCQHFWGTPLTFGGGTKVEIKGG GGSGGGGSGGGGSVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPG QGLEWIGEINPINGRSNYAEKFQGRVTLTVDTSSSTAYMELSRLRSDDTAVYYCARG TRAMHYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 6) |GSQIVLSQSPAILSASPGEKVTMT CRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAED AATYYCQQWTSNPPTFGGGTKLEIKGGGGSGGGGSGGGGSQVQLQQPGAELVKPG ASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATL TADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSAAAAA DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG K* (SEQ ID NO: 13)

[0358] The bispecific antibody comprising a knob sequence of SEQ ID NO: 6 and a hole sequence of SEQ ID NO: 14 (REF ID NO: 92).W0571.70067WO00103 / 202GSDIQMTQSPSSLSASVGDRVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAA TNLADGVPRFSGSGSGTDYTLTISSLQPEDFATYYCQHFWGTPLTFGGGTKVEIKGG GGSGGGGSGGGGSVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPG QGLEWIGEINPINGRSNYAEKFQGRVTLTVDTSSSTAYMELSRLRSDDTAVYYCARG TRAMHYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 6) |GSDIVMTQTPLSLSVTPGQPASIS CKSSQSLLMSDGKTYLNWYLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLK ISRVEAEDVGVYYCWQGAHFPYTFGQGTKLEIKGGGGSGGGGSGGGGSQVQLVESG GGVVQPGRSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWIAEINPDSSTINYTPSLR DKFTISRDNSKNTLYLQNSSLRAEDTAVYYCARQGDYWGQGTLVTVSSAAADKTHT CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 14)

[0359] The bispecific antibody comprising a knob sequence of SEQ ID NO: 6 and a hole sequence of SEQ ID NO: 15 (REF ID NO: 93). GSDIQMTQSPSSLSASVGDRVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAA TNLADGVPRFSGSGSGTDYTLTISSLQPEDFATYYCQHFWGTPLTFGGGTKVEIKGG GGSGGGGSGGGGSVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPG QGLEWIGEINPINGRSNYAEKFQGRVTLTVDTSSSTAYMELSRLRSDDTAVYYCARG TRAMHYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 6) |GSENVLTQSPAIMSASPGEKVTM TCSASSSVSYMHWYQQKSTTSPKLWIYDTSKLASGVPGRFSGSGSGNSYSLTISSME AEDVATYYCFQGSGYPLTFGGGTKLEIKGGGGSGGGGSGGGGSQGPPSLKESGPGL VAPSQSLSITCTVSGFSLTSYGVHWVRQPPGKGLEWIGVIWAGGSTNYNSALMSRLSI SKDNSKSQVFLKMNSLQTDDTAMYYCAVYYGYLFFAYWGQGTLVTVSAAAAADK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDW0571.70067WO00104 / 202GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI SKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 15)

[0360] The bispecific antibody comprising a knob sequence of SEQ ID NO: 6 and a hole sequence of SEQ ID NO: 16 (REF ID NO: 94). GSDIQMTQSPSSLSASVGDRVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAA TNLADGVPRFSGSGSGTDYTLTISSLQPEDFATYYCQHFWGTPLTFGGGTKVEIKGG GGSGGGGSGGGGSVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPG QGLEWIGEINPINGRSNYAEKFQGRVTLTVDTSSSTAYMELSRLRSDDTAVYYCARG TRAMHYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 6) |GSEIVLTQSPATLSLSPGERATLS CRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPE DFAVYYCQQRSNWPPTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLLESGGGLVQP GGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTIS RDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSSAAAA DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG K* (SEQ ID NO: 16)

[0361] The bispecific antibody comprising a knob sequence of SEQ ID NO: 6 and a hole sequence of SEQ ID NO: 17 (REF ID NO: 95). GSDIQMTQSPSSLSASVGDRVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAA TNLADGVPRFSGSGSGTDYTLTISSLQPEDFATYYCQHFWGTPLTFGGGTKVEIKGG GGSGGGGSGGGGSVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPG QGLEWIGEINPINGRSNYAEKFQGRVTLTVDTSSSTAYMELSRLRSDDTAVYYCARG TRAMHYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCW0571.70067WO00105 / 202SVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 6) |GSDIQMTQSPSSLSASVGDRVTIT CRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSGTDFTLTI SSLQPEDFATYFCSQTTHVPWTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLVESGG GLVQPGGSLRLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVIPNAGGTSNQKFKG RFTLSVDNSKNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGTLVTVSSAAAADKT HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI SKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 17)

[0362] The bispecific antibody comprising a knob sequence of SEQ ID NO: 6 and a hole sequence of SEQ ID NO: 18 (REF ID NO: 96). GSDIQMTQSPSSLSASVGDRVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAA TNLADGVPRFSGSGSGTDYTLTISSLQPEDFATYYCQHFWGTPLTFGGGTKVEIKGG GGSGGGGSGGGGSVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPG QGLEWIGEINPINGRSNYAEKFQGRVTLTVDTSSSTAYMELSRLRSDDTAVYYCARG TRAMHYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 6) |GSDIQMTQSPSSLSASVGDRVTIT CRTSENIYNNLAWYQQKPGKSPKLLIYAATNLADGVPRFSGSGSGTDYTLTISSLQPE DFATYYCQHFWGTPLTFGGGTKVEIKGGGGSGGGGSGGGGSVQLVQSGAEVKKPG ASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWIGEINPINGRSNYAEKFQGRVTLT VDTSSSTAYMELSRLRSDDTAVYYCARGTRAMHYWGQGTLVTVSSAAAADKTHTC PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 18)

[0363] The bispecific antibody comprising a knob sequence of SEQ ID NO: 6 and a hole sequence of SEQ ID NO: 19 (REF ID NO: 97). GSDIQMTQSPSSLSASVGDRVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAA TNLADGVPRFSGSGSGTDYTLTISSLQPEDFATYYCQHFWGTPLTFGGGTKVEIKGGW0571.70067WO00106 / 202GGSGGGGSGGGGSVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPG QGLEWIGEINPINGRSNYAEKFQGRVTLTVDTSSSTAYMELSRLRSDDTAVYYCARG TRAMHYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 6) |GSDIVLTQSPASLAVSLGQRATIS CKASQSVDYDGDSFLNWYQKPGQPPKLFIYAASNLESGIPARFSGSGSGTDFTLNIHP VEEEDAATYYCQQSNEDPLTFGAGTELELKGGGGSGGGGSGGGGSEVQLQQSGAEL MKPGASVKISCKATGYTFSSYWIEWKQRPGHGLEWIGEILPGGGDTNYNEIFKGKAT ETADTSSNTAYMLSSLISEDSAVYYCTRRVPVYFDYWGQGTSVTVSSAAAADKTHT CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 19)

[0364] The bispecific antibody comprising a knob sequence of SEQ ID NO: 6 and a hole sequence of SEQ ID NO: 20 (REF ID NO: 98). GSDIQMTQSPSSLSASVGDRVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAA TNLADGVPRFSGSGSGTDYTLTISSLQPEDFATYYCQHFWGTPLTFGGGTKVEIKGG GGSGGGGSGGGGSVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPG QGLEWIGEINPINGRSNYAEKFQGRVTLTVDTSSSTAYMELSRLRSDDTAVYYCARG TRAMHYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 6) |GSDIQLTQSPSFLSASVGDRVTIT CQASQTIYTNLAWYQQKPGKAPKLLIYAASTLASGVPSRFSGSGSGTEFTLTISSLQPE DFATYYCQSYYGSSTTGNGFGGGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGGLV QPGGSLRLSCAASGFSFSSSYCMCWVRQAPGKGLELVSCIYTDSSGATYYASWAKG RFTISRHNSKNTLYLQMNSLRAEDTAVYYCARGWDYEDPGYTDTTYFSLWGRGTL VTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS NKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWEW0571.70067WO00107 / 202SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPGK* (SEQ ID NO: 20)

[0365] The bispecific antibody comprising a knob sequence of SEQ ID NO: 6 and a hole sequence of SEQ ID NO: 21 (REF ID NO: 99). GSDIQMTQSPSSLSASVGDRVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAA TNLADGVPRFSGSGSGTDYTLTISSLQPEDFATYYCQHFWGTPLTFGGGTKVEIKGG GGSGGGGSGGGGSVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPG QGLEWIGEINPINGRSNYAEKFQGRVTLTVDTSSSTAYMELSRLRSDDTAVYYCARG TRAMHYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 6) |GSDIVMTQSPDSLAVSLGERATIS CRASESVEYYGTSLMQWYQQKPGQPPKLLIYVASNVESGVPDRFSGSGSGTDFTLTI SSLQAEDVAVYFCQQSTKVPWTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVESGG GLVKPGGSLRLSCAASGFTFNTNAMNWVRQAPGKGLEWVARIRSKSNNYATYYAE SVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCVTDGYYWGQGTTLTVSSAAAD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 21)

[0366] The bispecific antibody comprising a knob sequence of SEQ ID NO: 6 and a hole sequence of SEQ ID NO: 22 (REF ID NO: 100). GSDIQMTQSPSSLSASVGDRVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAA TNLADGVPRFSGSGSGTDYTLTISSLQPEDFATYYCQHFWGTPLTFGGGTKVEIKGG GGSGGGGSGGGGSVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPG QGLEWIGEINPINGRSNYAEKFQGRVTLTVDTSSSTAYMELSRLRSDDTAVYYCARG TRAMHYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 6) |GSEEELQIIQPDKSVLVAAGETA TLRCTITSLFPVGPIQWFRGAGPGRVLIYNQRQGPFPRVTTVSDTTKRNNMDFSIRIGNW0571.70067WO00108 / 202ITPADAGTYYCIKFRKGSPDDVEFKSGAGTELSVRAKPSAAADKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV YTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 22)

[0367] The bispecific antibody comprising a knob sequence of SEQ ID NO: 6 and a hole sequence of SEQ ID NO: 23 (REF ID NO: 101). GSDIQMTQSPSSLSASVGDRVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAA TNLADGVPRFSGSGSGTDYTLTISSLQPEDFATYYCQHFWGTPLTFGGGTKVEIKGG GGSGGGGSGGGGSVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPG QGLEWIGEINPINGRSNYAEKFQGRVTLTVDTSSSTAYMELSRLRSDDTAVYYCARG TRAMHYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 6) |GSDIQMTQSPSSLSASVGDRVTIT CRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPE DFVTYYCQQYNSYPRTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGGLVQPG GSLRLSCAAAGFTFSSYSMNWVRQAPGKGLEWVSYISSRSRTIYYADSVKGRFTISR DNAKNSLYLQMNSLRDEDTAVYYCARDYGGQPPYYYYYGMDVWGQGTTVTVSSA AAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL SPGK* (SEQ ID NO: 23)

[0368] The bispecific antibody comprising a knob sequence of SEQ ID NO: 6 and a hole sequence of SEQ ID NO: 24 (REF ID NO: 102). GSDIQMTQSPSSLSASVGDRVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAA TNLADGVPRFSGSGSGTDYTLTISSLQPEDFATYYCQHFWGTPLTFGGGTKVEIKGG GGSGGGGSGGGGSVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPG QGLEWIGEINPINGRSNYAEKFQGRVTLTVDTSSSTAYMELSRLRSDDTAVYYCARG TRAMHYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLW0571.70067WO00109 / 202VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 6) |GSEIVLTQSPATLSLSPGERATLS CRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPE DFAVYYCQQSSNWPRTFGQGTKVEIKGGGGSGGGGSGGGGSQVQLVESGGGVVQP GRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFT ISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSAAAADKTHTCPP CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 24)

[0369] The bispecific antibody comprising a knob sequence of SEQ ID NO: 6 and a hole sequence of SEQ ID NO: 25 (REF ID NO: 103). GSDIQMTQSPSSLSASVGDRVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAA TNLADGVPRFSGSGSGTDYTLTISSLQPEDFATYYCQHFWGTPLTFGGGTKVEIKGG GGSGGGGSGGGGSVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPG QGLEWIGEINPINGRSNYAEKFQGRVTLTVDTSSSTAYMELSRLRSDDTAVYYCARG TRAMHYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 6) |GSEEELQVIQPDKSVLVAAGETA TLRCTATSLIPVGPIQWFRGAGPGRELIYNQKEGHFPRVTTVSDLTKRNNMDFSIRIG NITPADAGTYYCVKFRKGSPDDVEFKSGAGTELSVRAKPSAAADKTHTCPPCPAPEL LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 25)

[0370] The bispecific antibody comprising a knob sequence of SEQ ID NO: 7 and a hole sequence of SEQ ID NO: 13 (REF ID NO: 104). GSDIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSFLNWYQKPGQPPKLFI YAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPLTFGAGTELEL KGGGGSGGGGSGGGGSEVQLQQSGAELMKPGASVKISCKATGYTFSSYWIEWKQRP GHGLEWIGEILPGGGDTNYNEIFKGKATETADTSSNTAYMLSSLISEDSAVYYCTRRVW0571.70067WO00110 / 202PVYFDYWGQGTSVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 7) |GSQIVLSQSPAILSASPGEKVTMTC RASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAED AATYYCQQWTSNPPTFGGGTKLEIKGGGGSGGGGSGGGGSQVQLQQPGAELVKPG ASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATL TADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSAAAAA DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG K* (SEQ ID NO: 13)

[0371] The bispecific antibody comprising a knob sequence of SEQ ID NO: 7 and a hole sequence of SEQ ID NO: 14 (REF ID NO: 105). GSDIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSFLNWYQKPGQPPKLFI YAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPLTFGAGTELEL KGGGGSGGGGSGGGGSEVQLQQSGAELMKPGASVKISCKATGYTFSSYWIEWKQRP GHGLEWIGEILPGGGDTNYNEIFKGKATETADTSSNTAYMLSSLISEDSAVYYCTRRV PVYFDYWGQGTSVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 7) |GSDIVMTQTPLSLSVTPGQPASISC KSSQSLLMSDGKTYLNWYLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKIS RVEAEDVGVYYCWQGAHFPYTFGQGTKLEIKGGGGSGGGGSGGGGSQVQLVESGG GVVQPGRSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWIAEINPDSSTINYTPSLRD KFTISRDNSKNTLYLQNSSLRAEDTAVYYCARQGDYWGQGTLVTVSSAAADKTHTC PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 14)W0571.70067WO00111 / 202

[0372] The bispecific antibody comprising a knob sequence of SEQ ID NO: 7 and a hole sequence of SEQ ID NO: 15 (REF ID NO: 106). GSDIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSFLNWYQKPGQPPKLFI YAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPLTFGAGTELEL KGGGGSGGGGSGGGGSEVQLQQSGAELMKPGASVKISCKATGYTFSSYWIEWKQRP GHGLEWIGEILPGGGDTNYNEIFKGKATETADTSSNTAYMLSSLISEDSAVYYCTRRV PVYFDYWGQGTSVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 7) |GSENVLTQSPAIMSASPGEKVTMT CSASSSVSYMHWYQQKSTTSPKLWIYDTSKLASGVPGRFSGSGSGNSYSLTISSMEA EDVATYYCFQGSGYPLTFGGGTKLEIKGGGGSGGGGSGGGGSQGPPSLKESGPGLV APSQSLSITCTVSGFSLTSYGVHWVRQPPGKGLEWIGVIWAGGSTNYNSALMSRLSIS KDNSKSQVFLKMNSLQTDDTAMYYCAVYYGYLFFAYWGQGTLVTVSAAAAADKT HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI SKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 15)

[0373] The bispecific antibody comprising a knob sequence of SEQ ID NO: 7 and a hole sequence of SEQ ID NO: 16 (REF ID NO: 107). GSDIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSFLNWYQKPGQPPKLFI YAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPLTFGAGTELEL KGGGGSGGGGSGGGGSEVQLQQSGAELMKPGASVKISCKATGYTFSSYWIEWKQRP GHGLEWIGEILPGGGDTNYNEIFKGKATETADTSSNTAYMLSSLISEDSAVYYCTRRV PVYFDYWGQGTSVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 7) |GSEIVLTQSPATLSLSPGERATLSC RASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPED FAVYYCQQRSNWPPTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLLESGGGLVQPG GSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRW0571.70067WO00112 / 202DNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSSAAAAD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 16)

[0374] The bispecific antibody comprising a knob sequence of SEQ ID NO: 7 and a hole sequence of SEQ ID NO: 17 (REF ID NO: 108). GSDIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSFLNWYQKPGQPPKLFI YAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPLTFGAGTELEL KGGGGSGGGGSGGGGSEVQLQQSGAELMKPGASVKISCKATGYTFSSYWIEWKQRP GHGLEWIGEILPGGGDTNYNEIFKGKATETADTSSNTAYMLSSLISEDSAVYYCTRRV PVYFDYWGQGTSVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 7) |GSDIQMTQSPSSLSASVGDRVTIT CRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSGTDFTLTI SSLQPEDFATYFCSQTTHVPWTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLVESGG GLVQPGGSLRLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVIPNAGGTSNQKFKG RFTLSVDNSKNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGTLVTVSSAAAADKT HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI SKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 17)

[0375] The bispecific antibody comprising a knob sequence of SEQ ID NO: 7 and a hole sequence of SEQ ID NO: 18 (REF ID NO: 109). GSDIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSFLNWYQKPGQPPKLFI YAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPLTFGAGTELEL KGGGGSGGGGSGGGGSEVQLQQSGAELMKPGASVKISCKATGYTFSSYWIEWKQRP GHGLEWIGEILPGGGDTNYNEIFKGKATETADTSSNTAYMLSSLISEDSAVYYCTRRV PVYFDYWGQGTSVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW0571.70067WO00113 / 202WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 7) |GSDIQMTQSPSSLSASVGDRVTIT CRTSENIYNNLAWYQQKPGKSPKLLIYAATNLADGVPRFSGSGSGTDYTLTISSLQPE DFATYYCQHFWGTPLTFGGGTKVEIKGGGGSGGGGSGGGGSVQLVQSGAEVKKPG ASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWIGEINPINGRSNYAEKFQGRVTLT VDTSSSTAYMELSRLRSDDTAVYYCARGTRAMHYWGQGTLVTVSSAAAADKTHTC PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 18)

[0376] The bispecific antibody comprising a knob sequence of SEQ ID NO: 7 and a hole sequence of SEQ ID NO: 19 (REF ID NO: 110). GSDIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSFLNWYQKPGQPPKLFI YAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPLTFGAGTELEL KGGGGSGGGGSGGGGSEVQLQQSGAELMKPGASVKISCKATGYTFSSYWIEWKQRP GHGLEWIGEILPGGGDTNYNEIFKGKATETADTSSNTAYMLSSLISEDSAVYYCTRRV PVYFDYWGQGTSVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 7) |GSDIVLTQSPASLAVSLGQRATISC KASQSVDYDGDSFLNWYQKPGQPPKLFIYAASNLESGIPARFSGSGSGTDFTLNIHPV EEEDAATYYCQQSNEDPLTFGAGTELELKGGGGSGGGGSGGGGSEVQLQQSGAEL MKPGASVKISCKATGYTFSSYWIEWKQRPGHGLEWIGEILPGGGDTNYNEIFKGKAT ETADTSSNTAYMLSSLISEDSAVYYCTRRVPVYFDYWGQGTSVTVSSAAAADKTHT CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 19)

[0377] The bispecific antibody comprising a knob sequence of SEQ ID NO: 7 and a hole sequence of SEQ ID NO: 20 (REF ID NO: 111).W0571.70067WO00114 / 202GSDIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSFLNWYQKPGQPPKLFI YAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPLTFGAGTELEL KGGGGSGGGGSGGGGSEVQLQQSGAELMKPGASVKISCKATGYTFSSYWIEWKQRP GHGLEWIGEILPGGGDTNYNEIFKGKATETADTSSNTAYMLSSLISEDSAVYYCTRRV PVYFDYWGQGTSVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 7) |GSDIQLTQSPSFLSASVGDRVTITC QASQTIYTNLAWYQQKPGKAPKLLIYAASTLASGVPSRFSGSGSGTEFTLTISSLQPED FATYYCQSYYGSSTTGNGFGGGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGGLVQ PGGSLRLSCAASGFSFSSSYCMCWVRQAPGKGLELVSCIYTDSSGATYYASWAKGRF TISRHNSKNTLYLQMNSLRAEDTAVYYCARGWDYEDPGYTDTTYFSLWGRGTLVT VSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK ALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK* (SEQ ID NO: 20)

[0378] The bispecific antibody comprising a knob sequence of SEQ ID NO: 7 and a hole sequence of SEQ ID NO: 21 (REF ID NO: 112). GSDIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSFLNWYQKPGQPPKLFI YAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPLTFGAGTELEL KGGGGSGGGGSGGGGSEVQLQQSGAELMKPGASVKISCKATGYTFSSYWIEWKQRP GHGLEWIGEILPGGGDTNYNEIFKGKATETADTSSNTAYMLSSLISEDSAVYYCTRRV PVYFDYWGQGTSVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 7) |GSDIVMTQSPDSLAVSLGERATIS CRASESVEYYGTSLMQWYQQKPGQPPKLLIYVASNVESGVPDRFSGSGSGTDFTLTI SSLQAEDVAVYFCQQSTKVPWTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVESGG GLVKPGGSLRLSCAASGFTFNTNAMNWVRQAPGKGLEWVARIRSKSNNYATYYAE SVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCVTDGYYWGQGTTLTVSSAAAD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVW0571.70067WO00115 / 202DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 21)

[0379] The bispecific antibody comprising a knob sequence of SEQ ID NO: 7 and a hole sequence of SEQ ID NO: 22 (REF ID NO: 113). GSDIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSFLNWYQKPGQPPKLFI YAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPLTFGAGTELEL KGGGGSGGGGSGGGGSEVQLQQSGAELMKPGASVKISCKATGYTFSSYWIEWKQRP GHGLEWIGEILPGGGDTNYNEIFKGKATETADTSSNTAYMLSSLISEDSAVYYCTRRV PVYFDYWGQGTSVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 7) |GSEEELQIIQPDKSVLVAAGETAT LRCTITSLFPVGPIQWFRGAGPGRVLIYNQRQGPFPRVTTVSDTTKRNNMDFSIRIGNI TPADAGTYYCIKFRKGSPDDVEFKSGAGTELSVRAKPSAAADKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV YTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 22)

[0380] The bispecific antibody comprising a knob sequence of SEQ ID NO: 7 and a hole sequence of SEQ ID NO: 23 (REF ID NO: 114). GSDIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSFLNWYQKPGQPPKLFI YAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPLTFGAGTELEL KGGGGSGGGGSGGGGSEVQLQQSGAELMKPGASVKISCKATGYTFSSYWIEWKQRP GHGLEWIGEILPGGGDTNYNEIFKGKATETADTSSNTAYMLSSLISEDSAVYYCTRRV PVYFDYWGQGTSVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 7) |GSDIQMTQSPSSLSASVGDRVTIT CRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPE DFVTYYCQQYNSYPRTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGW0571.70067WO00116 / 202GSLRLSCAAAGFTFSSYSMNWVRQAPGKGLEWVSYISSRSRTIYYADSVKGRFTISR DNAKNSLYLQMNSLRDEDTAVYYCARDYGGQPPYYYYYGMDVWGQGTTVTVSSA AAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL SPGK* (SEQ ID NO: 23)

[0381] The bispecific antibody comprising a knob sequence of SEQ ID NO: 7 and a hole sequence of SEQ ID NO: 24 (REF ID NO: 115). GSDIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSFLNWYQKPGQPPKLFI YAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPLTFGAGTELEL KGGGGSGGGGSGGGGSEVQLQQSGAELMKPGASVKISCKATGYTFSSYWIEWKQRP GHGLEWIGEILPGGGDTNYNEIFKGKATETADTSSNTAYMLSSLISEDSAVYYCTRRV PVYFDYWGQGTSVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 7) |GSEIVLTQSPATLSLSPGERATLSC RASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPED FAVYYCQQSSNWPRTFGQGTKVEIKGGGGSGGGGSGGGGSQVQLVESGGGVVQPG RSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTIS RDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSAAAADKTHTCPPC PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ PREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 24)

[0382] The bispecific antibody comprising a knob sequence of SEQ ID NO: 7 and a hole sequence of SEQ ID NO: 25 (REF ID NO: 116). GSDIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSFLNWYQKPGQPPKLFI YAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPLTFGAGTELEL KGGGGSGGGGSGGGGSEVQLQQSGAELMKPGASVKISCKATGYTFSSYWIEWKQRP GHGLEWIGEILPGGGDTNYNEIFKGKATETADTSSNTAYMLSSLISEDSAVYYCTRRV PVYFDYWGQGTSVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPW0571.70067WO00117 / 202EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 7) |GSEEELQVIQPDKSVLVAAGETAT LRCTATSLIPVGPIQWFRGAGPGRELIYNQKEGHFPRVTTVSDLTKRNNMDFSIRIGNI TPADAGTYYCVKFRKGSPDDVEFKSGAGTELSVRAKPSAAADKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV YTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 25)

[0383] The bispecific antibody comprising a knob sequence of SEQ ID NO: 8 and a hole sequence of SEQ ID NO: 13 (REF ID NO: 117). GSDIQLTQSPSFLSASVGDRVTITCQASQTIYTNLAWYQQKPGKAPKLLIYAA STLASGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQSYYGSSTTGNGFGGGTKVEIK GGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFSFSSSYCMCWVRQA PGKGLELVSCIYTDSSGATYYASWAKGRFTISRHNSKNTLYLQMNSLRAEDTAVYY CARGWDYEDPGYTDTTYFSLWGRGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 8) |GSQIVLSQSP AILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGS GTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKGGGGSGGGGSGGGGSQ VQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNG DTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVW GAGTTVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGK* (SEQ ID NO: 13)

[0384] The bispecific antibody comprising a knob sequence of SEQ ID NO: 8 and a hole sequence of SEQ ID NO: 14 (REF ID NO: 118). GSDIQLTQSPSFLSASVGDRVTITCQASQTIYTNLAWYQQKPGKAPKLLIYAA STLASGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQSYYGSSTTGNGFGGGTKVEIKW0571.70067WO00118 / 202GGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFSFSSSYCMCWVRQA PGKGLELVSCIYTDSSGATYYASWAKGRFTISRHNSKNTLYLQMNSLRAEDTAVYY CARGWDYEDPGYTDTTYFSLWGRGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 8) |GSDIVMTQT PLSLSVTPGQPASISCKSSQSLLMSDGKTYLNWYLQKPGQSPQRLIYLVSKLDSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCWQGAHFPYTFGQGTKLEIKGGGGSGGGG SGGGGSQVQLVESGGGVVQPGRSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWIA EINPDSSTINYTPSLRDKFTISRDNSKNTLYLQNSSLRAEDTAVYYCARQGDYWGQG TLVTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK* (SEQ ID NO: 14)

[0385] The bispecific antibody comprising a knob sequence of SEQ ID NO: 8 and a hole sequence of SEQ ID NO: 15 (REF ID NO: 119). GSDIQLTQSPSFLSASVGDRVTITCQASQTIYTNLAWYQQKPGKAPKLLIYAA STLASGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQSYYGSSTTGNGFGGGTKVEIK GGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFSFSSSYCMCWVRQA PGKGLELVSCIYTDSSGATYYASWAKGRFTISRHNSKNTLYLQMNSLRAEDTAVYY CARGWDYEDPGYTDTTYFSLWGRGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 8) |GSENVLTQS PAIMSASPGEKVTMTCSASSSVSYMHWYQQKSTTSPKLWIYDTSKLASGVPGRFSGS GSGNSYSLTISSMEAEDVATYYCFQGSGYPLTFGGGTKLEIKGGGGSGGGGSGGGGS QGPPSLKESGPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPGKGLEWIGVIWAGGS TNYNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAVYYGYLFFAYWGQGT LVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEW0571.70067WO00119 / 202WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK* (SEQ ID NO: 15)

[0386] The bispecific antibody comprising a knob sequence of SEQ ID NO: 8 and a hole sequence of SEQ ID NO: 16 (REF ID NO: 120). GSDIQLTQSPSFLSASVGDRVTITCQASQTIYTNLAWYQQKPGKAPKLLIYAA STLASGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQSYYGSSTTGNGFGGGTKVEIK GGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFSFSSSYCMCWVRQA PGKGLELVSCIYTDSSGATYYASWAKGRFTISRHNSKNTLYLQMNSLRAEDTAVYY CARGWDYEDPGYTDTTYFSLWGRGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 8) |GSEIVLTQSP ATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSG SGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKGGGGSGGGGSGGGGSE VQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGG TYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWG QGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDI AVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH NHYTQKSLSLSPGK* (SEQ ID NO: 16)

[0387] The bispecific antibody comprising a knob sequence of SEQ ID NO: 8 and a hole sequence of SEQ ID NO: 17 (REF ID NO: 121). GSDIQLTQSPSFLSASVGDRVTITCQASQTIYTNLAWYQQKPGKAPKLLIYAA STLASGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQSYYGSSTTGNGFGGGTKVEIK GGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFSFSSSYCMCWVRQA PGKGLELVSCIYTDSSGATYYASWAKGRFTISRHNSKNTLYLQMNSLRAEDTAVYY CARGWDYEDPGYTDTTYFSLWGRGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 8) |GSDIQMTQS PSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSW0571.70067WO00120 / 202RFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVEIKGGGGSGGGGSG GGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVI PNAGGTSNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGT LVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK* (SEQ ID NO: 17)

[0388] The bispecific antibody comprising a knob sequence of SEQ ID NO: 8 and a hole sequence of SEQ ID NO: 18 (REF ID NO: 122). GSDIQLTQSPSFLSASVGDRVTITCQASQTIYTNLAWYQQKPGKAPKLLIYAA STLASGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQSYYGSSTTGNGFGGGTKVEIK GGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFSFSSSYCMCWVRQA PGKGLELVSCIYTDSSGATYYASWAKGRFTISRHNSKNTLYLQMNSLRAEDTAVYY CARGWDYEDPGYTDTTYFSLWGRGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 8) |GSDIQMTQS PSSLSASVGDRVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAATNLADGVPRFSGSG SGTDYTLTISSLQPEDFATYYCQHFWGTPLTFGGGTKVEIKGGGGSGGGGSGGGGSV QLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWIGEINPINGR SNYAEKFQGRVTLTVDTSSSTAYMELSRLRSDDTAVYYCARGTRAMHYWGQGTLV TVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS NKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPGK* (SEQ ID NO: 18)

[0389] The bispecific antibody comprising a knob sequence of SEQ ID NO: 8 and a hole sequence of SEQ ID NO: 19 (REF ID NO: 123). GSDIQLTQSPSFLSASVGDRVTITCQASQTIYTNLAWYQQKPGKAPKLLIYAA STLASGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQSYYGSSTTGNGFGGGTKVEIK GGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFSFSSSYCMCWVRQA PGKGLELVSCIYTDSSGATYYASWAKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYW0571.70067WO00121 / 202CARGWDYEDPGYTDTTYFSLWGRGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 8) |GSDIVLTQSP ASLAVSLGQRATISCKASQSVDYDGDSFLNWYQKPGQPPKLFIYAASNLESGIPARFS GSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPLTFGAGTELELKGGGGSGGGGSGGG GSEVQLQQSGAELMKPGASVKISCKATGYTFSSYWIEWKQRPGHGLEWIGEILPGGG DTNYNEIFKGKATETADTSSNTAYMLSSLISEDSAVYYCTRRVPVYFDYWGQGTSVT VSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPGK* (SEQ ID NO: 19)

[0390] The bispecific antibody comprising a knob sequence of SEQ ID NO: 8 and a hole sequence of SEQ ID NO: 20 (REF ID NO: 124). GSDIQLTQSPSFLSASVGDRVTITCQASQTIYTNLAWYQQKPGKAPKLLIYAA STLASGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQSYYGSSTTGNGFGGGTKVEIK GGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFSFSSSYCMCWVRQA PGKGLELVSCIYTDSSGATYYASWAKGRFTISRHNSKNTLYLQMNSLRAEDTAVYY CARGWDYEDPGYTDTTYFSLWGRGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 8) |GSDIQLTQSP SFLSASVGDRVTITCQASQTIYTNLAWYQQKPGKAPKLLIYAASTLASGVPSRFSGSG SGTEFTLTISSLQPEDFATYYCQSYYGSSTTGNGFGGGTKVEIKGGGGSGGGGSGGG GSEVQLVESGGGLVQPGGSLRLSCAASGFSFSSSYCMCWVRQAPGKGLELVSCIYTD SSGATYYASWAKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARGWDYEDPGYT DTTYFSLWGRGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 20)W0571.70067WO00122 / 202

[0391] The bispecific antibody comprising a knob sequence of SEQ ID NO: 8 and a hole sequence of SEQ ID NO: 21 (REF ID NO: 125). GSDIQLTQSPSFLSASVGDRVTITCQASQTIYTNLAWYQQKPGKAPKLLIYAA STLASGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQSYYGSSTTGNGFGGGTKVEIK GGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFSFSSSYCMCWVRQA PGKGLELVSCIYTDSSGATYYASWAKGRFTISRHNSKNTLYLQMNSLRAEDTAVYY CARGWDYEDPGYTDTTYFSLWGRGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 8) |GSDIVMTQS PDSLAVSLGERATISCRASESVEYYGTSLMQWYQQKPGQPPKLLIYVASNVESGVPD RFSGSGSGTDFTLTISSLQAEDVAVYFCQQSTKVPWTFGQGTKLEIKGGGGSGGGGS GGGGSEVQLVESGGGLVKPGGSLRLSCAASGFTFNTNAMNWVRQAPGKGLEWVAR IRSKSNNYATYYAESVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCVTDGYYWG QGTTLTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK* (SEQ ID NO: 21)

[0392] The bispecific antibody comprising a knob sequence of SEQ ID NO: 8 and a hole sequence of SEQ ID NO: 22 (REF ID NO: 126). GSDIQLTQSPSFLSASVGDRVTITCQASQTIYTNLAWYQQKPGKAPKLLIYAA STLASGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQSYYGSSTTGNGFGGGTKVEIK GGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFSFSSSYCMCWVRQA PGKGLELVSCIYTDSSGATYYASWAKGRFTISRHNSKNTLYLQMNSLRAEDTAVYY CARGWDYEDPGYTDTTYFSLWGRGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 8) |GSEEELQIIQ PDKSVLVAAGETATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQRQGPFPRVTTVSDT TKRNNMDFSIRIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGTELSVRAKPSAAAD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVW0571.70067WO00123 / 202DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 22)

[0393] The bispecific antibody comprising a knob sequence of SEQ ID NO: 8 and a hole sequence of SEQ ID NO: 23 (REF ID NO: 127). GSDIQLTQSPSFLSASVGDRVTITCQASQTIYTNLAWYQQKPGKAPKLLIYAA STLASGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQSYYGSSTTGNGFGGGTKVEIK GGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFSFSSSYCMCWVRQA PGKGLELVSCIYTDSSGATYYASWAKGRFTISRHNSKNTLYLQMNSLRAEDTAVYY CARGWDYEDPGYTDTTYFSLWGRGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 8) |GSDIQMTQS PSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGS GSGTDFTLTISSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIKGGGGSGGGGSGGGGS EVQLVESGGGLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPGKGLEWVSYISSRSR TIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARDYGGQPPYYYYYG MDVWGQGTTVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEV TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 23)

[0394] The bispecific antibody comprising a knob sequence of SEQ ID NO: 8 and a hole sequence of SEQ ID NO: 24 (REF ID NO: 128). GSDIQLTQSPSFLSASVGDRVTITCQASQTIYTNLAWYQQKPGKAPKLLIYAA STLASGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQSYYGSSTTGNGFGGGTKVEIK GGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFSFSSSYCMCWVRQA PGKGLELVSCIYTDSSGATYYASWAKGRFTISRHNSKNTLYLQMNSLRAEDTAVYY CARGWDYEDPGYTDTTYFSLWGRGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVW0571.70067WO00124 / 202DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 8) |GSEIVLTQSP ATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSG SGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKGGGGSGGGGSGGGGSQ VQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGS KRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTV SSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK ALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK* (SEQ ID NO: 24)

[0395] The bispecific antibody comprising a knob sequence of SEQ ID NO: 8 and a hole sequence of SEQ ID NO: 25 (REF ID NO: 129). GSDIQLTQSPSFLSASVGDRVTITCQASQTIYTNLAWYQQKPGKAPKLLIYAA STLASGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQSYYGSSTTGNGFGGGTKVEIK GGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFSFSSSYCMCWVRQA PGKGLELVSCIYTDSSGATYYASWAKGRFTISRHNSKNTLYLQMNSLRAEDTAVYY CARGWDYEDPGYTDTTYFSLWGRGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 8) |GSEEELQVI QPDKSVLVAAGETATLRCTATSLIPVGPIQWFRGAGPGRELIYNQKEGHFPRVTTVSD LTKRNNMDFSIRIGNITPADAGTYYCVKFRKGSPDDVEFKSGAGTELSVRAKPSAAA DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG K* (SEQ ID NO: 25)

[0396] The bispecific antibody comprising a knob sequence of SEQ ID NO: 9 and a hole sequence of SEQ ID NO: 13 (REF ID NO: 130). GSDIVMTQSPDSLAVSLGERATISCRASESVEYYGTSLMQWYQQKPGQPPKL LIYVASNVESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYFCQQSTKVPWTFGQGTKL EIKGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLRLSCAASGFTFNTNAMNWV RQAPGKGLEWVARIRSKSNNYATYYAESVKDRFTISRDDSKNTLYLQMNSLKTEDTW0571.70067WO00125 / 202AVYYCVTDGYYWGQGTTLTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 9) |GSQIVLSQSPAILSASPGE KVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTIS RVEAEDAATYYCQQWTSNPPTFGGGTKLEIKGGGGSGGGGSGGGGSQVQLQQPGA ELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKF KGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTV SAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK ALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK* (SEQ ID NO: 13)

[0397] The bispecific antibody comprising a knob sequence of SEQ ID NO: 9 and a hole sequence of SEQ ID NO: 14 (REF ID NO: 131). GSDIVMTQSPDSLAVSLGERATISCRASESVEYYGTSLMQWYQQKPGQPPKL LIYVASNVESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYFCQQSTKVPWTFGQGTKL EIKGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLRLSCAASGFTFNTNAMNWV RQAPGKGLEWVARIRSKSNNYATYYAESVKDRFTISRDDSKNTLYLQMNSLKTEDT AVYYCVTDGYYWGQGTTLTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 9) |GSDIVMTQTPLSLSVTPG QPASISCKSSQSLLMSDGKTYLNWYLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGT DFTLKISRVEAEDVGVYYCWQGAHFPYTFGQGTKLEIKGGGGSGGGGSGGGGSQVQ LVESGGGVVQPGRSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWIAEINPDSSTINY TPSLRDKFTISRDNSKNTLYLQNSSLRAEDTAVYYCARQGDYWGQGTLVTVSSAAA DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG K* (SEQ ID NO: 14)W0571.70067WO00126 / 202

[0398] The bispecific antibody comprising a knob sequence of SEQ ID NO: 9 and a hole sequence of SEQ ID NO: 15 (REF ID NO: 132). GSDIVMTQSPDSLAVSLGERATISCRASESVEYYGTSLMQWYQQKPGQPPKL LIYVASNVESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYFCQQSTKVPWTFGQGTKL EIKGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLRLSCAASGFTFNTNAMNWV RQAPGKGLEWVARIRSKSNNYATYYAESVKDRFTISRDDSKNTLYLQMNSLKTEDT AVYYCVTDGYYWGQGTTLTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 9) |GSENVLTQSPAIMSASPG EKVTMTCSASSSVSYMHWYQQKSTTSPKLWIYDTSKLASGVPGRFSGSGSGNSYSLT ISSMEAEDVATYYCFQGSGYPLTFGGGTKLEIKGGGGSGGGGSGGGGSQGPPSLKES GPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPGKGLEWIGVIWAGGSTNYNSALM SRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAVYYGYLFFAYWGQGTLVTVSAAA AADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA PIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPE NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS PGK* (SEQ ID NO: 15)

[0399] The bispecific antibody comprising a knob sequence of SEQ ID NO: 9 and a hole sequence of SEQ ID NO: 16 (REF ID NO: 133). GSDIVMTQSPDSLAVSLGERATISCRASESVEYYGTSLMQWYQQKPGQPPKL LIYVASNVESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYFCQQSTKVPWTFGQGTKL EIKGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLRLSCAASGFTFNTNAMNWV RQAPGKGLEWVARIRSKSNNYATYYAESVKDRFTISRDDSKNTLYLQMNSLKTEDT AVYYCVTDGYYWGQGTTLTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 9) |GSEIVLTQSPATLSLSPGE RATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTI SSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLLESGG GLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKW0571.70067WO00127 / 202GRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVS SAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA LPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL SLSPGK* (SEQ ID NO: 16)

[0400] The bispecific antibody comprising a knob sequence of SEQ ID NO: 9 and a hole sequence of SEQ ID NO: 17 (REF ID NO: 134). GSDIVMTQSPDSLAVSLGERATISCRASESVEYYGTSLMQWYQQKPGQPPKL LIYVASNVESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYFCQQSTKVPWTFGQGTKL EIKGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLRLSCAASGFTFNTNAMNWV RQAPGKGLEWVARIRSKSNNYATYYAESVKDRFTISRDDSKNTLYLQMNSLKTEDT AVYYCVTDGYYWGQGTTLTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 9) |GSDIQMTQSPSSLSASVG DRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSGT DFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVEIKGGGGSGGGGSGGGGSEVQL VESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVIPNAGGTSN QKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGTLVTVSSAA AADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA PIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPE NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS PGK* (SEQ ID NO: 17)

[0401] The bispecific antibody comprising a knob sequence of SEQ ID NO: 9 and a hole sequence of SEQ ID NO: 18 (REF ID NO: 135). GSDIVMTQSPDSLAVSLGERATISCRASESVEYYGTSLMQWYQQKPGQPPKL LIYVASNVESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYFCQQSTKVPWTFGQGTKL EIKGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLRLSCAASGFTFNTNAMNWV RQAPGKGLEWVARIRSKSNNYATYYAESVKDRFTISRDDSKNTLYLQMNSLKTEDT AVYYCVTDGYYWGQGTTLTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTW0571.70067WO00128 / 202VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 9) |GSDIQMTQSPSSLSASVG DRVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAATNLADGVPRFSGSGSGTDYTLTI SSLQPEDFATYYCQHFWGTPLTFGGGTKVEIKGGGGSGGGGSGGGGSVQLVQSGAE VKKPGASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWIGEINPINGRSNYAEKFQ GRVTLTVDTSSSTAYMELSRLRSDDTAVYYCARGTRAMHYWGQGTLVTVSSAAAA DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG K* (SEQ ID NO: 18)

[0402] The bispecific antibody comprising a knob sequence of SEQ ID NO: 9 and a hole sequence of SEQ ID NO: 19 (REF ID NO: 136). GSDIVMTQSPDSLAVSLGERATISCRASESVEYYGTSLMQWYQQKPGQPPKL LIYVASNVESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYFCQQSTKVPWTFGQGTKL EIKGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLRLSCAASGFTFNTNAMNWV RQAPGKGLEWVARIRSKSNNYATYYAESVKDRFTISRDDSKNTLYLQMNSLKTEDT AVYYCVTDGYYWGQGTTLTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 9) |GSDIVLTQSPASLAVSLG QRATISCKASQSVDYDGDSFLNWYQKPGQPPKLFIYAASNLESGIPARFSGSGSGTDF TLNIHPVEEEDAATYYCQQSNEDPLTFGAGTELELKGGGGSGGGGSGGGGSEVQLQ QSGAELMKPGASVKISCKATGYTFSSYWIEWKQRPGHGLEWIGEILPGGGDTNYNEI FKGKATETADTSSNTAYMLSSLISEDSAVYYCTRRVPVYFDYWGQGTSVTVSSAAA ADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI EKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP GK* (SEQ ID NO: 19)

[0403] The bispecific antibody comprising a knob sequence of SEQ ID NO: 9 and a hole sequence of SEQ ID NO: 20 (REF ID NO: 137).W0571.70067WO00129 / 202GSDIVMTQSPDSLAVSLGERATISCRASESVEYYGTSLMQWYQQKPGQPPKL LIYVASNVESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYFCQQSTKVPWTFGQGTKL EIKGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLRLSCAASGFTFNTNAMNWV RQAPGKGLEWVARIRSKSNNYATYYAESVKDRFTISRDDSKNTLYLQMNSLKTEDT AVYYCVTDGYYWGQGTTLTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 9) |GSDIQLTQSPSFLSASVGD RVTITCQASQTIYTNLAWYQQKPGKAPKLLIYAASTLASGVPSRFSGSGSGTEFTLTIS SLQPEDFATYYCQSYYGSSTTGNGFGGGTKVEIKGGGGSGGGGSGGGGSEVQLVES GGGLVQPGGSLRLSCAASGFSFSSSYCMCWVRQAPGKGLELVSCIYTDSSGATYYAS WAKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARGWDYEDPGYTDTTYFSLWG RGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK* (SEQ ID NO: 20)

[0404] The bispecific antibody comprising a knob sequence of SEQ ID NO: 9 and a hole sequence of SEQ ID NO: 21 (REF ID NO: 138). GSDIVMTQSPDSLAVSLGERATISCRASESVEYYGTSLMQWYQQKPGQPPKL LIYVASNVESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYFCQQSTKVPWTFGQGTKL EIKGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLRLSCAASGFTFNTNAMNWV RQAPGKGLEWVARIRSKSNNYATYYAESVKDRFTISRDDSKNTLYLQMNSLKTEDT AVYYCVTDGYYWGQGTTLTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 9) |GSDIVMTQSPDSLAVSLG ERATISCRASESVEYYGTSLMQWYQQKPGQPPKLLIYVASNVESGVPDRFSGSGSGT DFTLTISSLQAEDVAVYFCQQSTKVPWTFGQGTKLEIKGGGGSGGGGSGGGGSEVQL VESGGGLVKPGGSLRLSCAASGFTFNTNAMNWVRQAPGKGLEWVARIRSKSNNYA TYYAESVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCVTDGYYWGQGTTLTVSS AAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFW0571.70067WO00130 / 202NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL SPGK* (SEQ ID NO: 21)

[0405] The bispecific antibody comprising a knob sequence of SEQ ID NO: 9 and a hole sequence of SEQ ID NO: 22 (REF ID NO: 139). GSDIVMTQSPDSLAVSLGERATISCRASESVEYYGTSLMQWYQQKPGQPPKL LIYVASNVESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYFCQQSTKVPWTFGQGTKL EIKGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLRLSCAASGFTFNTNAMNWV RQAPGKGLEWVARIRSKSNNYATYYAESVKDRFTISRDDSKNTLYLQMNSLKTEDT AVYYCVTDGYYWGQGTTLTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 9) |GSEEELQIIQPDKSVLVAA GETATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQRQGPFPRVTTVSDTTKRNNMDFS IRIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGTELSVRAKPSAAADKTHTCPPCPA PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 22)

[0406] The bispecific antibody comprising a knob sequence of SEQ ID NO: 9 and a hole sequence of SEQ ID NO: 23 (REF ID NO: 140). GSDIVMTQSPDSLAVSLGERATISCRASESVEYYGTSLMQWYQQKPGQPPKL LIYVASNVESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYFCQQSTKVPWTFGQGTKL EIKGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLRLSCAASGFTFNTNAMNWV RQAPGKGLEWVARIRSKSNNYATYYAESVKDRFTISRDDSKNTLYLQMNSLKTEDT AVYYCVTDGYYWGQGTTLTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 9) |GSDIQMTQSPSSLSASVG DRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTIW0571.70067WO00131 / 202SSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLVESGG GLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPGKGLEWVSYISSRSRTIYYADSVK GRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARDYGGQPPYYYYYGMDVWGQGT TVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK* (SEQ ID NO: 23)

[0407] The bispecific antibody comprising a knob sequence of SEQ ID NO: 9 and a hole sequence of SEQ ID NO: 24 (REF ID NO: 141). GSDIVMTQSPDSLAVSLGERATISCRASESVEYYGTSLMQWYQQKPGQPPKL LIYVASNVESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYFCQQSTKVPWTFGQGTKL EIKGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLRLSCAASGFTFNTNAMNWV RQAPGKGLEWVARIRSKSNNYATYYAESVKDRFTISRDDSKNTLYLQMNSLKTEDT AVYYCVTDGYYWGQGTTLTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 9) |GSEIVLTQSPATLSLSPGE RATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTI SSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKGGGGSGGGGSGGGGSQVQLVESGG GVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSV KGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSAAAADK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI SKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 24)

[0408] The bispecific antibody comprising a knob sequence of SEQ ID NO: 9 and a hole sequence of SEQ ID NO: 25 (REF ID NO: 142). GSDIVMTQSPDSLAVSLGERATISCRASESVEYYGTSLMQWYQQKPGQPPKL LIYVASNVESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYFCQQSTKVPWTFGQGTKL EIKGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLRLSCAASGFTFNTNAMNWV RQAPGKGLEWVARIRSKSNNYATYYAESVKDRFTISRDDSKNTLYLQMNSLKTEDTW0571.70067WO00132 / 202AVYYCVTDGYYWGQGTTLTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 9) |GSEEELQVIQPDKSVLVA AGETATLRCTATSLIPVGPIQWFRGAGPGRELIYNQKEGHFPRVTTVSDLTKRNNMD FSIRIGNITPADAGTYYCVKFRKGSPDDVEFKSGAGTELSVRAKPSAAADKTHTCPPC PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ PREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 25)

[0409] The bispecific antibody comprising a knob sequence of SEQ ID NO: 10 and a hole sequence of SEQ ID NO: 13 (REF ID NO: 143). GSEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQ RQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGT ELSVRAKPSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK* (SEQ ID NO: 10) |GSQIVLSQSPAILSASPGEKVTMTCRASSSVSY IHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQ WTSNPPTFGGGTKLEIKGGGGSGGGGSGGGGSQVQLQQPGAELVKPGASVKMSCK ASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTA YMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSAAAAADKTHTCPPC PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ PREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 13)

[0410] The bispecific antibody comprising a knob sequence of SEQ ID NO: 10 and a hole sequence of SEQ ID NO: 14 (REF ID NO: 144). GSEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQ RQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGTW0571.70067WO00133 / 202ELSVRAKPSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK* (SEQ ID NO: 10) |GSDIVMTQTPLSLSVTPGQPASISCKSSQSLLM SDGKTYLNWYLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDV GVYYCWQGAHFPYTFGQGTKLEIKGGGGSGGGGSGGGGSQVQLVESGGGVVQPGR SLRLSCAASGFTFSRYWMSWVRQAPGKGLEWIAEINPDSSTINYTPSLRDKFTISRDN SKNTLYLQNSSLRAEDTAVYYCARQGDYWGQGTLVTVSSAAADKTHTCPPCPAPEL LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 14)

[0411] The bispecific antibody comprising a knob sequence of SEQ ID NO: 10 and a hole sequence of SEQ ID NO: 15 (REF ID NO: 145). GSEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQ RQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGT ELSVRAKPSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK* (SEQ ID NO: 10) |GSENVLTQSPAIMSASPGEKVTMTCSASSSVS YMHWYQQKSTTSPKLWIYDTSKLASGVPGRFSGSGSGNSYSLTISSMEAEDVATYY CFQGSGYPLTFGGGTKLEIKGGGGSGGGGSGGGGSQGPPSLKESGPGLVAPSQSLSIT CTVSGFSLTSYGVHWVRQPPGKGLEWIGVIWAGGSTNYNSALMSRLSISKDNSKSQ VFLKMNSLQTDDTAMYYCAVYYGYLFFAYWGQGTLVTVSAAAAADKTHTCPPCP APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 15)

[0412] The bispecific antibody comprising a knob sequence of SEQ ID NO: 10 and a hole sequence of SEQ ID NO: 16 (REF ID NO: 146). GSEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQW0571.70067WO00134 / 202RQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGT ELSVRAKPSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK* (SEQ ID NO: 10) |GSEIVLTQSPATLSLSPGERATLSCRASQSVSS YLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQ QRSNWPPTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCA VSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTL YLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSSAAAADKTHTCPP CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 16)

[0413] The bispecific antibody comprising a knob sequence of SEQ ID NO: 10 and a hole sequence of SEQ ID NO: 17 (REF ID NO: 147). GSEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQ RQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGT ELSVRAKPSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK* (SEQ ID NO: 10) |GSDIQMTQSPSSLSASVGDRVTITCRSSQSLVH SNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFA TYFCSQTTHVPWTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSL RLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVIPNAGGTSNQKFKGRFTLSVDNS KNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGTLVTVSSAAAADKTHTCPPCPAP ELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 17)W0571.70067WO00135 / 202

[0414] The bispecific antibody comprising a knob sequence of SEQ ID NO: 10 and a hole sequence of SEQ ID NO: 18 (REF ID NO: 148). GSEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQ RQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGT ELSVRAKPSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK* (SEQ ID NO: 10) |GSDIQMTQSPSSLSASVGDRVTITCRTSENIYN NLAWYQQKPGKSPKLLIYAATNLADGVPRFSGSGSGTDYTLTISSLQPEDFATYYCQ HFWGTPLTFGGGTKVEIKGGGGSGGGGSGGGGSVQLVQSGAEVKKPGASVKVSCK ASGYTFTNYWMHWVRQAPGQGLEWIGEINPINGRSNYAEKFQGRVTLTVDTSSSTA YMELSRLRSDDTAVYYCARGTRAMHYWGQGTLVTVSSAAAADKTHTCPPCPAPEL LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 18)

[0415] The bispecific antibody comprising a knob sequence of SEQ ID NO: 10 and a hole sequence of SEQ ID NO: 19 (REF ID NO: 149). GSEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQ RQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGT ELSVRAKPSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK* (SEQ ID NO: 10) |GSDIVLTQSPASLAVSLGQRATISCKASQSVD YDGDSFLNWYQKPGQPPKLFIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAAT YYCQQSNEDPLTFGAGTELELKGGGGSGGGGSGGGGSEVQLQQSGAELMKPGASV KISCKATGYTFSSYWIEWKQRPGHGLEWIGEILPGGGDTNYNEIFKGKATETADTSSN TAYMLSSLISEDSAVYYCTRRVPVYFDYWGQGTSVTVSSAAAADKTHTCPPCPAPEL LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 19)W0571.70067WO00136 / 202

[0416] The bispecific antibody comprising a knob sequence of SEQ ID NO: 10 and a hole sequence of SEQ ID NO: 20 (REF ID NO: 150). GSEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQ RQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGT ELSVRAKPSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK* (SEQ ID NO: 10) |GSDIQLTQSPSFLSASVGDRVTITCQASQTIYT NLAWYQQKPGKAPKLLIYAASTLASGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQ SYYGSSTTGNGFGGGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRL SCAASGFSFSSSYCMCWVRQAPGKGLELVSCIYTDSSGATYYASWAKGRFTISRHNS KNTLYLQMNSLRAEDTAVYYCARGWDYEDPGYTDTTYFSLWGRGTLVTVSSAAAD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 20)

[0417] The bispecific antibody comprising a knob sequence of SEQ ID NO: 10 and a hole sequence of SEQ ID NO: 21 (REF ID NO: 151). GSEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQ RQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGT ELSVRAKPSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK* (SEQ ID NO: 10) |GSDIVMTQSPDSLAVSLGERATISCRASESVE YYGTSLMQWYQQKPGQPPKLLIYVASNVESGVPDRFSGSGSGTDFTLTISSLQAEDV AVYFCQQSTKVPWTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGS LRLSCAASGFTFNTNAMNWVRQAPGKGLEWVARIRSKSNNYATYYAESVKDRFTIS RDDSKNTLYLQMNSLKTEDTAVYYCVTDGYYWGQGTTLTVSSAAADKTHTCPPCP APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSW0571.70067WO00137 / 202DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 21)

[0418] The bispecific antibody comprising a knob sequence of SEQ ID NO: 10 and a hole sequence of SEQ ID NO: 22 (REF ID NO: 152). GSEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQ RQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGT ELSVRAKPSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK* (SEQ ID NO: 10) |GSEEELQIIQPDKSVLVAAGETATLRCTITSLF PVGPIQWFRGAGPGRVLIYNQRQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTY YCIKFRKGSPDDVEFKSGAGTELSVRAKPSAAADKTHTCPPCPAPELLGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM TKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 22)

[0419] The bispecific antibody comprising a knob sequence of SEQ ID NO: 10 and a hole sequence of SEQ ID NO: 23 (REF ID NO: 153). GSEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQ RQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGT ELSVRAKPSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK* (SEQ ID NO: 10) |GSDIQMTQSPSSLSASVGDRVTITCRASQGISS WLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFVTYYCQ QYNSYPRTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCA AAGFTFSSYSMNWVRQAPGKGLEWVSYISSRSRTIYYADSVKGRFTISRDNAKNSLY LQMNSLRDEDTAVYYCARDYGGQPPYYYYYGMDVWGQGTTVTVSSAAAADKTHT CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPW0571.70067WO00138 / 202PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 23)

[0420] The bispecific antibody comprising a knob sequence of SEQ ID NO: 10 and a hole sequence of SEQ ID NO: 24 (REF ID NO: 154). GSEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQ RQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGT ELSVRAKPSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK* (SEQ ID NO: 10) |GSEIVLTQSPATLSLSPGERATLSCRASQSVSS YLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQ QSSNWPRTFGQGTKVEIKGGGGSGGGGSGGGGSQVQLVESGGGVVQPGRSLRLDC KASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKN TLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSAAAADKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP REEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 24)

[0421] The bispecific antibody comprising a knob sequence of SEQ ID NO: 10 and a hole sequence of SEQ ID NO: 25 (REF ID NO: 155). GSEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQ RQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGT ELSVRAKPSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK* (SEQ ID NO: 10) |GSEEELQVIQPDKSVLVAAGETATLRCTATSL IPVGPIQWFRGAGPGRELIYNQKEGHFPRVTTVSDLTKRNNMDFSIRIGNITPADAGT YYCVKFRKGSPDDVEFKSGAGTELSVRAKPSAAADKTHTCPPCPAPELLGGPSVFLF PPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRE EMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 25)W0571.70067WO00139 / 202

[0422] The bispecific antibody comprising a knob sequence of SEQ ID NO: 11 and a hole sequence of SEQ ID NO: 13 (REF ID NO: 156). GSDIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAA SSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIKGG GGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPG KGLEWVSYISSRSRTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARD YGGQPPYYYYYGMDVWGQGTTVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPK PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 11) |GSQIVLSQSPAILS ASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSY SLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKGGGGSGGGGSGGGGSQVQLQ QPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSY NQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGT TVTVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK* (SEQ ID NO: 13)

[0423] The bispecific antibody comprising a knob sequence of SEQ ID NO: 11 and a hole sequence of SEQ ID NO: 14 (REF ID NO: 157). GSDIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAA SSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIKGG GGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPG KGLEWVSYISSRSRTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARD YGGQPPYYYYYGMDVWGQGTTVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPK PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 11) |GSDIVMTQTPLSL SVTPGQPASISCKSSQSLLMSDGKTYLNWYLQKPGQSPQRLIYLVSKLDSGVPDRFSG SGSGTDFTLKISRVEAEDVGVYYCWQGAHFPYTFGQGTKLEIKGGGGSGGGGSGGG GSQVQLVESGGGVVQPGRSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWIAEINPDW0571.70067WO00140 / 202SSTINYTPSLRDKFTISRDNSKNTLYLQNSSLRAEDTAVYYCARQGDYWGQGTLVTV SSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA LPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL SLSPGK* (SEQ ID NO: 14)

[0424] The bispecific antibody comprising a knob sequence of SEQ ID NO: 11 and a hole sequence of SEQ ID NO: 15 (REF ID NO: 158). GSDIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAA SSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIKGG GGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPG KGLEWVSYISSRSRTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARD YGGQPPYYYYYGMDVWGQGTTVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPK PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 11) |GSENVLTQSPAI MSASPGEKVTMTCSASSSVSYMHWYQQKSTTSPKLWIYDTSKLASGVPGRFSGSGS GNSYSLTISSMEAEDVATYYCFQGSGYPLTFGGGTKLEIKGGGGSGGGGSGGGGSQG PPSLKESGPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPGKGLEWIGVIWAGGSTN YNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAVYYGYLFFAYWGQGTLV TVSAAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS NKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPGK* (SEQ ID NO: 15)

[0425] The bispecific antibody comprising a knob sequence of SEQ ID NO: 11 and a hole sequence of SEQ ID NO: 16 (REF ID NO: 159). GSDIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAA SSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIKGG GGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPG KGLEWVSYISSRSRTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARD YGGQPPYYYYYGMDVWGQGTTVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPK PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVW0571.70067WO00141 / 202VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 11) |GSEIVLTQSPATL SLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGT DFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKGGGGSGGGGSGGGGSEVQL LESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGT LVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK* (SEQ ID NO: 16)

[0426] The bispecific antibody comprising a knob sequence of SEQ ID NO: 11 and a hole sequence of SEQ ID NO: 17 (REF ID NO: 160). GSDIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAA SSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIKGG GGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPG KGLEWVSYISSRSRTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARD YGGQPPYYYYYGMDVWGQGTTVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPK PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 11) |GSDIQMTQSPSSL SASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSG SGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVEIKGGGGSGGGGSGGGG SEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVIPNA GGTSNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGTLVT VSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPGK* (SEQ ID NO: 17)

[0427] The bispecific antibody comprising a knob sequence of SEQ ID NO: 11 and a hole sequence of SEQ ID NO: 18 (REF ID NO: 161).W0571.70067WO00142 / 202GSDIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAA SSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIKGG GGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPG KGLEWVSYISSRSRTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARD YGGQPPYYYYYGMDVWGQGTTVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPK PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 11) |GSDIQMTQSPSSL SASVGDRVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAATNLADGVPRFSGSGSGT DYTLTISSLQPEDFATYYCQHFWGTPLTFGGGTKVEIKGGGGSGGGGSGGGGSVQLV QSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWIGEINPINGRSNY AEKFQGRVTLTVDTSSSTAYMELSRLRSDDTAVYYCARGTRAMHYWGQGTLVTVS SAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA LPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL SLSPGK* (SEQ ID NO: 18)

[0428] The bispecific antibody comprising a knob sequence of SEQ ID NO: 11 and a hole sequence of SEQ ID NO: 19 (REF ID NO: 162). GSDIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAA SSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIKGG GGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPG KGLEWVSYISSRSRTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARD YGGQPPYYYYYGMDVWGQGTTVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPK PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 11) |GSDIVLTQSPASL AVSLGQRATISCKASQSVDYDGDSFLNWYQKPGQPPKLFIYAASNLESGIPARFSGSG SGTDFTLNIHPVEEEDAATYYCQQSNEDPLTFGAGTELELKGGGGSGGGGSGGGGSE VQLQQSGAELMKPGASVKISCKATGYTFSSYWIEWKQRPGHGLEWIGEILPGGGDT NYNEIFKGKATETADTSSNTAYMLSSLISEDSAVYYCTRRVPVYFDYWGQGTSVTVS SAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVW0571.70067WO00143 / 202KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA LPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL SLSPGK* (SEQ ID NO: 19)

[0429] The bispecific antibody comprising a knob sequence of SEQ ID NO: 11 and a hole sequence of SEQ ID NO: 20 (REF ID NO: 163). GSDIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAA SSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIKGG GGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPG KGLEWVSYISSRSRTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARD YGGQPPYYYYYGMDVWGQGTTVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPK PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 11) |GSDIQLTQSPSFL SASVGDRVTITCQASQTIYTNLAWYQQKPGKAPKLLIYAASTLASGVPSRFSGSGSGT EFTLTISSLQPEDFATYYCQSYYGSSTTGNGFGGGTKVEIKGGGGSGGGGSGGGGSE VQLVESGGGLVQPGGSLRLSCAASGFSFSSSYCMCWVRQAPGKGLELVSCIYTDSSG ATYYASWAKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARGWDYEDPGYTDTT YFSLWGRGTLVTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 20)

[0430] The bispecific antibody comprising a knob sequence of SEQ ID NO: 11 and a hole sequence of SEQ ID NO: 21 (REF ID NO: 164). GSDIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAA SSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIKGG GGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPG KGLEWVSYISSRSRTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARD YGGQPPYYYYYGMDVWGQGTTVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPK PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRW0571.70067WO00144 / 202WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 11) |GSDIVMTQSPDSL AVSLGERATISCRASESVEYYGTSLMQWYQQKPGQPPKLLIYVASNVESGVPDRFSG SGSGTDFTLTISSLQAEDVAVYFCQQSTKVPWTFGQGTKLEIKGGGGSGGGGSGGGG SEVQLVESGGGLVKPGGSLRLSCAASGFTFNTNAMNWVRQAPGKGLEWVARIRSKS NNYATYYAESVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCVTDGYYWGQGTT LTVSSAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS NKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPGK* (SEQ ID NO: 21)

[0431] The bispecific antibody comprising a knob sequence of SEQ ID NO: 11 and a hole sequence of SEQ ID NO: 22 (REF ID NO: 165). GSDIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAA SSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIKGG GGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPG KGLEWVSYISSRSRTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARD YGGQPPYYYYYGMDVWGQGTTVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPK PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 11) |GSEEELQIIQPDK SVLVAAGETATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQRQGPFPRVTTVSDTTKR NNMDFSIRIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGTELSVRAKPSAAADKTHT CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 22)

[0432] The bispecific antibody comprising a knob sequence of SEQ ID NO: 11 and a hole sequence of SEQ ID NO: 23 (REF ID NO: 166). GSDIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAA SSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIKGG GGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPG KGLEWVSYISSRSRTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARDW0571.70067WO00145 / 202YGGQPPYYYYYGMDVWGQGTTVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPK PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 11) |GSDIQMTQSPSSL SASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGT DFTLTISSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIKGGGGSGGGGSGGGGSEVQL VESGGGLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPGKGLEWVSYISSRSRTIYYA DSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARDYGGQPPYYYYYGMDVW GQGTTVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGK* (SEQ ID NO: 23)

[0433] The bispecific antibody comprising a knob sequence of SEQ ID NO: 11 and a hole sequence of SEQ ID NO: 24 (REF ID NO: 167). GSDIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAA SSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIKGG GGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPG KGLEWVSYISSRSRTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARD YGGQPPYYYYYGMDVWGQGTTVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPK PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 11) |GSEIVLTQSPATL SLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGT DFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKGGGGSGGGGSGGGGSQVQL VESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRY YADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSA AAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL SPGK* (SEQ ID NO: 24)W0571.70067WO00146 / 202

[0434] The bispecific antibody comprising a knob sequence of SEQ ID NO: 11 and a hole sequence of SEQ ID NO: 25 (REF ID NO: 168). GSDIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAA SSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIKGG GGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPG KGLEWVSYISSRSRTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARD YGGQPPYYYYYGMDVWGQGTTVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPK PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 11) |GSEEELQVIQPDK SVLVAAGETATLRCTATSLIPVGPIQWFRGAGPGRELIYNQKEGHFPRVTTVSDLTKR NNMDFSIRIGNITPADAGTYYCVKFRKGSPDDVEFKSGAGTELSVRAKPSAAADKTH TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 25)

[0435] The bispecific antibody comprising a knob sequence of SEQ ID NO: 12 and a hole sequence of SEQ ID NO: 13 (REF ID NO: 169). GSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDAS NRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKGGG GSGGGGSGGGGSQVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGK GLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCAT NDDYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 12) |GSQIVLSQSPAILSASPGEKVTMT CRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAED AATYYCQQWTSNPPTFGGGTKLEIKGGGGSGGGGSGGGGSQVQLQQPGAELVKPG ASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATL TADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSAAAAA DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYW0571.70067WO00147 / 202VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG K* (SEQ ID NO: 13)

[0436] The bispecific antibody comprising a knob sequence of SEQ ID NO: 12 and a hole sequence of SEQ ID NO: 14 (REF ID NO: 170). GSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDAS NRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKGGG GSGGGGSGGGGSQVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGK GLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCAT NDDYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLTSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 12) |GSDIVMTQTPLSLSVTPGQPASIS CKSSQSLLMSDGKTYLNWYLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLK ISRVEAEDVGVYYCWQGAHFPYTFGQGTKLEIKGGGGSGGGGSGGGGSQVQLVESG GGVVQPGRSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWIAEINPDSSTINYTPSLR DKFTISRDNSKNTLYLQNSSLRAEDTAVYYCARQGDYWGQGTLVTVSSAAADKTHT CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSREEMTKNQVSLYCLVKGFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* (SEQ ID NO: 14)

[0437] The bispecific antibody comprising a knob sequence of SEQ ID NO: 12 and a hole sequence of SEQ ID NO: 15 (REF ID NO: 171). GSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDAS NRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKGGG GSGGGGSGGGGSQVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGK GLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCAT NDDYWGQGTLVTVSSAAAADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE V...

Claims

CLAIMS What is claimed is:

1. A composition comprising one or more first antigen targeting molecules and for the treatment of proliferative disease.

2. The composition of claim 1, further comprising one or more second antigen targeting molecules.

3. The composition of any one of the preceding claims, wherein the one or more first antigen targeting molecules and / or the one or more second targeting molecules targets an antigen selected from CD20, CD22, CD27, CD38, CD47, CD71, CD79b, CD95, CXCR4, CD45RB, CD45RA, CD147, CD98, CD184, CD11b, 4-1BBL, Ly6A / E, HLA- A, HLA-B, HLA-C, HLA-DR, HLA-DP, HLA-DO, HLA-(A,B,C), HLA-(DR,DP,DQ), MHC I, CD24, CALR, CD40, PD-L1, APMAP, GPR84, VCAM1, CD11b, SIGLEC-10, PD-L2 , PD-1, B2M, CD73, Galectin-9, CD14, CD80, CD86, SIRPb, SIRPg, SLAMF7, MARCO, AXL, CLEVER-1, ILT4, TIM-3, TIM-4, LRP-1, calreticulin, TREM1, TREM2, GD2, FcgRI, FcgRIIa, FcgRIIb, FcgRIII, MUC1, CD44, CD63, CD36, CD84, CD164, CD82, CD18, SIGLEC-7, CD166, CD39, CD46, LILRA1, LILRA2, LILRA3, LILRA4, LILRB1(CD85j), LILRB2, LILRB3, LILRB4, LILRB5, CD85j, CD85b, CD85f, CD85m, CD276, CD88, CD99, PILRa, Siglec-9, CD206, CD163, CD84, C3aR, CD3, and CLEC12A.

4. The composition of any one of the preceding claims, wherein the one or more first antigen targeting molecules and one or more second targeting molecules target an antigen selected from CD20, CD24, CD24-2, CD38, CD40, CD71, CD95, CXCR4, PD- 1, CD79b, CD85j, CD47, CD45RB, CD45RA, β2M, CD147, CD98, CD184, HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DP, HLA-DO, HLA-(A,B,C), and HLA-(DR,DP,DQ).

5. The composition of any one of the preceding claims, wherein the one or more first antigen targeting molecules is selected from CD47, CD20, CD85j, and CD38.W0571.70067WO00184 / 2026. The composition of any one of the preceding claims, wherein the one or more first antigen targeting molecules target an antigen selected from CD20, CD47, CD85j, and CD38, and one or more second targeting molecules target an antigen selected from CD20, CD24, CD24-2, CD38, CD40, CD71, CD95, CXCR4, PD-1, CD79b, CD85j, CD47, CD45RB, CD45RA, β2M, CD147, CD98, CD184, HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DP, HLA-DO, HLA-(A, B, C), and HLA-(DR, DP, DQ).

7. The composition of any one of the preceding claims, wherein the one or more first antigen targeting molecules is selected from CD20, CD47, CD85j, and CD38, and one or more second targeting molecules target an antigen selected from CD20, CD24, CD24-2, CD38, CD40, CD71, CD95, PD-1, CD79b, CD85j, CD47, CD147, and CD184.

8. The composition of any one of the preceding claims, wherein the one or more first antigen targeting molecules targets CD47.

9. The composition of any one of the preceding claims, wherein the one or more first antigen targeting molecules targets CD47 and one or more second targeting molecules target an antigen selected from CD20, CD24, CD24-2, CD38, CD40, CD71 , PD-1 CD85j, CD147, and CD184.

10. The composition of any one of the preceding claims, wherein the one or more first antigen targeting molecules targets CD85j.

11. The composition of any one of the preceding claims, wherein the one or more first antigen targeting molecules targets CD85j and one or more second targeting molecules target an antigen selected from CD20, CD40, CD38, CD71, CD47, CD147, and CD184.

12. The composition of any one of the preceding claims, wherein the one or more first antigen targeting molecules targets CD85j and one or more second targeting molecules target an antigen selected from CD38, CD47, CD71, and CD147.

13. The composition of any one of the preceding claims, wherein the one or more first antigen targeting molecules targets CD38.W0571.70067WO00185 / 20214. The composition of any one of the preceding claims, wherein the one or more first antigen targeting molecules targets CD38 and one or more second targeting molecules target an antigen selected from CD20, CD24, CD24-2, CD38, CD-79b, CD40, CD71, CD95, PD-1, CD79b, CD85j, CD47, CD147, and CD184.

15. The composition of any one of the preceding claims, wherein the one or more first antigen targeting molecules targets CD20.

16. The composition of any one of the preceding claims, wherein the one or more first antigen targeting molecules targets CD20 and one or more second targeting molecules target an antigen selected from CD24, CD24-2, CD38, CD40, CD71, CD95, PD-1, CD79b, CD85j, CD47, CD147, and CD184.

17. The composition of any one of the preceding claims, wherein the one or more first antigen targeting molecules targets CD20 and one or more second targeting molecules target an antigen selected from CD38 and CD184.

18. The composition of any one of the preceding claims, wherein the one or more first antigen targeting molecules and one or more second antigen targeting molecules are selected from antibody, single-domain antibody, a Fab fragment, scFV, affibody, nanobody, peptide, DARPin, adnectin, anticalin, or fragment thereof.

19. The composition of any one of the preceding claims, wherein the one or more first antigen targeting molecules and one or more second antigen targeting molecules are operably linked to each other.

20. The composition of any one of the preceding claims, wherein the one or more first antigen targeting molecules and one or more antigen second targeting molecules are operably linked to each other by a covalent linker.

21. The composition of any one of the preceding claims, wherein the one or more first antigen targeting molecules and one or more second antigen targeting molecules are antibodies.W0571.70067WO00186 / 20222. The composition of any one of the preceding claims, wherein the antibodies are selected from an anti-CD3 antibody, anti-CD85 antibody, an anti-CD85j antibody, an anti-CD20 antibody, an anti-CD38 antibody, an anti-CD71 antibody, an anti-CD79b antibody, an anti-CD95 antibody, an anti-CXCR4 antibody, an anti-CD45RB antibody, an anti- CD45RA antibody, an anti-CD147 antibody, an anti-CD98 antibody, an anti-CD184 antibody, an anti-HLA-DR antibody, an anti---HLA-(A,B,C) antibody, an anti-HLA- (DR,DP,DQ) antibody, an anti-CD47 antibody, an anti-SIRPα antibody, a SIRPα-Fc fusion protein, an anti-MHC I antibody, an anti-CD24 antibody, an anti-CALR antibody, an anti-CD40 antibody, an anti-PD-L1 antibody, an anti-APMAP antibody, an anti- GPR84 antibody, an anti-VCAM1 antibody, an anti-CD11b antibody, an anti-SIGLEC- 10 antibody, an anti-PD-L2 antibody, an anti-PD-1 antibody, an anti-B2M antibody, an anti-CD73 antibody, an anti-Galectin-9 antibody, an anti-CD14 antibody, an anti-CD80 antibody, an anti-CD86 antibody, an anti-SIRPb antibody, an anti-SIRPg antibody, an anti-SLAMF7 antibody, an anti-MARCO antibody, an anti-AXL antibody, an anti- CLEVER-1 antibody, an anti-ILT4 antibody, an anti-TIM-3 antibody, an anti-TIM-4 antibody, an anti-LRP-1 antibody, an anti-calreticulin antibody, an anti-TREM1 antibody, an anti-TREM2 antibody, an anti-GD2 antibody, an anti-FcgRI antibody, an anti-FcgRIIa antibody, an anti-FcgRIIb antibody, an anti-FcgRIII antibody, an anti- MUC1 antibody, an anti-CD44 antibody, an anti-CD63 antibody, an anti-CD36 antibody, an anti-CD84 antibody, an anti-CD164 antibody, an anti-CD82 antibody, an anti-CD18 antibody, an anti-SIGLEC-7 antibody, an anti-CD166 antibody, an anti-CD39 antibody, an anti-CD46 antibody, an anti-LILRA1 antibody, an anti-LILRA2 antibody, an anti- LILRA3 antibody, an anti-LILRA4 antibody, an anti-LILRB1 antibody, an anti-LILRB2 antibody, an anti-LILRB3 antibody, an anti-LILRB4 antibody, an anti-LILRB5 antibody, an anti-CD85b antibody, an anti-CD85m antibody, an anti-CD85f antibody, an anti- CD276 antibody, an anti-CD88 antibody, an anti-CD99 antibody, an anti-PILRa antibody, an anti-Siglec-9 antibody, an anti-CD206 antibody, an anti-CD163 antibody, an anti-CD84 antibody, an anti-C3aR antibody, and an anti-CLEC12A antibody.

23. The composition of any one of the preceding claims, wherein the antibodies are selected from an anti-CD85 antibody, an anti-CD85j antibody, an anti-CD20 antibody, an anti- CD38 antibody, an anti-CD71 antibody, an anti-CD79b antibody, an anti-CD95 antibody, an anti-CXCR4 antibody, an anti-CD45RB antibody, an anti-CD45RA antibody, an anti- CD147 antibody, an anti-CD98 antibody, an anti-CD184 antibody, an anti-HLA-DRW0571.70067WO00187 / 202antibody, an anti---HLA-(A,B,C) antibody, an anti-HLA-(DR,DP,DQ) antibody, an anti-CD47 antibody, an anti-SIRPα antibody, a SIRPα-Fc fusion protein, an anti-MHC I antibody, an anti-CD24 antibody, an anti-CD24-2, antibody, an anti-CD40 antibody, an anti-PD-L1 antibody, an anti-PD-L2 antibody, an anti-PD-1 antibody, an anti-B2M antibody, , an anti-SIRPb antibody, an anti-SIRPg antibody, an anti-CD85b antibody, an anti-CD85m antibody, and an anti-CD85f antibody.

24. The composition of any one of the preceding claims, wherein at least one antibody binds an antigen on a cell.

25. The composition of any one of the preceding claims, wherein the cell is a human cell.

26. The composition of any one of the preceding claims, wherein the human cell is an immune cell.

27. The composition of any one of the preceding claims, wherein the immune cell is a macrophage.

28. The composition of any one of the preceding claims, wherein the cell is a cancer cell.

29. The composition of any one of the preceding claims, wherein the cancer cell is a lymphoma cell.

30. The composition of any one of the preceding claims, wherein the lymphoma cell is a B- cell lymphoma cell.

31. The composition of any one of the preceding claims, wherein the cancer cell is a B-cell lymphoma cell.

32. The composition of any one of the preceding claims, wherein the cancer cell is therapy resistant.

33. The composition of any one of the preceding claims, wherein the wherein the cell is a lymphoma cell or a macrophage.W0571.70067WO00188 / 20234. The composition of any one of the preceding claims, wherein the proliferative disease is cancer.

35. The composition of any one of the preceding claims, wherein the cancer is selected from B-cell malignancies that include Hodgkin Lymphoma, Nodular Lymphocyte- Predominant Hodgkin Lymphoma (NLPHL); Non-Hodgkin Lymphomas (NHL), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma (Nodal, Extranodal MALT, and Splenic), Small Lymphocytic Lymphoma (SLL), Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Intravascular Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma (including Waldenström's Macroglobulinemia), Primary Effusion Lymphoma, Hairy Cell Leukemia, Chronic Lymphocytic Leukemia (CLL), B-cell precursor Acute Lymphoblastic Leukemia (B-ALL), Plasma Cell Neoplasms, Multiple Myeloma, Solitary Plasmacytoma, Monoclonal Gammopathy of Undetermined Significance (MGUS), POEMS syndrome, B-cell Prolymphocytic Leukemia (B-PLL), Splenic Diffuse Red Pulp Small B-cell Lymphoma, and Lymphomatoid Granulomatosis; Myeloid malignancies, Acute Myeloid Leukemia (AML) with various subtypes, Chronic Myeloproliferative Neoplasms (MPNs), Chronic Myeloid Leukemia (CML), Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary Myelofibrosis (PMF), Chronic Neutrophilic Leukemia (CNL), Chronic Eosinophilic Leukemia (CEL- NOS), Myeloproliferative Neoplasm, unclassifiable (MPN-U), Myelodysplastic Syndromes (MDS), MDS with single lineage dysplasia, multilineage dysplasia, ring sideroblasts, isolated del(5q), excess blasts, MDS unclassifiable, Myelodysplastic / Myeloproliferative Neoplasms (MDS / MPN), Chronic Myelomonocytic Leukemia (CMML), Atypical Chronic Myeloid Leukemia (aCML), Juvenile Myelomonocytic Leukemia (JMML), MDS / MPN unclassifiable, Mastocytosis, Myeloid Sarcoma, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Pathologic B cells, and Pathologic myeloid cells.

36. The composition of any one of the preceding claims, wherein the cancer is selected from lymphoma and leukemia.W0571.70067WO00189 / 20237. One or more nucleic acid constructs encoding the composition of any one of the preceding claims.

38. The one or more nucleic acid constructs of the preceding claim, wherein the nucleic acid comprises DNA or RNA.

39. The one or more nucleic acid constructs of any one of the preceding claims, wherein the nucleic acid construct comprises DNA.

40. The one or more nucleic acid constructs of any one of the preceding claims, wherein the nucleic acid construct comprises RNA.

41. A vector comprising the nucleic acid of any one of the preceding claims.

42. A cell comprising the nucleic acid of any one of the preceding claims or the vector of the preceding claim.

43. The cell of the preceding claim, wherein the cell is an animal cell.

44. The cell of claim any one of the preceding claims, wherein the cell is a human cell.

45. The cell of the preceding claim, wherein the cell is an immune cell.

46. The cell of the preceding claim, wherein the immune cell is a T-cell.

47. A method for treating proliferative disease in a subject in need thereof, the method comprising administering to a subject an effective amount of two or more antibodies of the composition of any one of the preceding claims comprising: (aa) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 1; (bb) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 2;W0571.70067WO00190 / 202(cc) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 3; (dd) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 4; (ee) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 5; (ff) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 6; (gg) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 7; (hh) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 8; (ii) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 9; (jj) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 10; (kk) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 11; (ll) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 12; (mm) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 13; (nn) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 14; (oo) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 15; (pp) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 16; (qq) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 17; (rr) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 18; (ss) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 19;W0571.70067WO00191 / 202(tt) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 20; (uu) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 21; (vv) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 22; (ww) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 23; (xx) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 24; or (yy) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO:

25.

48. The method of the preceding claim, wherein two or more antibodies of the composition of any one of the preceding claims comprising: (a) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 4; (b) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 8; (c) a single chain binding arm comprising CV1 (a high-affinity SIRPa decoy protein) of the amino acid sequence of SEQ ID NO: 10; (d) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 16; (e) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 20; (f) a single chain binding arm comprising CV1 (a high-affinity SIRPa decoy protein) of the amino acid sequence of SEQ ID NO: 22; and / or (g) a single chain binding arm comprising WTa2d1 (a low-affinity SIRPa decoy protein) of the amino acid sequence of SEQ ID NO:

25.

49. The method of any one of the preceding claims, wherein the proliferative disease is cancer.W0571.70067WO00192 / 20250. The method of any one of the preceding claims, wherein the cancer is selected from B- cell malignancies that include Hodgkin Lymphoma, Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL); Non-Hodgkin Lymphomas (NHL), Diffuse Large B- Cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma (Nodal, Extranodal MALT, and Splenic), Small Lymphocytic Lymphoma (SLL), Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Intravascular Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma (including Waldenström's Macroglobulinemia), Primary Effusion Lymphoma, Hairy Cell Leukemia, Chronic Lymphocytic Leukemia (CLL), B-cell precursor Acute Lymphoblastic Leukemia (B-ALL), Plasma Cell Neoplasms, Multiple Myeloma, Solitary Plasmacytoma, Monoclonal Gammopathy of Undetermined Significance (MGUS), POEMS syndrome, B-cell Prolymphocytic Leukemia (B-PLL), Splenic Diffuse Red Pulp Small B-cell Lymphoma, and Lymphomatoid Granulomatosis; Myeloid malignancies, Acute Myeloid Leukemia (AML) with various subtypes, Chronic Myeloproliferative Neoplasms (MPNs), Chronic Myeloid Leukemia (CML), Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary Myelofibrosis (PMF), Chronic Neutrophilic Leukemia (CNL), Chronic Eosinophilic Leukemia (CEL- NOS), Myeloproliferative Neoplasm, unclassifiable (MPN-U), Myelodysplastic Syndromes (MDS), MDS with single lineage dysplasia, multilineage dysplasia, ring sideroblasts, isolated del(5q), excess blasts, MDS unclassifiable, Myelodysplastic / Myeloproliferative Neoplasms (MDS / MPN), Chronic Myelomonocytic Leukemia (CMML), Atypical Chronic Myeloid Leukemia (aCML), Juvenile Myelomonocytic Leukemia (JMML), MDS / MPN unclassifiable, Mastocytosis, Myeloid Sarcoma, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Pathologic B cells, and Pathologic myeloid cells.

51. The method of any one of the preceding claims, wherein the cancer is lymphoma, 52. A bispecific antibody comprising a first antigen-binding domain and a second antigen - binding domain, wherein each antigen-binding domain independently targets CD20, CD3, CD22, CD27, CD38, CD47, CD71, CD79b, CD95, CXCR4, CD45RB, CD45RA, CD147, CD98, CD184, CD11b, 4-1BBL, Ly6A / E, HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DP, HLA-DO, HLA-(A,B,C), HLA-(DR,DP,DQ), MHC I, CD24, CALR, CD40, PD-L1, APMAP, GPR84, VCAM1, CD11b, SIGLEC-10, PD-L2 , PD-1, B2M, CD73,W0571.70067WO00193 / 202Galectin-9, CD14, CD80, CD86, SIRPb, SIRPg, SLAMF7, MARCO, AXL, CLEVER-1, ILT4, TIM-3, TIM-4, LRP-1, calreticulin, TREM1, TREM2, GD2, FcgRI, FcgRIIa, FcgRIIb, FcgRIII, MUC1, CD44, CD63, CD36, CD84, CD164, CD82, CD18, SIGLEC- 7, CD166, CD39, CD46, LILRA1, LILRA2, LILRA3, LILRA4, LILRB1(CD85j), LILRB2, LILRB3, LILRB4, LILRB5, CD85j, CD85b, CD85f, CD85m, CD276, CD88, CD99, PILRa, Siglec-9, CD206, CD163, CD84, C3aR, and CLEC12A.

53. The bispecific antibody of the preceding claim, wherein each antigen-binding domain independently targets CD3, CD20, CD24, CD24-2, CD38, CD40, CD71, CD95, CXCR4, PD-1, CD79b, CD85j, CD47, CD45RB, CD45RA, β2M, CD147, CD98, CD184, LILRB1(CD85j), HLA-DR, HLA-(A,B,C), and HLA-(DR,DP,DQ).

54. The bispecific antibody of any one of the preceding claims, wherein the first antigen- binding domain targets an antigen selected from CD20, CD47, CD85j, and CD38, and the second antigen-binding domain targets an antigen selected from CD20, CD24, CD24-2, CD38, CD40, CD71, CD95, CXCR4, PD-1, CD79b, CD85j, CD47, CD45RB, CD45RA, β2M, CD147, CD98, CD184, HLA-DR, HLA-(A, B, C), and HLA-(DR, DP, DQ).

55. The bispecific antibody of any one of the preceding claims, wherein the first antigen- binding domain targets an antigen selected from CD20, CD47, CD85j, and CD38, and the second antigen-binding domain targets an antigen selected from CD20, CD24, CD24-2, CD38, CD40, CD71, CD95, PD-1, CD79b, CD85j, CD47, CD147, and CD184.

56. The bispecific antibody of the preceding claim, wherein the first antigen-binding domain targets an antigen selected from CD47, CD20, CD85j, and CD38.

57. The bispecific antibody of the preceding claim, wherein the first antigen-binding domain targets CD47.

58. The bispecific antibody of the preceding claim, wherein the first antigen-binding domain targets CD47 and second antigen-binding domain targets an antigen selected from CD20, CD24, CD38, CD40, CD71 , PD-1, CD85j, CD147, and CD184.W0571.70067WO00194 / 20259. The bispecific antibody of the preceding claim, wherein the first antigen-binding domain targets CD85j.

60. The bispecific antibody of any one of the preceding claims, wherein the first antigen- binding domain targets CD85j and the second antigen-binding domain targets an antigen selected from CD20, CD40, CD38, CD71, CD47, CD147, and CD184.

61. The bispecific antibody of any one of the preceding claims, wherein the first antigen- binding domain targets an antigen selected from CD85j and the second antigen-binding domain targets an antigen selected from CD38, CD47, and CD147.

62. The bispecific antibody of the preceding claim, wherein the first antigen-binding domain targets CD38.

63. The bispecific antibody of any one of the preceding claims, wherein the first antigen- binding domain targets CD38 and the second antigen-binding domain targets an antigen selected from CD20, CD24, CD24-2, CD38, CD-79b, CD40, CD71, CD95, PD-1, CD79b, CD85j, CD47, CD147, and CD184.

64. The bispecific antibody of any one of the preceding claims, wherein the first antigen- binding domain targets CD38 and the second antigen-binding domain targets CD47.

65. The bispecific antibody of any one of the preceding claims, wherein the first antigen- binding domain targets CD38 and the second antigen-binding domain targets an antigen selected from CD20.

66. The bispecific antibody of the preceding claim, wherein the first antigen-binding domain targets CD20.

67. The bispecific antibody of any one of the preceding claims, wherein the first antigen- binding domain targets CD20 and the second antigen-binding domain targets an antigen selected from CD24, CD24-2, CD38, CD40, CD71, CD95, PD-1, CD79b, CD85, CD47, CD147, and CD184.W0571.70067WO00195 / 20268. The bispecific antibody of any one of the preceding claims, wherein the first antigen- binding domain targets CD20 and the second antigen-binding domain targets an antigen selected from CD38 and CD184.

69. The bispecific antibody of any one of the preceding claims, wherein the first antigen- binding domain targets CD20 and the second antigen-binding domain targets CD38.

70. A bispecific comprising a SIRPα decoy domain and an antigen-binding domain that targets LILRB1(CD85j), CD20, CD24, CD24-2, CD38, CD40, CD71, CD95, CXCR4, PD-1, CD79b, CD85j, CD47, CD45RB, CD45RA, β2M, CD147, CD98, CD184, HLA- DR, HLA-(A, B, C), and HLA-(DR, DP, DQ).

71. The bispecific antibody of claim 70, wherein the antigen-binding domain targets LILRB1(CD85j), CD38, or CD20.

72. The bispecific antibody of claim 71, wherein the antigen-binding domain targets CD38.

73. The bispecific antibody of claim 71, wherein the antigen-binding domain targets LILRB1(CD85j).

74. The bispecific antibody of any one of the preceding claims, wherein the first antigen- binding domain or the second antigen binding domain targets CXCR4.

75. The bispecific antibody of any one of the preceding claims, wherein the first antigen- binding domain or the second antigen binding domain targets LILRB1(CD85j).

76. The bispecific antibody of any one of the preceding claims, wherein the first antigen- binding domain targets CXCR4 and the second antigen binding domain targets LILRB1(CD85j).

77. The bispecific antibody of any one of the preceding claims comprising at least one scFv.

78. The bispecific antibody of any one of the preceding claims comprising at least two of:W0571.70067WO00196 / 202a. a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 1; b. a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 2; c. a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 3; d. a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 4; e. a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 5; f. a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 6; g. a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 7; h. a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 8; i. a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 9; j. a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 10; k. a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 11; l. a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 12; m. a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 13; n. a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 14; o. a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 15; p. a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 16; q. a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 17;W0571.70067WO00197 / 202r. a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 18; s. a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 19; t. a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 20; u. a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 21; v. a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 22; w. a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 23; x. a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 24; or y. a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO:

25.

79. The bispecific antibody of any one of the preceding claims comprising: (a) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 4; (b) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 8; (c) a single chain binding arm comprising CV1 (a high-affinity SIRPa decoy protein) of the amino acid sequence of SEQ ID NO: 10; (d) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 16; (e) a HC CDR1, HC CDR2, HC CDR3, a LC CDR1, LC CDR2 and LC CDR3 of the amino acid sequence of SEQ ID NO: 20; (f) a single chain binding arm comprising CV1 (a high-affinity SIRPa decoy protein) of the amino acid sequence of SEQ ID NO: 22; and / or (g) a single chain binding arm comprising WTa2d1 (a low-affinity SIRPa decoy protein) of the amino acid sequence of SEQ ID NO: 25.W0571.70067WO00198 / 20280. The bispecific antibody of any one of the preceding claims comprising a “knob” sequence and a "hole” sequence.

81. The bispecific antibody of any one of the preceding claims wherein the “knob” sequence comprises an amino acid sequence selected from SEQ ID NO: 1-12.

82. The bispecific antibody of any one of the preceding claims wherein the “hole” sequence comprises an amino acid sequence SEQ ID NO: 13-25.

83. The bispecific antibody of any one of the preceding claims comprising a “knob” sequence selected from SEQ ID NOs: 1-12 and one heavy chain comprises a "hole” sequence selected from SEQ ID NOs: 13-25.

84. The bispecific antibody of any one of the preceding claims comprising an amino acid sequence at least 85% identical, or optionally 90% identical, or optionally 95% identical to the amino acid sequences set forth in REF ID NOs: 26-181.

85. The bispecific antibody of any one of the preceding claims consisting of an amino acid sequence at least 85% identical, or optionally 90% identical, or optionally 95% identical to the amino acid sequences set forth in REF ID NOs: 26-181.

86. One or more nucleic acid constructs encoding the composition of any one of the preceding claims.

87. The one or more nucleic acid constructs of the preceding claim, wherein the nucleic acid comprises DNA or RNA.

88. The one or more nucleic acid constructs of any one of the preceding claims, wherein the nucleic acid construct comprises DNA.

89. The one or more nucleic acid constructs of any one of the preceding claims, wherein the nucleic acid construct comprises RNA.

90. A vector comprising the nucleic acid of any one of the preceding claims.W0571.70067WO00199 / 20291. A cell comprising the nucleic acid of any one of the preceding claims or the vector of the preceding claim.

92. The cell of the preceding claim, wherein the cell is an animal cell.

93. The cell of claim any one of the preceding claims, wherein the cell is a human cell.

94. The cell of the preceding claim, wherein the cell is an immune cell.

95. The cell of the preceding claim, wherein the immune cell is a T-cell.

96. A method of treating disease in a subject or a cell, the method comprising administering to the subject or cell an effective amount of the bispecific antibody of any one of the preceding claims.

97. The method of any one of the preceding claims, wherein the disease is a proliferative disease or an autoimmune disease.

98. The method of any one of the preceding claims, wherein the proliferative disease is cancer.

99. The method of any one of the preceding claims, wherein the cancer is selected from B- cell malignancies that include Hodgkin Lymphoma, Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL); Non-Hodgkin Lymphomas (NHL), Diffuse Large B- Cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma (Nodal, Extranodal MALT, and Splenic), Small Lymphocytic Lymphoma (SLL), Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Intravascular Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma (including Waldenström's Macroglobulinemia), Primary Effusion Lymphoma, Hairy Cell Leukemia, Chronic Lymphocytic Leukemia (CLL), B-cell precursor Acute Lymphoblastic Leukemia (B-ALL), Plasma Cell Neoplasms, Multiple Myeloma, Solitary Plasmacytoma, Monoclonal Gammopathy of Undetermined Significance (MGUS), POEMS syndrome, B-cell Prolymphocytic Leukemia (B-PLL), SplenicW0571.70067WO00200 / 202Diffuse Red Pulp Small B-cell Lymphoma, and Lymphomatoid Granulomatosis; Myeloid malignancies, Acute Myeloid Leukemia (AML) with various subtypes, Chronic Myeloproliferative Neoplasms (MPNs), Chronic Myeloid Leukemia (CML), Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary Myelofibrosis (PMF), Chronic Neutrophilic Leukemia (CNL), Chronic Eosinophilic Leukemia (CEL- NOS), Myeloproliferative Neoplasm, unclassifiable (MPN-U), Myelodysplastic Syndromes (MDS), MDS with single lineage dysplasia, multilineage dysplasia, ring sideroblasts, isolated del(5q), excess blasts, MDS unclassifiable, Myelodysplastic / Myeloproliferative Neoplasms (MDS / MPN), Chronic Myelomonocytic Leukemia (CMML), Atypical Chronic Myeloid Leukemia (aCML), Juvenile Myelomonocytic Leukemia (JMML), MDS / MPN unclassifiable, Mastocytosis, Myeloid Sarcoma, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Pathologic B cells, and Pathologic myeloid cells.

100. The method of any one of the preceding claims, wherein the cancer is lymphoma.

101. The method of any one of the preceding claims, wherein the cancer is rituximab resistant.

102. The method of any one of the preceding claims, further comprising administering an additional pharmaceutical agent.

103. A kit comprising the bispecific antibody of any one of the preceding claims and a pharmaceutical excipient.W0571.70067WO00201 / 202

Images